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ABSTRACT 
 
The rise on antimicrobial resistance rates among main bacterial pathogens is a growing 
challenge for healthcare institutions all over the world. Acinetobacter, and particularly 
Acinetobacter baumannii, are among the most concerning bacteria, being associated with a 
prodigious ability to persist in the hospital environment and to become resistant to multiple 
antimicrobial agents, including the most relevant and last-resource options, such as carbapenems.  
Although A. baumannii is still considered the most prevalent Acinetobacter species within 
the hospital setting, the reports of infections caused by non-baumannii species, including 
multidrug resistant strains, increased in the last years. In Portugal, besides the endemicity of 
carbapenem-hydrolyzing class D β-lactamase (CHDL)-producing A. baumannii isolates observed 
for more than two decades, this scenario seems to be worsening, with the increase of isolates with 
an enlarged antibiotic resistance profile, being needed further clarification regarding their clonality 
and antimicrobial resistance mechanisms. Moreover, other clonal features (e.g. virulence or 
resilience traits), as well as relevance of other settings for the emergence and proliferation of 
particular A. baumannii clones, are still poorly understood. Additionally, the interspecies transfer 
of resistance traits that occur between non-baumannii and A. baumannii species also account for 
carbapenem resistance, with non-baumannii species/non-hospital niches potentially constituting 
an important source/reservoir of relevant resistance genes that worth to be explored.  
The increasing availability of whole genome sequencing (WGS) provided an opportunity for 
defining these organisms’ evolutionary processes, and also for the recognition of dispersion 
drivers/transmission pathways, associated with antibiotic resistance genes. However, most of these 
methods are still expensive and time-consuming which is incompatible with a quick infection 
control surveillance (mainly in an outbreak context). Thus, alternative high-throughput quick and 
low-cost methods are highly demanded. 
The main goals of this work were to identify the features contributing for the clonal 
dynamics and success of particular A. baumannii lineages that were observed in Portuguese clinical 
settings since 1995; to understand the role of non-baumannii Acinetobacter species in the 
carbapenem resistance dissemination; to unveil unrecognized niches for Acinetobacter; and to 
explore the potential of high-throughput omic technologies [WGS, Fourier transform infrared 
(FTIR) spectroscopy, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight mass 
spectrometry (MALDI-TOF MS)], for an accurate and quick typing of Acinetobacter. Moreover, 
combining information of these different approaches to identify bacterial cell components explain 
the discriminatory ability of MALDI-TOF MS and FTIR spectroscopy. To accomplish these 
purposes, a multilevel characterization (including bacterial species, clones, and genomic pieces 
contributing to virulence and adaptation to different stressors), of a recent carbapenem-resistant 
Acinetobacter spp. Portuguese clinical collection (hospital, LTCF and community laboratory; 2010-
2015), was performed. Additionally, for a more comprehensive analysis, whole genome sequences 
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of representatives of this collection and of older Portuguese isolates were compared. Moreover, the 
occurrence, diversity and antimicrobial resistance of Acinetobacter spp. in non-clinical clinical 
niches of an African country was also evaluated. Finally, a representative national and international 
collection of Acinetobacter species from the ACB complex was used to assess the potential of FTIR-
ATR and MALDI-TOF MS for these species identification and typing. 
The results of this Thesis revealed that, since 2010, ST218 gradually replaced the 
previously dominant ST208, being now the main clone associated with carbapenem-resistance 
among Portuguese clinical settings. The extended resistance profile of ST218 isolates affecting all 
aminoglycosides (possibly associated with the presence of armA, aph(3´)-Ia and aac(6´)-Ib 
genes), together with an enlarged virulence potential (includes heme oxygenase) and a capsular 
type (displaying legionaminic acid) more adapted to the host colonization, were found to be the 
main advantages of this clone. Interestingly, the chromosome located blaOXA-23, associated with 
Tn2006 is still the most prevalent carbapenem resistance determinant associated with A. 
baumannii. Moreover, a clear potential of non-baumannii species to acquire and act as a 
source/reservoir of carbapenem-resistance determinants, with potential for further dissemination 
was evidenced, being the description of new CHDL-carrying plasmids among A. pittii clinical 
isolates (including a conjugative blaOXA-23-plasmid) and the detection of A. bereziniae carrying 
blaIMP-5 plasmid-encoded, important findings. The observation of CHDL-Acinetobacter spp. 
producers in non-clinical niches in an African country indicates the ongoing selective pressure by 
unrecognized agents. Moreover, in this region, a possible water–human transmission cycle for 
Acinetobacter spp., including CHDL producers, was observed. Finally, it was demonstrated the 
potential of FTIR for the identification of ACB closely related species, and also for the 
discrimination of clinically relevant A. baumannii clones. Conversely, MALDI-TOF MS showed a 
good suitability for ACB species identification but a limited potential to discriminate MDR A. 
baumannii clones, apparently explained by the high degree of conservation of ribosomal proteins. 
This Thesis identified important features contributing for the emergence and success of 
carbapenem-resistant Acinetobacter spp. in the clinical setting, the non-A. baumannii species 
contribution for the dissemination of important carbapenemases among the genus Acinetobacter, 
and unveiled a possible significant human exposition through water consumption to these 
worrisome resistant bacteria in an African country. Moreover, the suitability of FTIR spectroscopy 
and MALDI-TOF MS for species and clonal discrimination with potential application for routine 
microbiology laboratories is demonstrated. 
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RESUMO 
 
O aumento da resistência a antimicrobianos entre as principais bactérias patogénicas é um 
desafio cada vez maior para os serviços de saúde em todo o mundo. Acinetobacter, e em particular 
Acinetobacter baumannii, é considerado um grupo preocupante de bactérias, dada a sua 
extraordinária capacidade em persistir no ambiente hospitalar e adquirir resistência a múltiplos 
agentes antimicrobianos, incluindo as opções de última linha, como é o caso dos carbapenemos.  
Embora A. baumannii ainda seja a espécie mais frequente em ambiente hospitalar, nos 
últimos anos assistiu-se a um aumento de infeções causadas por outras espécies de Acinetobacter, 
incluindo isolados resistentes a múltiplos antibióticos. Em Portugal, para além da endemicidade de 
clones de A. baumannii produtores de carbapenemases de classe D (CHDL), observada há mais de 
duas décadas, verifica-se atualmente um agravamento deste cenário em resultado do aparecimento 
de isolados resistentes a um maior número de antibióticos, sendo necessário elucidar quais os 
clones e mecanismos de resistência associados a este comportamento. Adicionalmente, 
características de virulência e resiliência, bem como a contribuição de nichos não hospitalares no 
aparecimento e disseminação de clones particulares de A. baumannii, foram ainda pouco 
exploradas. Acresce ainda que, a contribuição de espécies não-baumannii e nichos não hospitalares 
como fontes/reservatórios de genes de resistência relevantes carece de elucidação. 
A crescente utilização da sequenciação do genoma completo (WGS) tem proporcionado a 
definição de processos evolutivos em diferentes organismos, assim como o reconhecimento de 
mecanismos e vias de transmissão e disseminação da resistência a antibióticos. No entanto, tratam-
se de métodos caros e demorados, o que é incompatível com uma vigilância rápida, essencial para o 
controlo de infeção (principalmente em situações de surto). Por isso, torna-se imprescindível o 
desenvolvimento de métodos alternativos de alto rendimento, que sejam rápidos, precisos e de 
baixo custo.  
Este trabalho teve como principais objetivos a identificação das características que 
contribuem para a dinâmica clonal e o sucesso das linhagens de A. baumannii detetadas, desde 
1995, nos hospitais Portugueses; compreender o papel das espécies de Acinetobacter não-
baumannii na disseminação da resistência aos carbapenemos; reconhecer novos nichos para 
Acinetobacter e explorar o potencial de tecnologias de alto rendimento [WGS, Espectroscopia de 
Infravermelho com Transformada de Fourier (FTIR), “Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight mass spectrometry” (MALDI-TOF MS], para uma 
caracterização mais rápida e precisa de Acinetobacter, contribuindo para o reconhecimento das 
características bacterianas subjacentes à discriminação obtida com essas metodologias. 
Para o efeito, foi efetuada numa coleção recente de isolados clínicos (hospital, LTCF e 
laboratório comunitário, 2010-2015) de Acinetobacter spp. resistentes aos carbapenemos, uma 
caracterização a múltiplos níveis (espécies, clones e elementos genéticos putativamente envolvidos 
na virulência e adaptação a diferentes agentes seletivos). Adicionalmente, para uma análise mais 
abrangente, dados de WGS de isolados representativos desta coleção e de isolados Portugueses 
mais antigos foram comparados. Além disso, a ocorrência, diversidade e resistência a 
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antimicrobianos de uma coleção de isolados não clínicos de Acinetobacter spp. de um país africano 
foram também avaliadas. Por fim, uma coleção representativa de isolados nacionais e 
internacionais pertencentes a espécies de Acinetobacter do complexo Acinetobacter calcoaceticus-
baumannii (ACB) foi utilizada para avaliar o potencial de FTIR-ATR e MALDI-TOF MS na 
discriminação dessas espécies. 
 Os resultados obtidos no âmbito desta Tese revelaram que, desde 2010, o ST218 
substituiu gradualmente o ST208 anteriormente dominante, sendo agora o principal clone 
associado à resistência ao carbapenemos em diferentes contextos clínicos portugueses. 
Comparando os dois clones, verificou-se que o ST218 apresentava vantagens relativamente ao clone 
anterior, nomeadamente um perfil de resistência aumentado afetando todos os aminoglicosídeos 
(possivelmente associados à presença dos genes armA, aph(3´)-Ia e aac(6´)-Ib), um maior 
potencial de virulência (incluindo a presença de heme oxigenase) e um tipo capsular (apresentando 
o ácido legionamínico) mais adaptado à colonização do hospedeiro. Curiosamente, o gene blaOXA-23 
cromossómico, associado ao Tn2006 continua a ser o determinante de resistência aos 
carbapenemos mais frequente em A. baumannii. Adicionalmente, verificou-se um claro potencial 
das espécies não-baumannii para adquirir e/ou atuar como fonte/reservatório de determinantes de 
resistência aos carbapenemos, o que pode resultar num considerável aumento da sua disseminação. 
São exemplos a descrição de novos plasmídeos associados a CHDL em isolados clínicos de A. pittii 
(incluindo um plasmídeo conjugativo com blaOXA-23) e a deteção de A. bereziniae resistentes aos 
carbapenemos em resultado da presença de blaIMP-5 plasmídica. A deteção de isolados de 
Acinetobacter spp. produtores de CHDL em isolados clínicos de África indicia uma contínua 
pressão seletiva por agentes ainda não determinados. Para além disso, parece ocorrer nesta região 
um ciclo de transmissão água-humanos de Acinetobacter spp., incluindo isolados produtores de 
CHDL. Finalmente, foi demonstrado o potencial do FTIR para a identificação de espécies 
estreitamente relacionadas pertencentes ao complexo ACB e também para a discriminação de 
clones de A. baumannii clinicamente relevantes. Por outro lado, o MALDI-TOF MS mostrou uma 
boa adequação para a identificação de espécies de ACB, mas um potencial limitado para 
discriminar clones de A. baumannii, provavelmente devido ao alto grau de conservação das 
proteínas ribossómicas nessas espécies. 
Esta Tese identificou características importantes que contribuem para a emergência e 
sucesso de Acinetobacter spp. resistentes aos carbapenemos em contexto hospitalar, a contribuição 
de espécies não-baumannii para a disseminação de carbapenemases importantes no género 
Acinetobacter, revelando uma possível e potencialmente grave exposição humana, em África, a 
Acinetobacter spp. resistentes através do consumo de água. Para além disso, foi demonstrada a 
adequação da espectroscopia de FTIR e MALDI-TOF MS para a identificação de espécies e 
discriminação clonal em Acinetobacter com potencial aplicação em laboratórios de rotina. 
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1.1. The genus Acinetobacter 
 
1.1.1. The challenging taxonomy of Acinetobacter 
 
 
“Taxonomy is described sometimes as a science and sometimes as an art, but 
really it´s a battleground.” 
Bill Bryson 
 
 
The history of Acinetobacter genus is very ancient, being predicted that its last 
common ancestor was a close contemporary of the last common ancestor of 
Enterobacteriaceae, with this antiquity explaining Acinetobacter genus metabolic and 
ecological diversity [1]. However, an accurate dating is almost impossible given the lack of 
fossil records [1]. The first description of an Acinetobacter organism have occurred in 
1911, when the botanist Martinus Beijerinck isolated Micrococcus calcoaceticus from the 
soil [2]. In 1954, Brisou and Prevot proposed the current genus designation, Acinetobacter 
(from the Greek words “akinetos” and “bactrum”, which means non-motile and rod, 
respectively), composed by non-pigmented Gram-negative bacteria and comprising both 
oxidase-negative and oxidase-positive species [3]. A few years later, in 1971, based on 
several studies performed by Paul Baumann, the Subcommittee on the taxonomy of 
Moraxella recommended that the genus Acinetobacter should include only oxidase-
negative strains [4,5]. Currently, Acinetobacter genus is included in the Kingdom 
Bacteria, Phylum Proteobacteria, Class Gammaproteobacteria, Order Pseudomonadales 
and Family Moraxellaceae, comprised by Gram-negative non-fermenting coccobacilli, 
with a DNA G+C content of 39-47%, strictly aerobic, catalase positive and oxidase negative 
[6]. More than 60 named and unnamed species (including strains not yet recognized by 
the International Committee on Systematic Bacteriology, Table 1) were described among 
this genus, in different environments (e.g. as inhabitants of human and other animal guts, 
in sewage, water, soil, food and also as important agents of opportunistic infections in 
humans) (Table 1). The taxonomy of Acinetobacter still suffers from unclear taxonomic 
positions, confusing nomenclature of some provisional species, high number of 
unidentifiable environmental strains and a number of controversial interpretations of 
taxonomic data [7,8]. Thus, understanding the diversification of this genus is, currently, a 
real challenge. 
The following sections, include an update overview of the main methodologies 
used for Acinetobacter identification (at species level) along with the evolution and 
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applications of the typing methods used for the characterization of Acinetobacter 
populations (mainly among A. baumannii).  
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1.1.2. Identification and typing: overview of the methods applied to 
Acinetobacter species 
 
“Science never solves a problem without creating ten more.” 
                        George Bernard Shaw 
 
For many years, some Acinetobacter species were very difficult to identify by the 
conventional phenotypic tests (based on morphological, physiological and metabolic 
characteristics) that were used by the majority of routine microbiology laboratories. This 
identification was particularly difficult within the phenotypically more homogeneous 
species, like those belonging to the Acinetobacter calcoaceticus - Acinetobacter 
baumannii complex (ACB complex) that includes A. baumannii, A. calcoaceticus, 
Acinetobacter pittii, Acinetobacter nosocomialis, Acinetobacter seifertii and 
Acinetobacter dijkshoorniae [50]. Thus, for a long time, it was only possible to 
discriminate these species using genomic tools. However, and since the antibiotic 
susceptibility and clinical relevance are significantly different among the different 
Acinetobacter species, their exact identification should be included under the routine 
practice, being important to guide therapy.  
Recently, more sophisticated omic methodologies [average nucleotide identity 
(ANI) determined with whole genome sequencing (WGS), Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-TOF MS) and Fourier 
transform infrared (FTIR) spectroscopy] have been explored and used for bacterial species 
identification and typing (Box 1) [59,60], being applied in a wide variety of contexts: in 
retrospective epidemiological studies; to recognize and track individual strains or 
epidemic clones (clones with higher or specific pathogenicity); to identify patterns of 
infection and sources of transmission; to study the population structure and phylogeny of 
a given species, and also for the detection of outbreaks and reservoirs or sources of human 
pathogens [61,62].  
 
Glossary of concepts commonly used in bacterial typing. 
 
Phenotyping: discrimination of a bacterial isolate/strain based on the observable characteristics 
(e.g. morphology of colonies on various culture media, biochemical tests, serology, pathogenicity 
and antibiotic susceptibility) [63].  
Genotyping: refers to the discrimination of bacterial strains based on their genetic content [63]. 
BOX 
1 
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Fingerprint: specific pattern (e.g. DNA banding pattern; peak patterns) or a set of markers scores 
(e.g. absorbance values) displayed by an isolate resulting from the application of one or more 
typing methods, that can be used to assess epidemiological relatedness among bacterial isolates 
[62]. 
Reproducibility: ability of a typing method to generate the same results upon repeating testing 
[64].  
Discriminatory power: ability of a typing method to distinguish between epidemiologically 
unrelated strains.  
Sensitivity: proportion of positives that are correctly identified as such [61]. 
Specificity: proportion of negatives that are correctly identified as such [61]. 
Typeability: The proportion of strains that are assigned a type by a giving typing method [64].  
Taxonomy: The science of naming, describing and classifying organisms, and includes all plants, 
animals and microorganisms of the world (https://www.cbd.int/gti/taxonomy.shtml) [62].  
Phylogeny: evolutionary relationships among members of the same taxon (e.g. species, strains, 
clones) [62]. 
Phylogenetic tree: a diagram that depicts the hypothetical evolutionary history of the taxa under 
study. The points at which lineages split represent ancestor taxa to the descendant taxa appearing 
at the terminal points of the tree [62].  
Species: The basic taxonomic category of bacteria; consists of strains of common origin which are 
more similar to each other than they are to any other strain [65].  
Type strain: pure and well-characterized strain with which the name of the species is 
permanently associated. The type strain is one of the first specimens of a described species and is 
marked by a superscript T at the end of its identification number [62,64]. 
Strain: isolate or group of isolates exhibiting common phenotypic and/or genotypic traits that 
differ from other isolates of the same species [64].  
Isolate: population of microbial cells in pure culture, usually obtained by sub-culturing a single 
colony from a preliminary isolation plate [66]. 
Lineage: group of isolates sharing essential characteristics due to a common ancestor. Lineages 
are generally inferred from a phylogenetic tree [62]. 
Clone: bacterial isolates descending from a common ancestor and exhibiting identical or closely 
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similar phenotypic or genotypic traits (even if they have been cultured independently from different 
sources in different locations and even at different times) [62].  
Population: group of organisms of the same species inhabiting a particular environment [67]. 
Population dynamics: the study of factors that interfere with the variability of bacterial 
populations over time and space, including the interactions of these two factors [62]. 
Endemic: The constant presence of diseases or infectious agents within a given geographic area or 
population group [62].  
Epidemic: refers to an increase, often rapid and extensive, in the number of cases involving a 
particular organism above what is normally expected in that population in that area [62].  
Outbreak: temporal increase in the incidence of infection (or colonization) by a certain bacterial 
species, caused by enhanced transmission of a single epidemic strain (clonal outbreak) or 
combinations of different strains (multi-strain outbreaks) [64].  
Pandemic clone: epidemic clone that has spread over several countries or continents (e.g. ST208 
A. baumannii) [68–70].  
Sequence Type (ST): MLST-based term representing isolates with a particular allelic profile 
(http://eburst.mlst.net). 
Clonal complex (CC): MLST-based term representing a group of related STs sharing alleles at 
5/7 or 6/7 of the loci (http://eburst.mlst.net). 
Genome: complete genetic information of an organism as encoded in its DNA and/or RNA 
(http://www.nature.com/subjects/genomics). 
Genomics: refers to the study of the full genetic complement of an organism (the genome) 
(http://www.nature.com/subjects/genomics). 
Core genome: set of genes shared by all of the genomes studied (e.g. genomes belonging to the 
same clone, bacterial species, etc.). These genes are generally involved in essential cellular 
processes (housekeeping and regulatory functions) [71].  
Accessory genome: set of genes shared by some organisms, which are not present in all of the 
studied organisms (these elements are generally associated with mobile genetic elements) [71]. 
Pan-genome: refers to the total number of non-redundant genes that are present in a given 
dataset. It comprises basically three parts: i) core genome, ii) accessory genome, and iii) species-
specific or strain-specific genes, which are those genes that are present in a single genome [71].  
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1.1.2.1. Phenotypic and genotypic methods 
 
Currently, Acinetobacter species are defined by both phenotypic and genotypic 
characteristics, and are represented by type strains deposited in international culture 
collections. Phenotypic tests are based on colony morphology, colour, odour or other 
macroscopic features, and also on biochemical traits, such as the ability to use certain 
substrates (e.g. API 20NE). In addition, commercially platforms (automated and semi-
automated) are also available but, per se, insufficient and inaccurate [72]. Thus, several 
genomic methods (based on nucleic acid analysis) have been developed or improved, with 
several significant advantages [73,74]. DNA-DNA hybridization (DDH) techniques have 
been used as the “gold standard” for the genomic similarity analysis of pair-wise sets of 
strains for classification purposes [72], and the amplified fragment length polymorphism 
(AFLP); the study of ribosomal DNA (e.g. amplified 16S ribosomal DNA restriction 
analysis-ARDRA); and the phylogenetic analysis based on single or multilocus sequence 
analysis (MLSA) of housekeeping genes [(mainly 16S rRNA or the intergenic spacer (ITS) 
region 16S-23S rRNA genes, RNA polymerase β-subunit (rpoB), and DNA gyrase subunit 
B (gyrB)]. In addition, some of the clinically relevant Acinetobacter species harbour 
species-specific genes for a class D β-lactamase, whose detection can be used for 
identification (e.g. blaOXA-51-like in A. baumannii, blaOXA-134-like in A. lwoffii, blaOXA-211-like in A. 
calcoaceticus and blaOXA-228-like in A. bereziniae) [75]. However, these housekeeping genes 
may not be sufficiently variable to distinguish all Acinetobacter species and some of these 
methodologies are laborious and available only in reference laboratories, making the 
identification of Acinetobacter species in routine diagnostic laboratories very difficult.  
Currently, with the advances in sequencing technologies, the continuing reduction 
costs and the shortening of the results delivery, microbiology laboratories have increased 
their access to the whole genome sequencing (WGS), a technique that promises to replace 
some older tools used to identify and characterize strains at the genomic level. Thus, the 
whole genome-based average nucleotide identity (ANI) and digital DNA-DNA 
hybridization (dDDH) are starting to replace DDH for species identification. The ANI is a 
similarity index calculated between a given pair of genomes that can be applicable to 
prokaryotic organisms independently of their G+C content. An ANI cut-off score >95% 
indicates that the comparing genomes belong to the same species, with ANI values ≥ 95% 
corresponding to the traditional 70% DDH threshold [76].  
In what concerns the infra-species level characterization, typing methodologies are 
mainly used for A. baumannii due to its clinical relevance. There is a wide range of 
epidemiological methods available for researchers and organizations specialized in 
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different domains, such as medical routine microbiology, infection control management 
and surveillance, being important that the selected method fit their epidemiological 
purposes. These methods can be divided in the DNA banding pattern- and DNA 
sequencing- based methods [74], and also according to their applicability at local scale 
(e.g. pulsed-field gel electrophoresis, PFGE) or at a large scale (e.g. multilocus sequence 
typing, MLST) (Table 2). 
Despite the emergence of new approaches, PFGE is still considered one important 
epidemiological tool for A. baumannii characterization [77]. The genome is cut by a 
restriction enzyme (e.g. ApaI, SmaI), producing a few large fragments that are separated 
by electrophoresis, periodically changing the direction of an electric field, and allowing the 
resolution of large fragments up to 1000 kb [74]. The PFGE resulting patterns are usually 
analysed by computer software programs (e.g. Infoquest from Biorad). The most 
commonly used similarity cut-off in the prediction of A. baumannii putative clones is 
>87% [77]. Despite the high discriminatory power of PFGE, which is useful in outbreak 
investigations, it cannot be considered as a method of choice for large scale studies due to 
genetic events that may occur from one generation to another that may interfere with the 
patterns generated [78]. Besides, PFGE suffers from several limitations: is technically 
demanding and time-consuming, some strains are non-typeable and the inter-laboratory 
reproducibility and comparability is difficult mainly due to the high sensitivity of 
electrophoresis-based method and the subjective analysis of the results (Table 2) [74]. 
MLST provides a uniform nomenclature owing to a standard reproducible system 
and thus is suitable for large-scale epidemiology, being extensively used in the 
identification and characterization of main clones implicated in the dissemination of 
multidrug-resistance (MDR) and extensive drug-resistance (XDR) A. baumannii strains 
worldwide [79–81]. It assesses the genetic variation that accumulates slowly within a 
population by targeting seven housekeeping genes involved in essential metabolic 
processes. For A. baumannii two MLST schemes have been developed: one proposed by 
Bartual et al. [82] (Oxford Database), and other proposed by Diancourt et al. [83] 
(Pasteur database), with some studies pointing for a better discrimination of the first one 
[84]. Recently, these MLST databases (https://pubmlst.org/abaumannii/) were developed 
for the Bacterial Isolate Genome Sequence Database (BIGSdb genomics platform) [85] to 
assist the broader community in elucidating the structure and function of this 
microorganism. MLST has many advantages that makes it the current gold standard for 
population structure investigations: its portability and its ability to generate highly 
standardized, reproducible data that can be stored in a database; and its high 
discriminatory power in long-term global studies [74].  
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The recent burst of new high-throughput sequencing technologies was crucial to 
provide a higher resolution of A. baumannii populations, and to explore factors 
responsible for its global expansion and maintenance. Unlike traditional typing methods, 
WGS-based approaches decipher the total information present in bacterial genomes, being 
suitable to be used in different epidemiological contexts, ranging from fine 
epidemiological [86], to local [87] and global studies through to phylogenetic and 
population structure studies [87]. Within a small-scale outbreak, WGS can resolve genetic 
differences between very closely related strains (sometimes indistinguishable by PFGE 
and MLST) and can enlighten unclear routes of transmission between patients [86]. At the 
strain level, WGS provides opportunities to explore and identify useful gene contents 
within bacterial genomes such as antimicrobial resistance determinants including 
resistance islands, virulence genes and additional informative genome sequences that can 
also serve for fine epidemiological ends or to explain some exhibited phenotypes [75,88]. 
Moreover, WGS can also be used to define the set of genes of core and accessory genomes 
[89] and in phylogenetic analyses of core genomes, either by the development of a 
cgMLST scheme [90] or by the comparison of single nucleotide polymorphisms (SNPs) 
across the whole genome [91]. However, the use of WGS in routine clinical laboratories for 
typing is still costly and requires specific skills for data processing.  
Table 2 summarizes the main characteristics, applicability, advantages and 
limitations of the typing methods frequently used for A. baumannii characterization. 
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1.1.2.2. Spectroscopic (FTIR) and Spectrometric (MALDI-TOF MS) 
approaches 
 
 
Fourier transform infrared (FTIR) spectroscopy and Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-TOF MS) are becoming 
important tools in microbiology for bacterial identification and characterization.  
FTIR spectroscopy is a whole-organism fingerprinting method that generates 
metabolic specific patterns from a bacterial cell (Box 2). It reflects the phenotype of the 
microorganism under investigation, through the detection of a diversity of biomolecules 
(lipids, polysaccharides, proteins and nucleic acids), and represents an attractive 
alternative to the genotyping methods [106].  
 
Principle of FTIR identification of microorganisms. 
¨  FTIR spectra results from the interaction of infrared radiation with the bacterial isolate, which 
changes the vibrational behaviour of molecules by delivering energy quanta and changing their 
vibrational and rotational modes. This provides a specific fingerprint that reflects the structure 
and composition of the whole cell [107]. However, in order to obtain a highly reproducible 
spectra, is indispensable to follow a strictly standardized protocol for isolates culture (media, 
time and temperature), sample preparation and spectra acquisition [108].  
 
¨  Different sampling techniques such as transmittance diffuse reflectance and attenuated total 
reflectance (ATR) are used in FTIR (Figure 1). In ATR mode, the sample is placed directly onto 
a crystal of relatively higher refractive index, needing little or no sample preparation. 
 
¨  The term “Fourier transform infrared spectroscopy” originates from the fact that a Fourier 
transform is required to convert the raw data (interferogram) into the actual spectrum. 
Moreover, to obtain a relevant picture of the relationships between spectra and assist in the 
classification process, several chemometric procedures that use mathematical methods can be 
applied. Are examples of these the supervised techniques (e.g. partial least squares 
discriminant analysis - PLSDA), that make use of a priori knowledge of classes to guide in the 
characterization or classification process, and the unsupervised methods (e.g. principal 
component analysis - PCA), that try to disclose naturally-occurring groups and structures 
within the data set without previous knowledge of class assignment [107,108]. 
BOX 
2 
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FIGURE 1. Schematic representation of the main spectroscopic methods used by FTIR 
spectroscopy. (A) FTIR transmission (B) Diffuse reflectance FTIR (C) FTIR-Attenuated Total 
Reflectance (reprinted with permission from [107]). 
 
This method was introduced into bacteriology in the 1970´s and, since then, has 
gained growing interest to detect and differentiate several microorganisms [bacteria (e.g. 
Staphylococcus spp., Enterococcus spp., Salmonella spp. and Escherichia spp. strains), 
yeast (e.g. Malassezia species), fungi (e.g. Candida species) and algae (e.g. order 
Sphaeropleales)] at different taxonomic levels, including for species identification [109–
117] [111,118–122]. Among Acinetobacter, FTIR spectroscopic typing started in 1995 with 
a collection of A. baumannii isolates [123] but, since then, their discriminatory power for 
the characterization of this genus has been poorly analysed [122,124]. The spectral region 
more used in these studies corresponds to the phospholipids/DNA/RNA and 
polysaccharides vibrations (1500-900 cm-1; Figure 2) for being the most discriminatory 
one [122,125]. 
FTIR is quick, low-cost, environmentally friendly, requires minimal sample 
preparation, no consumables or reagents and allows the analysis of small quantities of 
biomass [118,124].  
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FIGURE 2. Significant regions of bacterial spectra. 
 
MALDI-TOF MS (Box 3) is a high-throughput analytical technique based on the 
ionization and separation of ions according to mass-to-charge (m/z) ratio, yielding a 
characteristic fingerprint of a given microbial cell that reflects mostly the content of 
peptides and small proteins (mainly ribosomal proteins) (Figure 3) [126]. Over the past 
few years, MALDI-TOF MS has been spotlighted as a powerful tool for the identification, 
at genus and species level, of a broad spectrum of bacterial species (including Gram-
positive and Gram-negative), replacing the traditional biochemical or molecular 
techniques in many clinical microbiology laboratories worldwide [126,127]. Microbial 
identification is established by the comparison of the mass spectra obtained with those 
from known species included in a reference database. Moreover, MALDI-TOF MS has also 
been used to detect antibiotic resistance (e.g. for the detection of ESBL-producing [128] 
and carbapenemase-producing strains [129,130]); for environmental bacteriology, food 
and water quality control, occupational safety, detection and identification of agents of 
biological warfare, and others [131]. 
 
Principle of MALDI-TOF MS identification of microorganisms. 
¨ The sample is deposited on a metal plate and embedded in a matrix that crystallizes the 
analytes, being then bombarded by brief laser pulses that achieve the ionization (MALDI-TOF 
MS) by proton transfer from the matrix, which results in positively charged analytes; 
 
¨ The desorbed ions are then accelerated by an electrostatic field and directed in the flight tube, 
in which they are separated according to their time of flight (TOF) in the flight tube (with a high 
vacuum generated by a pump); 
 
BOX 
3 
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¨ Ions are detected at the exit of the flight tube, where a software generates a mass spectrum.  
 
¨ Microbial identification is established by the comparison of the mass fingerprint obtained 
(characteristic for each microorganism), directly from the colony or after using adequate 
extraction protocols, with those from known species included in a reference library [126,132]. 
 
 
 
FIGURE 3. Principle of MALDI-TOF MS (reprinted with permission from [132]). 
 
This method is easy to use, cost-effective, accurate, sensitive and rapid, with 
potential to enhance the implementation of infection control measures. A number of 
examples of the potential usefulness of this proteomic technology for the identification of 
microorganisms have been published [133,134]. However, the majority of these studies 
presented several flaws, since the current automatic MALDI-TOF MS databases, available 
for routine laboratories, do not cover all Acinetobacter species, being needed a 
chemometric analysis for an accurate species identification. Moreover, although many 
attempts have been made in order to adapt this technology also for the identification at 
the strain level [135], the great majority of the results obtained are still controversial, with 
many inconsistencies being observed even for the same species [136,137]. These could be 
due to the wide diversity of analysis workflows (e.g. variations in growth conditions, 
extraction methods, matrix, mass spectrometers and bioinformatics tools used for data 
analysis) and also because the closely related strains express many similar, if not the same, 
proteins [61,138]. Thus, one of the next challenges in the development and 
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implementation of MALDI-TOF MS for typing in the routine diagnostic workflow of 
clinical laboratories will be to standardize the procedures for cell culturing/preparation 
and data analysis (with a user-friendly software), in order to improve its inter-laboratory 
reproducibility, discriminatory power, robustness, resolution and portability [61].  
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1.1.3. Acinetobacter ecology 
 
 
“I fear all we have done is to awaken a sleeping giant and fill him with a 
terrible resolve.” 
Isoroku Yamamoto 
 
 
Acinetobacter species comprise a broad group of biochemically and physiologically 
versatile bacteria that are ubiquitous in nature and can be found in different ecological 
niches, such as environment, food, animals and humans. Thus, several Acinetobacter 
species appear in the environment (e.g. A. baylyi, A. towneri and A. gerneri from 
activated sludge, sewage and wastewater; A. seohaensis from seawater; A. soli from forest 
soil and A. johnsonii from water); in the food chain (e.g. A. calcoaceticus, A. pittii, A. 
lwoffii, A. bereziniae and A. soli from vegetables, raw meat, cheese and milk); in animals 
(e.g. A. variabilis from rectal cow samples; A. gandensis from horse and cattle, A. 
radioresistens and A. schindleri from head lice); and in humans (e.g. A. lwoffii, A. 
johnsonii, A. haemolyticus, A. radioresistens, A. pittii and A. junii as colonizers of skin 
and A. johnsonii and A. pittii from faecal samples) (Table 3) [139]. The ability to adapt to 
many ecological niches has led some authors to consider these bacteria as “microbial 
weeds” [140]. Despite the several descriptions of Acinetobacter spp. in the environment, 
animals and healthy humans, the precise environmental reservoirs are unknown. 
Recently, it has been shown that the environment could also constitute a potential 
reservoir for Acinetobacter spp. resistant isolates, being carbapenemase and extended-
spectrum β-lactamase (ESBL) producing strains isolated from, for example, soil of farms 
[141], municipal wastewater [142], and  in tap water and rivers [143,144]. Thus, further 
studies outside hospital units are of outmost importance for a precise definition of 
reservoirs and for elucidating the emergence of infections by MDR Acinetobacter spp.. 
In opposition to the other species, A. baumannii is mostly reported as an infection 
agent in the hospital setting, particularly in Intensive Care Units (ICUs), despite 
community-acquired infections may also occur [145,146]. Increasing evidence reveal a 
similar behaviour in the veterinary practice [143,147,148]. Moreover, many descriptions of 
occasional isolates of A. baumannii from non-human sources, such as animals, lice, 
vegetables, aquaculture and soils were also published [149–152] 
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1.1.4. Acinetobacter spp.: the emergence of the pathogen 
 
 
“In the field of biological weapons, there is almost no prospect of detecting a 
pathogen until it has been used in an attack.” 
Barton Gellman 
 
For many years, organisms belonging to the genus Acinetobacter were regarded as 
low-virulence bacteria. However, some species have become successful pathogens in the 
1970s (with the introduction of broad-spectrum antibiotics for Enterobacteriaceae 
treatment), with A. baumannii being now considered, by the World Health Organization 
(WHO) (http://www.who.int/en/), as one of the most serious ESKAPE organisms 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, A. baumannii, 
Pseudomonas aeruginosa and Enterobacter species), due to the emergence of drug-
resistant strains and an increased number of infections (with high mortality rates) 
[153,154]. Although A. baumannii is undoubtedly the main species associated with 
nosocomial infections, it is of note the fact that in recent years, we have assisted to 
increasing reports of infections (including outbreaks) and/or colonization caused by non-
baumannii Acinetobacter species [155]. Species like A. pittii [156], A. bereziniae [157], A. 
ursingii [158], A. johnsonii [159], A. junii [160], among others, have been entering in the 
clinical setting. Moreover, these species can also acquire and act as a source (silent in 
some cases) of resistance genes, contributing for their dissemination among different 
Acinetobacter species [161,162]. 
The majority of infections caused by A. baumannii are mostly hospital-acquired, 
commonly in the ICUs, with the major risk factors including recent exposure to 
antimicrobial agents (in particular carbapenems), presence of central venous or urinary 
catheters, mechanical ventilation, severity of illness, underlying malignancy, history of 
transplant, older age, prolonged hospital stays, or larger hospital size. In addition, this 
organism was also found colonizing inpatients from long-term care facilities (LTCFs) and 
as a cause of infections acquired in the community and in wounded military personnel 
[163,164]. The associated infections include, but are not limited to, pneumonia (both 
hospital and community-acquired), bacteraemia, endocarditis, skin and soft tissue 
infections, urinary tract infections and meningitis. In most cases, it is thought that the 
acquisition and spread of this organism inside the clinical settings is associated with 
contaminated equipment, contact with colonized patients and/or healthcare workers 
[165,166]. Healthcare workers, besides being considered important vehicles for infections 
transmission, could also be affected by infectious agents, e.g., by contact with patients, 
respiratory droplets, airborne spread, among others [167]. This risk may be enhanced by 
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factors such as the age or the presence of chronic diseases like diabetes, workload, 
overcrowded hospitals, and the pathogenic potential of the microorganism. To date, a case 
of a life-threatening pneumonia resulting in septic shock due to an A. baumannii 
transmission from a patient to a healthcare worker was reported [168]. 
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1.1.5. Overview of virulence features and antimicrobial resistance 
among Acinetobacter 
 
“With increasing resistance even to last-line antibiotics we face a frightening future 
where routine surgery, childbirth, pneumonia and even skin infections could once again 
become life threatening.” 
 
                   Vytenis Andriukaitis 
 
Important Acinetobacter spp. features, with emphasis on A. baumannii will be 
addressed in this section, in order to understand their clinical relevance and evolution 
towards MDR phenotypes.  
 
1.1.5.1. Virulence determinants 
 
Compared to other Gram-negative pathogens, relatively few virulence factors have 
been identified in Acinetobacter. Moreover, most known virulence factors of A. 
baumannii are found in its core genome and are also present in other Acinetobacter 
species, thus, in this section, we focused only on A. baumannii [169]. The recent 
sequencing of several complete genomes of this species, together with the use of animal 
models, have been crucial for shedding light on how this pathogen persists in the 
environment, interacts with host cells and causes host cell damage, although there are 
undoubtedly numerous additional factors that have yet to be identified [170].  
Table 3 summarizes the most common virulence factors identified, until now, in A. 
baumannii, and their main role in this species pathogenesis. 
 
TABLE 3. Virulence factors identified in A. baumannii and their proposed role in 
pathogenesis. Adapted from [168,170]. 
Virulence factor Description/Examples Proposed role in pathogenesis References 
Porins and efflux 
proteins 
OmpA, Omp22, Omp33-36, CarO, 
OprD-like and AceI 
Adherence and 
invasion, induction 
of apoptosis, serum 
resistance, surface 
motility, biofilm 
formation, 
persistence and 
chlorhexidine 
resistance 
[168,171,172] 
Phospholipases  Phospholipases- A (PLA), -C (PLC) 
and -D (PLD) 
Serum resistance, 
invasion, in vivo 
survival 
[173,174] 
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Virulence factor Description/Examples Proposed role in pathogenesis References 
Outer membrane 
vesicles (OMV) 
 Delivery of virulence 
factors, horizontal 
gene transfer 
[168,175–177] 
Metal acquisition 
systems 
Iron acquisition systems: 
enterolisin E, heme oxygenase, and 
siderophores like acinetobactin and 
fimsbactin A-F; Zinc acquisition 
system: ZnuABC, His-Zn complex 
and calprotectin; Manganese 
acquisition system: MumC and 
MumT 
In vivo survival, 
persistence, killing of 
host cells 
[178–184] 
Capsular 
polysaccharides (KL) 
KL variants (e.g. KL1, KL2, KL4) Growth in serum, 
survival in tissue 
infection, biofilm 
formation; evasion of 
host immune 
response, survival to 
desiccation 
[168,185,186] 
Lipopolysaccharides 
(LOS) 
LpsB, LpxC  Serum resistance, 
survival in tissue 
infection, evasion of 
the host immune 
response, antibiotic 
resistance by target 
alteration 
[168,170,187] 
Protein secretion 
systems 
Type II protein secretion system 
Type VI protein secretion system 
 
 
Type I secretion system (BapAb) 
Type V protein secretion system 
In vivo survival, 
export of effector 
proteins (e.g. LipA 
and CpaA); 
[168,188–191] 
Killing of competing 
bacteria, host 
colonization 
Biofilm formation, 
adherence 
Photoreceptors BlsA Motility, biofilm 
formation, killing 
ability 
[192,193] 
Pili systems Type I pili - Csu pili 
Type IV pili - Pilin subunit (e.g. 
fimbrial protein PilA) 
 
GacSA system - csu gene 
expression 
 
 
Adherence, surface-
associated and 
twitching motility, 
biofilm formation, 
horizontal gene 
transfer 
[194,195] 
 
 
The most well-characterized virulence factor identified to date in A. baumannii is 
probably the outer membrane protein A (OmpA), a porin that has been associated, in vivo, 
with pneumonia, bacteraemia and host cells death [196] and with a variety of interesting 
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biological properties identified in in vitro model systems [168]. OmpA interacts with 
peptidoglycan and has been shown that binds to host epithelia, target mitochondria, 
translocate to the nucleus, and induces cell death by promoting the release of pro-
apoptotic molecules, such as cytochrome C and apoptosis-inducing factor. Moreover, this 
porin also enhances surface motility, adherence, biofilm formation and resistance to the 
complement-mediated killing [197], being also considered a slow porin for β-lactams [198] 
and associated with antimicrobial resistance to chloramphenicol and nalidixic acid [171]. 
The low permeability of this porin, together with the presence of constitutive β-lactamases 
and multidrug efflux pumps, appears to be essential for the high levels of intrinsic 
resistance of A. baumannii to a high number of antibiotics [198]. OmpA also regulates 
biogenesis of outer membrane vesicles (OMVs) by controlling their production and 
protein composition [199].  
Other Omps have also been associated with cytotoxicity (and antibiotic resistance) 
in A. baumannii, although on a smaller scale. Some examples include the 33- to 36-kDa 
Omp protein (Omp33-36) and the carbapenem-associated outer membrane protein 
(CarO) and OprD-like (Table 2) [171,172]. 
 
Besides OmpA, the A. baumannii envelope is associated with many other factors 
that contribute to pathogenicity, like capsular polysaccharides (KL), glycosylated proteins, 
lipopolysaccharide (LOS) [184], and peptidoglycan. The KL (Box 4, Figure 4) is an 
extraordinary virulence factor, essential for bacterial adhesion, host colonization, survival 
in human serum, and also for enhancing resistance to phagocytosis, disinfection and 
desiccation [168,200]. This structure can even be considered the main virulence factor of 
A. baumannii as strains lacking the capsule are avirulent and readily killed by 
complement [201]. All KL gene clusters described for A. baumannii have similar general 
genetic organization with differences found predominately in the central sugars region. In 
other species, like in K. pneumoniae, capsular types are related to the severity of infection 
[186]. Although the knowledge on the prevalence of specific capsular types in each A. 
baumannii-related diseases could be crucial for disease control and prevention (e.g. for 
the development of capsule-based vaccines), little is known to date for this species. 
 
A. baumannii capsule biosynthesis. 
 
          KL: capsular polysaccharide; long-chain polymer composed of oligosaccharide repeats 
synthesized under the direction of genes clustered at the chromosomal KL locus [located between 
lipid II flippase (mviN) and L-lactate dehydrogenase (lldD) genes] [185]. 
 
          Synthesis of capsule begins with the synthesis of the repeat unit in the cytoplasm. A pre-
BOX 
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formed sugar precursor is linked to the undecaprenyl phosphate (UndP) lipid carrier by an 
initiating transferase (Itr) and then, substrate-specific glycosyltransferases (Gtr) sequentially link 
sugars to complete the oligosaccharide, which is translocated across the membrane by the Wzx 
flippase. The Wzy polymerase links the capsular units together to form the KL, which is then 
exported from the periplasm to the cell surface by Wza, Wzb and Wzc [185].  
 
FIGURE 4. Examples of A. baumannii capsule biosynthesis gene clusters. Colour scheme shown 
below corresponds to the function of the gene products, and functions of enzymes encoded by gene 
modules are shown above. Reprinted with permission from [202]. 
 
The lipopolysaccharide (LPS), the major component of the outer membrane leaflet 
and a hallmark of gram-negative bacteria, in Acinetobacter presents an important 
structural difference, lacking the O antigen. Thus, is called lipooligosacharide (LOS), being 
also an important virulence factor. The role of LOS in A. baumannii pathogenesis was 
investigated using a mutant lacking the LpsB glycotransferase that results in a highly 
truncated LOS glycoform showing decreased resistance to human serum and decreased 
bacterial survival in a rat model of soft tissue infection [187]. Moreover, many studies have 
shown that modifications in LOS decrease the susceptibility of A. baumannii to many 
clinical important antibiotics, such as colistin, reflecting an important role for the surface 
carbohydrate residues of LOS in virulence and survival [168]. 
 
Bacterial phospholipases are lipolytic enzymes essential for phospholipid 
metabolism. Degradation of phospholipids affects the stability of host cell membranes, 
and the cleaved head group can interfere with cellular signalling by generating second 
messengers (e.g. phosphatidic acid), that results in changes in the host immune response 
[173]. In A. baumannii, phospholipases C (cleave the phosphorylated head group from the 
phospholipid) and D (cleave off only the head group of phospholipid after its release by 
phospholipase C) have been identified as virulence factors, being responsible for survival 
in human serum and epithelial cell invasion [174,203].  
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Outer membrane vesicles (OMVs) are spherical vesicles (20 to 300 nanometers in 
size), whose formation is triggered by the reduction in the cross-linking between 
peptidoglycan and the outer membrane [175]. They are secreted by the outer membrane of 
various Gram-negative bacteria, including Acinetobacter species [188], and are composed 
of LOS, outer membrane and periplasmic proteins, phospholipids and DNA, or RNA 
[168]. Stresses such as high temperature, or presence of antibiotics seem to increase OMV 
formation [204]. OMVs are recognized as delivery vehicles for bacterial effectors to host 
cells allowing inter- and intra-species communication and strengthening the interaction 
with the host [204]. In A. baumannii they were originally identified as the secretion 
platform for OmpA but this species also secrete OMVs containing other virulence factors, 
including phospholipases, proteases and catalase (which induce cellular damage or innate 
immune responses) and toxins [168,188]. Interestingly, some works have reported other 
functions for A. baumannii OMVs, related with the spread of antibiotic resistance by 
horizontal transfer of the OXA-24, OXA-58 and NDM-1 carbapenemase genes 
[176,177,205]. OMVs also participate in quorum sensing, transfer of nutrients, as well as 
adsorption of antibiotic peptides for the survival of bacterial population [206,207]. It has 
also been demonstrated that OMVs can deliver bacterial proteins directly to the host cell 
cytoplasm via fusion of the OMV with lipid rafts on the host cell membrane, which 
suggests that one function of OMVs may be the transport of bacterial products over long 
distances [206].  
 
Siderophores are high-affinity iron-chelating compounds produced by bacteria to 
overcome iron limitation, since this metal is one of the essential nutrients for host and 
bacteria but it is rarely found in a free form [178]. Siderophores are classified into three 
major groups: catecholates, hydroxamates and carboxylates, based in the ligands that are 
used to chelate the ferric iron [179]. Acinetobactin, a catechol-hydroxamate siderophore 
composed of 2,3-dihydroxybenzoic acid (DHBA), L-threonine and N-hydroxyhistamine, is 
the best-characterized siderophore from A. baumannii [69]. The gene cluster responsible 
for acinetobactin production and transport is composed of three systems: 
basABCDEFGHIJ for acinetobactin biosynthesis, barAB for acinetobactin release, via a 
efflux system of the ATP-binding cassette (ABC) transporters superfamily, and 
bauABCDEF for movement of ferric-acinetobactin complexes into bacterial cells via a 
receptor [180]. Under iron-limited conditions the genes involved in the biosynthesis and 
transport of acinetobactin are usually significantly up-regulated [195]. Moreover, the 
acinetobactin production/expression occurs more frequently in MDR/XDR A. baumannii 
isolates [69]. The concentration of extracellular free iron is also a factor that affects the 
amount of biofilms formed on surfaces. In fact, A. baumannii clinical isolates showed a 
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significant reduction in adhesiveness and biofilm formation ability on biotic and abiotic 
surfaces, when grown in the presence of an iron-chelating agent [208].  
 
A. baumannii has a high capacity to survive and prosper in the harsh hospital 
environment, mostly due to its ability to interact, adhere and colonize different types of 
surfaces, including desiccated abiotic ones (e.g. medical equipment like catheters), as well 
as biotic surfaces (e.g. human epithelial cells) [170]. Although the desiccation resistance is 
multifactorial and not yet fully defined, a few studies point out for the importance of 
capsular polysaccharides for survival during periods of desiccation [200]. Moreover, and 
since desiccation-rehydration causes various DNA lesions and induces oxidative stress, A. 
baumannii relies on the protective role of the RecA protein (an enzyme required for 
homologous recombination and recombination repair) and also substantially upregulates 
proteins associated with detoxifying reactive oxygen species [209]. 
Generally, the adherence of A. baumannii to biotic and abiotic surfaces results in 
the development of biofilms, which are complex multicellular three-dimensional 
structures with cells in intimate contact with each other and encased in an extra-cellular 
matrix that can be comprised of carbohydrates, nucleic acids, proteins, and other 
macromolecules [210]. Adhesiveness and biofilm formation has been linked to increased 
antimicrobial resistance, resistance to desiccation and disinfection, and, therefore, 
represents an important virulence factor [211]. A number of environmental conditions and 
A. baumannii gene products have been shown to play a role in biofilm formation and 
adherence on both abiotic and biotic surfaces. For the initial steps of bacterial attachment 
and microcolony formation are required pili-like structures whose production is mediated 
by the CsuA/BABCDE usher-chaperone assembly system [regulated by a two-component 
system constituted by the sensor kinase (bfmS gene) and the response regulator (bfmR 
gene)] [212]. Moreover, a second two-component system termed GacSA has been shown 
to moderately control csu gene expression and thus indirectly biofilm formation [213]. 
The bacterial adhesin BapAb (biofilm-associated protein), expressed on the cell 
surface and conserved among different clinical isolates, appears to be needed for cell-to-
cell interactions and intercellular adhesion that support biofilm development and 
maturation [211]. The two latter processes also depend on the capacity of A. baumannii 
clinical isolates to produce and secrete poly-β-1-6-N-acetylglucosamine (PNAG). This 
major component of the biofilm exopolysaccharide matrix (that provides adhesion 
between bacterial cells) is encoded by a cluster of four genes (pgaABCD), produced by 
almost all clinical strains, being critical for the grow and formation of fully developed 
biofilms [214]. Several surface proteins, like OmpA, are also involved in the process, 
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contributing to the attachment of cells and development of biofilms in biotic (e.g. human 
alveolar epithelial cells) and abiotic (e.g. plastic) surfaces [211].  
Light, in particular blue light, seems to affect several aspects of A. baumannii 
physiology such as motility, virulence and biofilm production. In what concerns biofilms, 
blue light seems to inhibit their formation. This response is mediated by the BlsA 
photoreceptor protein, which contains a N-terminal blue-light sensing-using flavin 
(BLUF) domain [192]. The mechanisms by which BlsA transduces the light signal and 
controls gene expression are not yet well known. However, it has been demonstrated that 
the diverse transcription of blsA gene at 28ºC and 37ºC differentially affects the response 
of A. baumannii biofilm to the light. Ethanol has also been reported to affect biofilm 
formation and motility on abiotic surfaces, enhancing the first and decreasing the second 
[215]. Moreover, physiological concentrations of ethanol found in the bloodstream of 
individuals with a history of alcohol use disorder sufficiently impair phagocytosis and thus 
elimination of A. baumannii [216]. Both clinical and environmental isolates of 
Acinetobacter spp. were reported to produce quorum-sensing (QS) signal molecules (e.g. 
N-acyl-homoserine lactone) by which bacteria control adhesiveness, biofilm formation 
and activate adaptations in response to nutrient conditions and cell population density 
[217,218].  
 
 
1.1.5.2. Antimicrobial resistance 
 
 
Since their introduction into medicine about 70 years ago, antibiotics are arguably 
the most powerful drugs in medicine. However, their success also threatens to be their 
downfall [219]. Antimicrobial resistance (see Box 5 to review concepts about this topic) is 
considered one of the major threats to human health by several world health entities, such 
as the WHO and the European Centre for Disease Prevention and Control (ECDC) [220]. 
This grim scenario results from the extraordinary adaptation of bacteria to selective 
pressures, mainly caused by the intensive use of antibiotics [not only in human medicine 
but also in non-human applications (e.g. in animal husbandry)], as well as the greater 
movement of people and the increased industrialization (Figure 5) [153,219,221,222]. In 
fact, several classes of antimicrobials may accumulate in diverse environments/hosts 
under non-lethal (sub-inhibitory) concentrations, which may provide a constant selection 
pressure for maintenance of particular pathogenic bacteria, such as Acinetobacter spp. 
strains or clones carrying antibiotic resistance genes and other adaptive features 
associated with survival or improved host and environmental colonization ability 
[221,222]. 
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FIGURE 5. Overview of antibiotics cycle among different environments, such as clinical 
setting, agriculture, aquaculture, pharmaceutical industry and the wider environment 
(adapted from [222]).  
Glossary of concepts related with antibiotic resistance in  
Acinetobacter spp. 
          The susceptibility of a microorganism to a particular antibiotic can be quantified by 
phenotypic tests such as the determination of the minimum inhibitory concentration (MIC), which 
is the lowest concentration of an antimicrobial agent that completely inhibits the growth of 
bacterial cells. The use of clinical breakpoints (calculated based on MIC distributions, clinical 
outcome data, accepted dosing and pharmacokinetic/pharmacodynamics data) is useful to define 
the clinical resistance, used by clinicians to access the likelihood of therapeutic outcome in 
human patients (Figure 6). Thus, based on clinical breakpoints, the isolate is defined as: resistant 
(level of antimicrobial activity associated with a high likelihood of therapeutic failure), 
intermediate (level of antimicrobial activity associated with uncertain therapeutic effect) or 
susceptible (level of antimicrobial activity associated with a high likelihood of therapeutic 
success), according to annual published guidelines and recommendations such as those published 
by the Clinical & Laboratory Standards Institute (CLSI - http://clsi.org/), the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST - http://mic.eucast.org/Eucast2/) or other 
national organisms [e.g. British Society for Antimicrobial Chemotherapy (BSAC - 
http://www.bsac.org.uk)]. 
          Epidemiological resistance is defined using epidemiological cut-offs (ECOFFs) 
values (Figure 6). ECOFFs are the MIC values that correspond to the upper-limit of the wild-type 
population (population without any acquired resistance mechanism to a particular antibiotic) of a 
Humans travel 
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bacterial species. ECOFFs can be applied to distinguish within a particular species the strains with 
(non-wild-type) or without (wild-type) resistance mechanisms 
(https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=init). 
 
 
FIGURE 6. Clinical and epidemiological breakpoints of susceptibility to antibiotics (reprinted 
with permission from reference [223]).  
          A bacterial isolate is considered non-susceptible to an antimicrobial agent if results resistant 
or intermediate when using clinical breakpoints as interpretive criteria, and not epidemiological 
cut-offs. Only acquired antimicrobial resistance was taken into consideration in creating definitions 
for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) 
isolates [224]. The criteria for defining MDR, XDR and PDR in Acinetobacter spp. according to an 
international expert proposal to standardise definitions for acquired resistance (Figure 7) [224] is: 
• MDR: non-susceptibility to ≥1 agent in ≥3 antimicrobial categories. 
• XDR: non-susceptibility to ≥1 agent in all but ≤2 antimicrobial categories. 
• PDR: non-susceptibility to all antimicrobial agents. 
 
 
FIGURE 7. Diagram showing the relationship of MDR, XDR and PDR to each other. Adapted from 
[224]. 
 
Chapter 1 - Introduction 
      35 
As previously mentioned, among Acinetobacter species, A. baumannii has become 
one of the most successful pathogens in modern healthcare, partly because of its natural 
reduced susceptibility to antibiotics and amazing ability to acquire new resistance 
determinants. Antimicrobial resistance among Acinetobacter vary with species, the type of 
antibiotic and geographical location, and is either intrinsic, explained by the low 
permeability of the outer membrane, the constitutive expression of some efflux pumps 
and the presence of some intrinsic β-lactamases or acquired, due to the presence of β-
lactamases, aminoglycoside-modifying enzymes, efflux pumps, permeability defects and 
modifications on target sites [167,168]. The accumulation of these resistance mechanisms 
has progressively increased since the 1970s, at which time the vast majority of strains were 
sensitive to commonly used antibiotics. Nowadays, often in several countries, only a small 
number of therapeutic options are available to treat Acinetobacter infections, with 
descriptions of resistance to all antibiotics also reported [225].  
Combined resistance to fluoroquinolones, aminoglycosides and carbapenems was 
the most frequently reported resistance phenotype in 2016, accounting for almost half of 
the reported isolates in European countries (Figure 8). This is an indication of seriously 
limited options for the treatment of patients infected with Acinetobacter spp. [220].  
 
 
 
FIGURE 8. Percentage of Acinetobacter spp. invasive isolates with combined resistance 
to fluoroquinolones, aminoglycosides and carbapenems, European Union/European 
Economic Area, 2013 (left), 2016 (right) [220]. The antibiotic resistance in this bacterium 
shows large variations across Europe, with generally high resistance percentages reported 
from the Baltic countries and southern/south-eastern Europe. 
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In the next section will be summarized the major resistance mechanisms for the 
different classes of antibiotics that have been identified in Acinetobacter spp. (Table 4), 
with special details for resistance to β-lactams. 
 
1.1.5.2.1. Resistance to β-lactams 
 
β-lactams (see Box 6 for details) are the most widely used bactericidal antibiotics 
in clinical practice worldwide, with carbapenems being the main therapeutic option for 
the treatment of infections caused by Acinetobacter isolates. However, over the last two 
decades, resistance to this class of antibiotics has been extensively reported, becoming a 
serious public health problem. 
Mechanisms of action, classification and spectrum  
of activity of β-lactam antibiotics  
 
          Mechanisms of action: β-lactam antibiotics are characterized by the presence of a β-
lactam ring in their core structure. Their targets are the bacterial penicillin binding proteins 
(PBPs) (e.g. transpeptidases), which are involved in the biosynthesis of peptidoglycan layer, the 
main component of the bacterial cell wall. The β-lactam ring binds to these different PBPs, 
rendering them unable to perform their role and leading to bacterial death by osmotic instability or 
autolysis (Figure 9). For these reasons, β-lactams are considered bactericidal antibiotics.  
          Classification: According to their chemical structure, β-lactams are divided into four 
families: 1) penicillins (e.g. amoxicillin, ampicillin, ticarcillin, piperacillin, mecillinam); 2) 
cephalosporins (1st-5th generation, e.g. ceftriaxone, ceftazidime, cefotaxime, cefepime, 
ceftaroline); 3) carbapenems (e.g. imipenem, ertapenem, meropenem, doripenem); and 4) 
monobactams (e.g. aztreonam) (Figure 10).  
 
FIGURE 9. β-lactams target interactions and associated cell death mechanisms (reprinted with 
permission from [226]).  
BOX 
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FIGURE 10. Chemical structure of β-lactams (reprinted from 
http://tmedweb.tulane.edu/pharmwiki/doku.php/antibiotic_pharmacology). 
 
Acquired resistance to β-lactams in Acinetobacter spp. can occur due to 
enzymatic (β-lactamases) or non-enzymatic mechanisms (loss of or decrease in the 
expression of porins and/or increased expression of efflux pumps) (Table 4). Inactivation 
of β-lactams by β-lactamases is a major antibiotic resistance mechanism in Acinetobacter 
spp. and, based on sequence homology, these enzymes are grouped into molecular classes, 
A, B, C and D. Classes A, C and D are serine-dependent enzymes with a serine moiety at 
the active site, whereas class B enzymes require divalent metal cations as cofactors (e.g. 
Zn2+), being designated metallo-β-lactamases (MBLs). Most of these enzymes are 
associated with mobile or mobilizable genetic elements, such as insertion sequences (ISs) 
and integrons (see section 1.1.5.2.3.1 for more details), which could lead to enzyme 
production and dissemination [168,227]. 
 
v Enzymatic mechanisms: 
 
Class A β-lactamases: A number of class A β-lactamases, including TEM, SHV, GES, 
CTX-M, SCO, PER, VEB, KPC and CARB have been identified in A. baumannii (Table 4). 
Class A β-lactamases inhibited by clavulanate hydrolyse penicillins and cephalosporins 
more efficiently than carbapenems, except for some variants of KPC and GES enzymes 
[228]. Some of these enzymes (e.g. TEM-1, CARB-4 and SCO-1) are narrow-spectrum β-
lactamases, whereas others (e.g. PER-1, TEM-92, CARB-10, SHV-5, PER-2, CTX-M-2, 
CTX-M-15, VEB-1, GES-14 and PER-7) are ESBLs which in addition were detected in non-
baumannii isolates (e.g. PER-1 and SCO-1) [229]. GES and KPC carbapenemases have 
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been observed in A. baumannii mainly from Mediterranean and Middle East countries 
[230,231] and in Latin America [232], respectively. 
 
Class B β-lactamases: This family includes the enzymes IMP, VIM, SIM, SPM and 
NDM (Table 4), which are inhibited in vitro by ethylenediaminetetraacetic acid (a chelator 
of Zn2+ and other divalent cations) but not by clavulanic acid. These enzymes catalyse the 
hydrolysis of all β-lactam antibiotics (with exception of aztreonam), conferring high levels 
of resistance to carbapenems and can be located either in the chromosome or in plasmids. 
MBL-producing Acinetobacter spp. have been reported in clinical and non-clinical niches, 
mainly in Asian and European countries, including in Portugal (Figures 11 and 13) 
[229,233,234]. 
 
 
 
 
FIGURE 11. Global distribution of carbapenemases (class B) reported in Acinetobacter 
spp. in clinical niches.  
 
Class C β-lactamases: This class of β-lactamases poses therapeutic problems because 
they can confer resistance to penicillins, cephalosporins, cephamycins and β-lactamase 
inhibitor combinations, such as clavulanic acid. A. baumannii has an intrinsic AmpC 
cephalosporinase, also called ADC (for Acinetobacter derived cephalosporinase). Several 
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allelic variants of this enzyme have been reported in A. baumannii with some of them 
being also found in non-baumannii Acinetobacter species (Table 4) (e.g. ADC-5, ADC-12 
to -23 in A. pittii and ADC-8 in A. baylyi) [229,235,236]. 
 
Class D β-lactamases: These enzymes are also called oxacillinases - OXAs (in reference 
to their preferred substrate oxacillin). In Acinetobacter species, carbapenem-hydrolysing 
class D β-lactamases (CHDLs) have been largely identified (including in the environment), 
being more frequently than class B carbapenemases [237]. Currently, more than 500 
different OXAs are known, with many variants possessing carbapenemase activity 
(https://www.lahey.org/Studies/).  
The first acquired CHDL with carbapenemase activity - the OXA-23 enzyme – was 
identified in 1985 in Edinburgh, in a multidrug-resistant A. baumannii clinical isolate 
[238]. In the following years, this enzyme and its 26 closely related derivatives (Table 4) 
have been disseminated worldwide, either in clinical and non-clinical niches (Figures 12 
and 13), being the blaOXA-23 gene identified as part of various transposon (Tn) structures, 
namely Tn2006, Tn2007, Tn2008, Tn2008B and Tn2009, with plasmid and/or 
chromosomal location in A. baumannii and non-baumannii isolates. Interestingly, the 
natural reservoir of this gene has been identified as A. radioresistens, a commensal 
species which is usually identified on the skin of hospitalized and healthy patients 
[239,240]. 
A second group of CHDLs identified on either the chromosome or plasmids in 
Acinetobacter species comprises OXA-24/40 and its 7 derivatives (Table 4). OXA-24/40 
producers were originally recovered in carbapenems-resistant A. baumannii isolates in 
Spain, France, and Portugal, but after that have also been reported worldwide (e.g. USA, 
Bulgaria, China), including in non-baumannii species (e.g. A. haemolyticus and A. 
calcoaceticus) (Figures 12 and 13) [241–244]. Although some authors considered that 
OXA-24/40 show weak activity against cephalosporins and the carbapenems [241], other 
studies revealed high levels of carbapenems resistance when this enzyme was acquired by 
a susceptible strain [245]. 
A third group of CHDLs, represented by OXA-58 and its 3 variants (Table 4), was 
first identified in France in 2003 [246]. These enzymes have weak activity against 
penicillin and carbapenems and ability to hydrolyse cefpirome and cephalothin but not 
ceftazidime, cefotaxime or cefepime [241]. Like blaOXA-23, epidemiological surveys have 
identified the blaOXA-58 gene in worldwide isolates of A. baumannii, being plasmid-
encoded and associated with specific ISs (but are not part of Tns). These ISs play a role in 
enhancing expression of these enzymes but not in their encoding genes acquisition, which 
seems to occur by homologous recombination. OXA-58 has also been identified in other 
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Acinetobacter species, such as A. junii [247], A. pittii [248], A. johnsonii [249] and 
Acinetobacter genomospecies 14TU (Figures 12 and 13) [229]. 
OXA-143, a fourth group of acquired OXA-type β-lactamases, was discovered in 
Brazil in 2004. As with other acquired OXA-type β-lactamases, the enzyme kinetics for 
OXA-143 showed low levels of carbapenems hydrolysis. To date, this group of enzymes 
(that includes more 4 amino acid variants), has been identified only in A. baumannii and 
A. pittii isolates from Brazil, USA, South Korea and Iran and only on plasmids (Figure 12) 
[250–254]. 
OXA-235, and the amino acid variants OXA-236, OXA-237 and OXA-278, were 
identified in A. baumannii isolates from the USA and Mexico, and also represent a novel 
subclass of OXAs with carbapenemase activity (Figure 12) [255]. 
Besides the acquired CHDLs, A. baumannii naturally produces chromosomally-
encoded OXA-51-group carbapenemases (the largest group of OXA-type β-lactamases 
identified), some of which could confer resistance to carbapenems when the genetic 
environment flanking the gene promoted its expression [241] or due to point mutations 
leading to resistance (e.g. OXA-82) [256]. Other Acinetobacter species also present 
naturally occurring OXAs, such as A. haemolyticus (OXA-214-like), A. lwoffii (OXA-
134-like), A. johnsonii (OXA-211-like), A. radioresistens (OXA-23-like), A. 
calcoaceticus (OXA-213-like), A. bereziniae (OXA-229), and A. schindleri (OXA-235), 
which, however, do not confer resistance to carbapenems (Table 4). 
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Figure 12. Global distribution of acquired class D carbapenemases reported in 
Acinetobacter spp. in clinical niches.  
 
 
 
 
FIGURE 13. Global distribution of acquired carbapenemases (classes B and D) reported 
in Acinetobacter spp. in non-clinical niches [257–265]. 
 
v Non-Enzymatic mechanisms: 
 
Resistance to β-lactams in A. baumannii may be enhanced by the association of β-
lactamases with non-enzymatic mechanisms, including alterations on membrane 
permeability (decrease or absence of porins, overexpression of efflux pumps). Besides the 
naturally reduced membrane permeability displayed by A. baumannii when compared to 
other Gram-negative organisms (which might be explained by the small number and size 
of porins), several reports have associated reduced expression of some porins with 
antimicrobial resistance in this bacterium. These include several Omps, such as the OmpA 
(also found in other Acinetobacter species like A. radioresistens and A. junii), the Omp22-
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33, Omp33-36, Omp37, Omp43, Omp44, Omp47 and CarO (Table 4). Besides outer 
membrane proteins, envelope components, such as LOS and peptidoglycans, also 
contribute for antibiotic resistance in A. baumannii (e.g. loss or modification of LOS 
decreases membrane integrity and increases colistin resistance) [168,227].  
 
Antimicrobial efflux is another important mechanism of resistance in 
Acinetobacter spp. In general, efflux constitutes a resistance mechanism that involves the 
extrusion of antimicrobial agents (as well as other compounds) from the inner side of 
bacterial membranes to the external environment by means of specific proteins typically 
named efflux pumps. Although only a few efflux systems have been described in this 
genus, they contribute to the greatly feared MDR phenotype of nosocomial Acinetobacter 
species [266]. The vast majority of studies regarding efflux in Acinetobacter spp. are 
focused on A. baumannii and very little is known about both the presence and the impact 
of this resistance mechanism in other Acinetobacter species [229]. Among the six 
categories of efflux pumps that have been associated with antimicrobial resistance in A. 
baumannii, the most prevalent belong to the resistance-nodulation-division (RND) 
superfamily: AdeABC, AdeFGH and the AdeIJK efflux pumps (Figure 14) [237]. The 
expression of each pump is tightly regulated by different mechanisms: AdeABC is 
controlled by a two-component regulatory system AdeRS, encoded by the genes adeR 
(regulator gene) and adeS (sensor kinase), AdeFGH is regulated by the LysR-type 
transcriptional regulator Ade, and the AdeIJK by the TetR-type transcriptional regulator 
AdeN. Mutations in these regulatory systems lead to the constitutive overexpression of the 
corresponding efflux pumps [associated with decreased susceptibility to a wide variety of 
antimicrobials such as aminoglycosides, tetracyclines, chloramphenicol, and meropenem 
(Table 4)]. Moreover, the AdeIJK is considered to have a predominant role in the intrinsic 
low-level resistance phenotype of A. baumannii to a broad range of antibiotics, that 
includes β-lactams, fluoroquinolones, tetracyclines (tigecycline), macrolides 
(lincosamides), chloramphenicol, antifolates and fusidic acid [267]. Two additional RND 
efflux systems were described among non-baumannii species, AdeDE (lacking the outer 
membrane protein gene) and AdeXYZ in A. pittii [229,266]. It is also important to 
highlight that these mechanisms may also affect other antibiotic classes. 
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FIGURE 14. Schematic representation of multidrug transporters from the six identified 
multidrug-resistant superfamilies’ in Acinetobacter (Table 3). Arrows indicate the 
pathway of the drug or proton (or ATP)-dependent transport. Pi, inorganic phosphate. 
Reprinted with permission from [268]. 
 
1.1.5.2.2. Resistance to aminoglycosides, tetracyclines, 
fluoroquinolones and polymyxins 
 
 
Aminoglycosides are a class of bactericidal antibiotics first developed in the 
1940s, that bind to the 16S ribosomal RNA of the 30S ribosomal subunit, inhibiting 
protein synthesis (Figure 15). These antibiotics can be used parenterally (gentamicin, 
tobramycin and amikacin), orally (neomycin), by inhalation through a nebulizer 
(tobramycin) and by intraperitoneal and intraventricular administration (gentamicin) 
[269]. Despite the nephrotoxicity and ototoxicity associated, this class remains an 
important alternative therapy for infections caused by MDR strains, usually in 
combination with other antimicrobials [168]. However, many MDR A. baumannii isolates 
may produce one or more aminoglycoside modifying enzymes (acetyltransferases, 
phosphotransferases and adenylyltransferases), that lead to aminoglycoside resistance 
and are usually associated with class 1 integrons harbouring additional antibiotic 
resistance genes (Table 4). Additionally, a 16S ribosomal RNA methyltransferase ArmA 
enzyme can confer high levels of resistance to all aminoglycosides [227,270,271]. 
Moreover, overexpression of efflux pumps such as AdeABC and AbeM (MATE family) also 
contributes for aminoglycoside resistance (Table 4). This scenario is worsen by the fact 
that some A. baumannii lineages have the ability to develop heteroresistance, a 
phenomenon in which different bacterial cells within the same population present diverse 
responses to the antibiotic, thus contributing for the therapeutic failure [272–274]. 
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FIGURE 15. Aminoglycosides mechanism of action (reprinted with permission from 
[226]).  
 
 Tetracyclines and glycylcyclines are a broad-spectrum classes of 
bacteriostatic antibiotics that present a similar mechanism of action [226,275]. They cause 
conformational changes to the RNA by binding to the 30S ribosomal subunit inhibiting 
protein synthesis. Tetracyclines class includes tetracycline, doxycycline and minocycline, 
while glycylcycline includes tigecycline (a semisynthetic derivative of minocycline) [275]. 
Among Gram-negative organisms, the main mechanisms leading to tetracycline resistance 
are mediated by active efflux pumps or target protection by production of Tet proteins that 
bind to the 70S ribosomal subunit. In vitro, efflux pumps seen in A. baumannii are 
effective in transporting out tetracycline and doxycycline, with the exception of the TetB 
pump which is ineffective in transporting out minocycline, remaining this antibiotic 
(especially if combined with colistin) as a good treatment option for difficult to treat MDR 
Acinetobacter infections, mainly if combined with colistin) [275].  
 Tigecycline was synthetically designed to overcome these efflux pumps being active 
in the presence of TetA or TebB. However, rapid development of different resistance 
mechanisms was observed, being actually associated with the tetX gene and, perhaps most 
importantly for A. baumannii, the overexpression of various efflux pumps (AdeABC, 
AdeIJK, AdeFGH, AbeM, AdeDE) and the upregulation of the macrolide export ATP-
binding/permease protein MacB (which is part of the tripartite efflux system MacAB-
TolC) [276,277]. Moreover, some studies with A. baumannii isolates have revealed that a 
deletion mutation in the trm (which encodes S-adenosyl-L-methionine-dependent 
methyltransferase), and a frameshift mutation in plsC (encoding 1-acyl-sn-glycerol-3-
phosphate acyltransferase) genes, decreases susceptibility to this antibiotic, although the 
exact mechanism was not determined [168,278]. 
 
Fluoroquinolones are broad-spectrum bactericidal agents (e.g. levofloxacin and 
ciprofloxacin) that act by binding to bacterial gyrase (encoded by gyrA and gyrB genes) 
and topoisomerase IV (encoded by parA and parC genes) enzymes (Figure 16). Mutations 
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in the target sites of fluoroquinolones have been extensively reported in A. baumannii 
[278]. In particular, mutations resulting in a Ser-86-Leu substitution in GyrA, and a Ser-
80-Leu substitution in ParC increase the MICs of ciprofloxacin in clinical isolates. In A. 
baumannii were also found active efflux by efflux pumps of the RND, SMR and MATE 
families, responsible for fluoroquinolones resistance (Table 4) [227,279]. All of these 
mechanisms are chromosomally-encoded and, to date, no plasmid-mediated 
fluoroquinolones resistance determinants have been identified in A. baumannii. 
 
  
FIGURE 16. Quinolone antibiotics interfere with changes in DNA supercoiling by 
binding to topoisomerase II or topoisomerase IV (reprinted with permission from [226]).  
 
Polymyxins are lipopeptide bactericidal antibiotics that interact with lipid A, the 
lipid anchor of LOS of outer membrane of Gram-negative bacteria leading to disruption of 
membrane, and thereby promoting cell death (Figure 17) [280]. In general, they have a 
narrow-spectrum, as they are active against common Gram-negative bacteria (e.g. 
Acinetobacter spp., Klebsiella spp., Citrobacter spp.). These antibiotics, that include 
colistin (polymyxin E) and polymyxin B, originally discovered in 1940, were abandoned in 
1970 due to the high incidence of nephrotoxicity and neurotoxicity, but have been recently 
re-introduced as last resort drug in the treatment of infections caused by XDR Gram-
negative bacteria [281]. Polymyxin resistance remains relatively rare in A. baumannii 
though it can develop after treatment with colistin, in particular in monotherapy. In A. 
baumannii, colistin resistance manifests either through lipid A modifications or by the 
complete loss of LOS, both of which alter the binding affinity of colistin. Most commonly, 
colistin-resistant clinical isolates harbour mutations in the two-component regulatory 
system PmrAB, associated with the addition of phosphoethanolamine (PEtN) by PmrC 
and galactosamine (GalN) to lipid A, which presumably alters the binding affinity of 
colistin (Figure 17). The addition of GalN is dependent on the deacetylase activity of NaxD, 
which is regulated by the PmrAB system [184]. Moreover, the dual activity of the lipid A 
biosynthesis lauroyltransferase LpxM leads to the constitutive expression of a 
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predominately hepta-acylated form of LOS, providing increased resistance against 
colistin. In extreme cases, A. baumannii will acquire mutations in the lipid A biosynthetic 
pathway, thereby halting its production. In the absence of lipid A, A. baumannii has been 
shown to upregulate lipoproteins, namely, A1S_1944, A1S_1945 and A1S_2739, which 
stabilize the outer membrane. The accumulation of the capsular polysaccharide poly-β-
1,6-N-acetylglucosamine (PNAG) has also been observed in strains lacking lipid A as a 
proposed mechanism of membrane stabilization [184]. 
 
 
 
FIGURE 17. Colistin resistance mechanisms of A. baumannii (reprinted with permission 
from [184]). Abbreviations: lpxA, acyl-[acyl-carrier-protein]-UDP-N-
acetylglucosamine O-acyltransferase, lpxC, UDP-3-O-acyl-N-acetylglucosamine 
deacetylase, lpxD, UDP-3-O-acylglucosamine N-acyltransferase. 
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1.1.5.2.3. Acquisition and dissemination of antimicrobial resistance 
 
1.1.5.2.3.1. Genetic support and expression of antimicrobial resistance 
genes 
 
The high genetic plasticity presented by Acinetobacter and particularly in A. 
baumannii, contributed for the accumulation of many resistance determinants, which 
resulted in the emergence of MDR strains. One plausible explanation for this capacity is 
the reduction, or even complete loss of the so called CRISPR-Cas systems. These systems, 
which are similar to an adaptive immune system, can protect bacteria from foreign genetic 
elements such as plasmids and bacteriophage phages infection and thus, their loss would 
enable bacteria to acquire genetic elements more easily [285]. In fact, it is proposed, not 
only for Acinetobacter, but also for other critical bacterial pathogens such as E. 
faecalis and K. pneumoniae inverse correlations between antibiotic resistance and the 
presence of CRISPR-Cas loci [286].  
Acinetobacter genomes display a wide variety of mobilizable and mobile genetic 
elements (MGEs) carrying antibiotic resistance genes, such as integrons, transposons, 
which may also be included in genomic islands [287–289], as well as in plasmids. Besides 
mobilization, these elements assure often the expression level of the associated genes. In 
this section, an overview of the main MGEs linked to carriage of bla genes and multidrug 
resistance phenotypes in Acinetobacter species will be presented (table 5). For concepts 
regarding mobile and mobilizable genetic elements (see Box 7). 
Integrons: Class 1 integrons are the most widespread and clinically relevant in 
Acinetobacter sp. isolates, although other classes may also occur (e.g. class 2 integrons in 
Latin American countries) [290–292]. The dissemination of integrons occurs through 
association with transposons: class 1 integrons are usually associated with functional or 
non-functional transposons derived from Tn402 which may be inserted into larger 
transposons such as Tn21; whereas class 2 integrons are usually associated with Tn7 
family [293–295].   More than 130 different gene cassettes encoding antibiotic resistance 
have been identified in integrons. Table 5 summarizes the main integrons structures 
associated with β-lactamase genes in Acinetobacter species. 
Insertion Sequences: Bacterial insertion sequences (ISs) are the simplest type of 
transposable elements and very frequent among Acinetobacter (from 0 to ~400 per 
genome). In addition, when two copies of the same IS are flanking a resistance gene they 
form a complex structure called composite or class 1 transposon, which can mobilize a 
Chapter 1 - Introduction 
      51 
variety of resistance genes, contributing to antimicrobial resistance dissemination [293]. 
ISs also contribute to increase the expression of neighbour genes due to the presence of 
promotor regions. ISAba1, ISAba2, ISAba3, ISAba4, ISAba10, ISAba125, and IS18 are the 
most frequent ISs associated with the expression of CHDL genes in A. baumannii (Table 
5). ISAba1 (IS4 family) has been found upstream the blaOXA-23-like, blaOXA-51-like, blaOXA-58-like 
and blaAmpC genes in A. baumannii, being proposed that is “customized” for Acinetobacter 
species, since it contains promoter sequences recognized by Acinetobacter typical 
transcription factors [296–298]. In some cases, an IS can be disrupted by other (or more) 
ISs, which provides additional promoter sequences for the resistance genes [299]. Besides 
being involved in the expression and spread of CHDLs, some ISs have also been associated 
with MBLs (e.g. ISAba125) and class A β-lactamases (e.g. ISEcp1), and can be associated 
with reduced susceptibility to carbapenems by disruption coding sequences of certain 
genes (e.g. carO gene) [300,301]. 
Transposons: In A. baumannii, transposons have been characterized as genetic 
structures harbouring important resistance genes, such as blaOXA-23. Five transposons have 
been related to this carbapenemase gene (Tn2006, Tn2007, Tn2008, Tn2008b and 
Tn2009), all of them globally disseminated except Tn2009, identified only in China 
(Figure 18) [239,293,297,302]. Despite all of these structures have been named as 
transposons, only Tn2006 and Tn2009 are typical class 1 transposons, with two copies of 
ISAba1 in opposite or the same orientation, respectively, flanking an internal segment 
containing blaOXA-23. Tn2008 and Tn2008b are similar to Tn2006 but the first two lack 
one copy of ISAba1 and in the second the two ISAba1 elements were transcribed in the 
same orientation. Tn2007 is associated with one copy of ISAba4, which is located 
upstream the blaOXA-23 gene, but there is currently no evidence that this transposon is 
mobilizable [239].  
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FIGURE 18. The five known structures harbouring blaOXA-23 in Acinetobacter. Reprinted 
with permission from [239]. 
 
Genomic Islands (GI): Genomic islands were discovered for the first time in A. 
baumannii by Fournier and colleagues [287]. The first reported, AbaR, the first island 
described, comprises a transposition module (orf1, tniA, tniB, orf2, orf3) and two other 
genes encoding an universal stress protein (uspA) and a sulphate permease (sul) 
[287,303,304]. Since then, several others GIs were described, mainly among A. 
baumannii but also in other Acinetobacter species, and particularly in epidemic lineages 
[305]. These islands, usually contain a variety of genes encoding resistance to multiple 
antibiotics and heavy metals, and most of them are preferentially incorporated into a 
specific location within the comM gene [306,307]. The blaOXA-23 gene is one of the 
resistance genes found associated with an antibiotic resistance island, Tn6167, in an 
ST208Ox isolate from Australia [91]. The large majority of GIs was found in strains 
belonging to IC I (e.g. AbaR1, AbaR3, AbaR5, AbaR6, AbaR7, AbaR8, AbaR9, and 
AbaR10). All except the AbaR6 and AbaR7, share a common structure represented by a 
backbone transposon (Tn6019), interrupted by a large compound transposon that 
contains a variable-resistance region bounded by directly oriented copies of Tn6018. 
Conversely, much less is known about the resistance islands harboured by IC II this clone 
[308]. 
  The largest resistance island described to date is AbaR1 and was described in IC I 
epidemic A. baumannii lineage AYE strain. This island contains an 86 kb region with a 
G+C content of 52.8% (in opposition to the typical 38.8% of A. baumanni chromosome), 
and many resistance determinants (including genes that had not been previously 
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described in Acinetobacter species) [287]. AbaR2, in turn, was described in IC II epidemic 
and MDR A. baumannii strain ACICU, a strain that carries the plasmid-mediated blaOXA-58 
[287,309]. Finally, AbaR3 contains eight genes associated with antibiotic resistance (e.g. 
blaTEM gene associated with a Tn3 transposon) [310,311].  
 
Plasmids: Acinetobacter plasmids range from 2 kb to more than 100 kb in size [84,312–
315]. The large plasmids of A. baumannii are characterized by the presence of multiple 
antibiotic resistance genes and are usually self-transmissible [314,316–318]. Despite the 
importance of plasmids in the potential transmission of antibiotic resistance and virulence 
genes in A. baumannii, we know very little is known regarding the basic replicons of these 
plasmids, their replication mechanisms and transmissibility. So far, Acinetobacter 
plasmids have been classified according to the replicase (Rep) proteins [plasmid-based 
replicon typing scheme (PBRT), being actually known 19 homology groups (GR1-GR19)] 
[105]. The majority of plasmids from Acinetobacter encode replicase proteins belonging to 
the Rep-3 superfamily with the larger plasmids usually harbouring more than one replicon 
type [105]. CHDLs genes were found to be particularly associated with repAci6 and 
repAci1 (blaOXA-23), repAci1, repAci3, repAci4, repAci6, repAci9, repAci10 and repAciX 
(blaOXA-58), and repAci2, repAci6, p2ABSDF0001, and repA_AB (blaOXA-40) [245,315,319] 
 
Glossary - Mobile and mobilizable genetic elements concepts  
 
Integrons - genetic units able to capture, mobilize and express genes that are contained in mobile 
elements called gene cassettes. Integrons are organized in three regions: the 5´conserved region, 
the 3´conserved region, and a variable region. The 5´region consists of the int gene, encoding a 
site-specific recombinase of the integrase family, an att adjacent site recognized by the integrase 
and acting as a receptor site for gene cassettes, and a Pc promoter for gene cassette expression 
[320]. They are not mobile by themselves (but gene cassettes can readily be exchanged to other 
integrons), but they can spread to different chromosomal locations or plasmids by insertion 
sequences (IS)-mediated transposition or homologous recombination. According to the integrase 
sequence (int) they can be classified into five different classes. In class 1 integrons, the 
3´conserved region often consists of a partially deleted qac gene (qacEΔ1) fused to a sul gene 
conferring resistance to quaternary ammonium compounds and sulphonamides, respectively. 
Gene cassettes - small mobilizable elements comprising one gene or open reading frame (often 
an antibiotic resistance gene) and a recombination site (attC), known as 59-be element, that allows 
them to be recognized by the integrase (intI) [294]. 
Transposable elements - comprise IS and transposons [293].  
Insertion sequences (IS) - correspond to the least complex transposable element, consisting on 
a gene codifying for a transposase, usually flanked by inverted repeats (IR) sequences (single 
BOX 
7 
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stranded sequence of nucleotides followed downstream by its reverse complement). IS are able to 
move from one location to another in the genome (causing insertion mutations and genome 
rearrangements), and they can exist as autonomous or as part of class 1 transposons [321,322]. 
Besides their transposition role, some IS have been shown to activate or to increase the expression 
of neighbour genes [293].  
Transposons - these elements may vary in size from 3 to 40 kb and are divided into two main 
classes: composite (class I) or complex (class II) transposons. Composite transposons have 
antibiotic resistance genes in its central region, flanked by the same IS (or two closely related) at 
each end. Complex transposons include genes coding for a transposase (tnpA, enzyme involved in 
excision and integration) and resolvase (tnpR, a site-specific recombinase for co-integrate 
resolution within the res site), and one variable DNA fragment flanked by two IR sequences 
[293,295]. 
Genomic islands (GIs) - large clusters of genes involved in horizontal gene transfer that can be 
mobilized by, for example, plasmids or phages. GIs are flanked by direct perfect repeats and usually 
carry mobility genes coding for integrases or transposases that are needed for chromosomal 
integration and excision, and also other additional genes codifying for adaptive features. GIs are 
usually identified due to differences in G+C content from the rest of the genome and by the 
presence of direct repeats at their ends.  
Plasmids - extra chromosomal genetic units able to replicate autonomously in a given host 
bacterial cell, and which can be transmitted to other cells by conjugation, transformation or 
transduction. Plasmids comprise genes coding for essential (replication, maintenance and transfer) 
and adaptive (e.g. antibiotic resistance genes, metal tolerance, virulence) functions and may cross 
many species and genus barriers, contributing for a successful dissemination [323]. They can be 
classified according to the number of copies, host range, replication (incompatibility group) and 
mobility. According to the mobility, plasmids can be classified as conjugative or mobilizable. 
The mobility machinery includes a set of plasmid mobility (MOB) genes [oriT, relaxase and type IV 
coupling proteins (T4CP)] necessary for the conjugative process, and a mating pair formation 
(MPF) complex which is a type 4 secretion system (T4SS) [324–326]. By definition two plasmids 
that belong to the same Inc group cannot stably coexist in the same cell. Mobilizable plasmids 
(Figure 19) use the T4SS of another genetic element present in the cell to be transferred, are usually 
smaller and present in high copy numbers [324]. Conjugative plasmids encode the functions 
needed for their own transfer (MOB and MPF), replication and stability, and are generally large 
(>30 kb) and appear in low copy numbers in the bacterial cell.  
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FIGURE 19. The modular and hierarchical composition of MGEs. Reprinted with permission from 
[324].  
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TABLE 7. Characterization of the main MGEs associated with the most widespread bla 
genes in Acinetobacter spp. Adapted with permission from [161]. 
Antibiotic 
resistance gene Genetic platform 
Acinetobacter 
spp. 
GenBank 
accession no. & 
References 
Class 
B blaIMP-1 
intI1-blaIMP-1-aac6-II-aadA4-dfrA1-orfC 
In86: intI1-blaIMP-1-aac(6´)-31-aadA1-
qacEΔ1 
intI1-aacA4-blaIMP-1-blaOXA-2-qacEΔ1 
A. pittii 
A. baumannii 
A. baumannii, A. 
bereziniae 
[327] 
[328] 
EF375699.1, 
EU686386.1 
blaIMP-2 intI1-blaIMP-2-aacA4-aadA1 A. baumannii [329] 
blaIMP-4 intI1-blaIMP-4-qacG2-aacA4-catB3 A. baumannii AF445082.1 
blaIMP-5 In76 (Tn402-like): MITE-intI1-blaIMP-5-qacEΔ1-sul1-orf5-tniBΔ1-tniA-MITE A. baumannii 
[234] 
blaIMP-8 
intI1-blaIMP-8-aac(6´)-Ib 
intI1-blaIMP-8-aac(6´)II-aadA4-qacEΔ1 
A. baumannii 
A.baumannii, A. 
pittii 
DQ845788.1 
[327] 
blaIMP-19 In477: intI1-blaIMP-19-aac(6´)-31-blaOXA-
21-aadA1 
A. baumannii, A. 
bereziniae, 
Acinetobacter 
genomosp. 16, A. 
guillouiae, A. junii, 
A. nosocomialis, A. 
pittii 
[330,331] 
blaIMP-34 
intI1-blaIMP-34-aacA4-blaOXA-1- qacEΔ1-
sul1-NAT-tniBΔ 
Acinetobacter 
genomosp. 13BJ 
LC276939.1 
blaVIM-1 
intI1-blaVIM-1-qacEΔ1 
intI1-orf11-aacA(6´)-Ib-blaVIM-1-qacEΔ1 
intI1-blaVIM-1-aacA7-dhfrI-aadA1-qacEΔ1-
sul1 
A. baumannii 
A. baumannii 
A. baumannii 
EF690696.1 
EF690695.1 
[332] 
blaVIM-2 
intI1-blaVIM-2-aacA7-aadA1-qacEΔ1 
intI1-blaVIM-2-aacA4-aadA1-orfII-orfIII-
qacEΔ1 
intI1-blaVIM-2-aadB-ISpa21-like-blaOXA-2 
intI1-aacA7-blaVIM-2-aacA1-qacEΔ1-sul1-
orf-tniBΔ1-tniA 
A. baumannii, A. 
bereziniae 
A. pittii 
A. baumannii 
A. bereziniae 
AF324464.1, 
EU014075.1 
AF369871.1 
AM749812.1 
JX235356.1 
blaVIM-3 intI1-blaVIM-3-orf2-aacA4-qacEΔ1 A. baumannii [333] 
blaVIM-11 intI1-blaVIM-11 A. baumannii EF116550.1 
blaSIM-1 intI1-blaSIM-1-arr3-catB3-aadA1-qacEΔ1 A. baumannii [334] 
blaNDM-1 
Tn125: ISAba125-blaNDM-1-ISAba125 
Tn125: ISAba125-blaNDM-1-ble-trpF-tat-
dct-groES-groL-IS91-ISAba125 
Tn125: ISAba125-blaNDM-1-ble-Δiso-tat-
dvt-groES-groEL-ISCR21-Δpac-ISAba125 
Tn125: ISAba125-blaNDM-1-ble-trpF-dsbC-
cutA1-groES-groEL-insE-pac-ISAba125 
Tn125: ISAba125-blaNDM-1-ble-trpF-tat-
cutA1-groES-groEL-insE-Δpac-ISAba125 
 
A. baumannii 
A. towneri 
A. baumannii 
A. bereziniae 
A. pittii 
[335] 
KT965093.1 
JN872329.1 
KT072713.1 
KR153289.1 
blaNDM-2 
Tn125: ISAba125-blaNDM-2-ble-ΔtrpF-
ISAba125 
Tn125: ISAba125-blaNDM-2-ble-Δiso-tat-
dvt-groES-groEL-ISCR21-Δpac-ISAba125 
A. baumannii 
A. baumannii 
[336] 
[337] 
Class 
D blaOXA-2-
like 
intI1-aacA4-blaIMP-1-blaOXA-2-qacEΔ1 
intI1-blaVIM-2-aadB-ISpa21-like-blaOXA-2 
intI1-aadB-blaOXA-21 
In477: intI1-blaIMP-19-aac(6´)-31-blaOXA-
21-aadA1 
A. baumannii, A. 
bereziniae 
A. baumannii 
A. baumannii 
A. baumannii, A. 
EF375699.1, 
EU686386.1 
AM749812.1 
[338] 
[330,331] 
Chapter 1 - Introduction 
      57 
Antibiotic 
resistance gene Genetic platform 
Acinetobacter 
spp. 
GenBank 
accession no. & 
References 
bereziniae, 
Acinetobacter 
genomosp. 16, A. 
guillouiae, A. junii, 
A. nosocomialis, A. 
pittii 
blaOXA-10-
like 
intI1-IS1999-blaVEB-1-aadB-arr2-cmlA5-
blaOXA-10-aadA1-qacEΔ1-sul1 
intI1-aadB-cat-blaOXA-10-aadA1 
intI1-blaOXA-10-aacA4-blaIMP-55-cmlA5 
In3-6: intI3-aac(6´)Ib-blaOXA-10-aadA1-
like-qacE2-like 
A. baumannii 
A. baumannii 
A. baumannii 
A. johnsonii 
[161] 
DQ288250.1 
KT935306.2 
[320] 
blaOXA-
20-like 
intI1-aacA4-orfO-blaOXA-20-qacEΔ1 
intI1-aacA4-blaOXA-37 
A. baumannii 
A. baumannii 
[339,340]  
[341] 
blaOXA-
23-like 
Tn2006: ISAba1-blaOXA-23-ATPase----
ISAba1 
Tn2007: ISAba4-blaOXA-23-ATPase 
Tn2008: ISAba1-blaOXA-23-ATPase 
Tn2008b: ISAba1-like-blaOXA-23-ATPase-
like 
Tn2009: ISAba1-blaOXA-23-ATPase-orf1-
orf2-orf3-orf4-ISAba1 
A. baumannii, A. 
nosocomialis 
A. baumannii 
A. baumannii, A. 
baylyi, A. 
radioresistens 
A. baumannii, A. 
radioresistens 
A. baumannii, A. 
junii 
[299] 
[298]; 
KP888560.1 
[298]; JF731029.1 
[239] 
[239,302,342,343] 
blaOXA-51-
like 
ISAba1-blaOXA-51-like 
ISAba9-blaOXA-51 
Tn6080: ISAba1-blaOXA-51-like-str-orf14 
A. baumannii 
A. baumannii 
A. baumannii 
[344–347] 
[344] 
[348] 
blaOXA-
58-like 
ISAba3-like-ISAba825-ISAba3-like-
blaOXA-58-ISAba3 
ISAba125-ISAba3-like-blaOXA-58-ISAba3-
araC1-lysE-ISAba3-like-ISAba125-
ISAba3-like-blaOXA-58 
ISAba3-like-ISAba2-ISAba3-like-blaOXA-
58-ISAba3 
IS26-ISAba2-blaOXA-58-ISAba3-IS26 
ISAba2-blaOXA-58-ISAba3-IS26-ISAba2-
blaOXA-58-ISAba3-IS26 
ISAba2-blaOXA-58-ISAba3 
IS18-blaOXA-58-ISAba3 
ISAba1-blaOXA-58-ISAba3 
ISAba3-blaOXA-58-ISAba3 
blaOXA-97-ISAba3-araC1-lysE-araC2-reg-
orf-ISAba8 
ISAba3-like-IS1006-blaOXA-58-ISAba3 
IS1008-ΔISAba3-blaOXA-58 
ISAba2-ΔISAba3-blaOXA-58-ISAba3 
IS18-ΔISAba3-blaOXA-58-ISAba3 
A. baumannii 
A. pittii 
 
A. baumannii 
A. baumannii 
A. baumannii 
A. baumannii 
A. baumannii 
A. baumannii 
A. pittii 
A. baumannii 
Genomosp. 13TU 
A. baumannii 
A. baumannii 
A. baumannii 
[349] 
[350] 
[297] 
[351] 
[351] 
[352] 
[352] 
[352] 
[327] 
[353] 
[354] 
[355] 
[297] 
[297] 
 
blaOXA-
143-like 
XerC/XerD-blaOXA-253 
rep-mob-blaOXA-143-rep 
pAb25: tonB-orf2-orf1-blaOXA-253-repA-
repB 
A. baumannii 
A. baumannii 
A. baumannii 
KC479324.2 
GQ861437.1 
KF824909.1 
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1.1.5.2.3.2. Population structure of carbapenem-resistant A. 
baumannii 
 
 
The global population structure of multidrug-resistant and carbapenem non-
susceptible A. baumannii isolates is characterized by a low diversity of clones/clonal 
complexes (CCs). Initial typing studies attributed the spread of MDR A. baumannii to 
three predominant clonal lineages, initially designated as European clones I-III [96,356]. 
However, these three European clones have subsequently become endemic in many 
worldwide countries, being accordingly re-named as “international clones (ICs) I–III” 
[83], whose diversity was uncovered with the use of MLST. CC109Ox/CC1Pa, CC92Ox/CC2Pa 
and CC187Ox/CC3Pa, representing international clones I, II and III respectively; where 
“Ox” refers to Oxford MLST scheme and “Pa” to Institute Pasteur MLST scheme. They are 
globally disseminated, including in non-clinical niches (e.g. in animals), which is 
suggestive of their adaptation to diverse habitats [357]. Among the numerous STs 
included in these two CCs, ST92Ox and ST109Ox (which were further reassigned as ST208 
and ST231, respectively) [358] are the most disseminated, being frequently associated 
with genes encoding resistance to carbapenems (e.g. blaVIM-like, blaOXA-23-like, blaOXA-24-like, 
and/or blaOXA-58-like) or aminoglycosides (armA, a 16S rRNA methylase) [359]. Worryingly, 
the occurrence of ST92Ox/ST208Ox isolates resistant to all available antimicrobial agents 
has already been described [84,360]. 
Actually, almost 1900 MLST sequence types (STs) are listed in the A. baumannii 
MLSTOx database and some other highly successful lineages are known to be widely 
distributed [83,94,352,361,362]. Some of these “new” epidemic lineages (e.g. 
CC103Ox/CC15Pa, CC110Ox/CC25Pa, CC113Ox/CC79Pa) in some cases, harbour subtypes with 
distinctive temporal and geographical distributions [83,363,364]. 
In Portugal, particular clones have dominated over the last years: the ST98 
producing OXA-40 was dominant until 2006 and subsequently replaced by the worldwide 
epidemic ST208 producing OXA-23. The specific determinants favouring transmission, 
colonization, and/or invasion, and hence the successful spread and epidemic behaviour of 
these clones, still have not yet be completely defined [84]. However, their remarkable 
capabilities for antibiotic resistance determinants and mobile genetic elements 
acquisition, as well as for biofilm formation, together with the inter-hospital transfer of 
colonized patients, seem to be also important factors that need to be further clarified 
[365]. 
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2.1. Statement of objectives 
 
In the last decades, we have witnessed a dramatic increase in antimicrobial 
resistance of infectious bacterial agents, representing a difficult challenge for healthcare 
institutions all over the world. Acinetobacter species are among the most concerning 
bacteria, showing a prodigious ability to become resistant to multiple antimicrobial agents 
(including carbapenems), and to persist in the hospital environment. Although A. 
baumannii is still considered the most prevalent Acinetobacter species within the hospital 
setting, the number of reports of infections caused by non-baumannii species and 
associated with multidrug resistant strains increased in the last years. 
A lasting (1995-2008) high occurrence of carbapenem-resistant A. baumannii in 
Portuguese hospitals was previously associated with an interesting clonal dynamic, 
supported by the expansion of specific CHDL-harbouring clones in different time-periods 
(2002-2006 ST98-OXA-24/40; 2001-2004 ST103-OXA-58; 2006-2010 ST208-OXA-23). 
The enlargement on the antibiotic resistance profile was associated with this clonal switch. 
Nevertheless, other clonal features (e.g. resistance to other antimicrobial agents, virulence 
traits or resilience traits) as well as the relevance of other settings for the emergence and 
proliferation of particular A. baumannii clones are still poorly understood. Moreover, and 
although less explored, the interspecies transfer of resistance traits that occur between 
non-baumannii and A. baumannii species (e.g. the previously reported blaOXA-40 
associated plasmids), also account for carbapenem resistance, with non-baumannii 
species/non-hospital niches potentially constituting an important source/reservoir of 
relevant resistance genes that is worth to be explored. 
The increasing use of DNA-based strain typing tools like MLST and WGS is 
contributing for a more precise definition of the population structure and antibiotic 
resistance drivers among Acinetobacter. However, most of these methods are still too 
expensive, time-consuming and/or require specialized skills, hindering their 
implementation in routine clinical laboratories. Thus, alternative methods offering a high-
throughput, low-cost and quick performance are highly required in order to block 
transmission and support appropriate therapeutic decisions. Some progress have been 
attained with FTIR spectroscopy for some bacterial species, or MALDI-TOF MS 
spectrometry, an already thoroughly adopted technique in clinical microbiology 
laboratories for species identification, paving the way for further developments on 
Acinetobacter and envisioning a bright future for real-time application for typing. Since 
these methodologies are based on different non-DNA-based principles and target different 
biomolecules from the bacterial cell, they provide an opportunity to integrate 
multidisciplinary data (genomics, proteomics, metabolomics), and can additionally 
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provide relevant insights into key molecular features that can be of utmost interest to 
understand bacterial evolution, pathogenesis and host-pathogen interactions. 
 
The main goals of this Thesis were: 
Ø To identify the main features contributing for the clonal dynamics and success 
of particular A. baumannii lineages and also to understand the role of non-
baumannii Acinetobacter species in the dissemination of carbapenem 
resistance.  
 
Ø To explore the potential of different DNA- and non-DNA-based high-
throughput omic technologies (WGS, FTIR and MALDI-TOF MS) for 
Acinetobacter characterization and accurate typing, at species and sub-species 
level.  
 
To accomplish these purposes, a recent Portuguese collection of Acinetobacter spp. 
clinical isolates (2010-2015), selected based on the origin (nosocomial and community 
infections, type of infection, different wards), geographical region (North and Centre) and 
antibiotic susceptibility profile, was screened for bacterial species, clones, and genomic 
pieces contributing to virulence and adaptation to different stressors, with emphasis to 
carbapenems. Furthermore, the occurrence, diversity and antimicrobial resistance of a 
collection of Acinetobacter species from non-clinical sources from Benguela, Angola 
(healthy volunteers, aquatic environments, healthy animals and their environments; 2013) 
was also evaluated, as part of a larger antimicrobial resistance surveillance project in this 
region. Finally, the potential of FTIR and MALDI-TOF MS for Acinetobacter species 
identification and typing was also explored. 
 
The specific aims of this thesis were: 
1. To characterize the phenotypic and molecular features of recent A. baumannii 
clinical isolates [two hospitals, one Long-Term Care Facility and one Community 
Clinical Laboratory (2010-2015)] in order to identify the clones currently causing 
infection in our area and identify potential important reservoirs and transmission 
routes. Comparison of this data with the ones from previous collections will help 
on the identification of key features contributing for the success of particular 
lineages.  
 
2. To characterize the carbapenem resistance mechanisms and mobile genetic 
elements responsible for the spread of carbapenem resistance determinants among 
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different Acinetobacter species. 
 
3. To assess the pathogenicity potential and the possibility of non-baumannii 
Acinetobacter species acting as reservoirs of resistance genes.  
 
4. To assess the suitability of high-throughput spectroscopic (FTIR) and 
spectrometric (MALDI-TOF MS) technologies for accurate, quick and low-cost 
Acinetobacter species identification and typing. 
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2.2. Outline of the thesis 
 
This Thesis is organized in four chapters as follows: 
 
Chapter 1 presents an overview of the state of the art regarding the topics of this 
Thesis, and is subdivided in five main sections. Section 1.1.1 presents a brief 
summary of the history of Acinetobacter genus and respective taxonomic changes and 
an updated overview of the Acinetobacter species described until now. Section 1.1.2 
presents the main features and recent methodologies used for Acinetobacter species 
delineation and characterization. Section 1.1.3 focuses on the distribution of 
Acinetobacter species in different ecological niches, such as human and non-human 
(e.g. environment, food and animals) sources. Section 1.1.4 presents a little overview 
of the history behind the emergence and evolution of Acinetobacter spp., and also their 
clinical relevance. Finally, Section 1.1.5 includes an overview concerning the 
virulence traits and the antibiotic resistance in Acinetobacter spp., mainly in A. 
baumannii, the molecular trends involving resistance to β-lactams (mainly 
carbapenems) and non-β-lactams (aminoglycosides, tetracyclines, fluoroquinolones 
and colistin) and also the population structure and mobile genetic elements involved in 
the current global scenario of MDR/XDR A. baumannii.  
 
Chapter 2 includes the objectives and outline of the Thesis. 
 
Chapter 3 presents the findings regarding the specific aims of the Thesis. Results 
from the experimental research performed yielded different research articles (n=9; 7 
publications in peer review journals and 2 manuscripts in preparation). Such results 
have been organized throughout the papers, according to the following rationale: 
 
Section 3.1. Carbapenem-resistant Acinetobacter baumannii clonal 
dynamics in Portuguese clinical settings explained by a highly successful 
interplay between antimicrobial resistance and virulence. Using the high-
throughput technology WGS, the relevant traits (mainly related with antibiotic 
resistance and virulence potential) that may explain the dynamics of carbapenem-
resistant A. baumannii clones in Portuguese clinical settings, in particular the 
replacement of ST208 by ST218, are analyzed. The data obtained is presented in the 
following research article: 
 
Silva L, Ksiezarek M, Ramos H, Grosso F, Peixe L. Carbapenem-resistant 
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Acinetobacter baumannii clonal dynamics in Portuguese clinical settings explained by 
a successful interplay between antimicrobial resistance and virulence (manuscript 
final draft). 
 
Section 3.2. Contribution of non-baumannii Acinetobacter species as 
reservoirs of resistance genes in clinical and non-clinical settings. The 
characterization of blaOXA-23 and blaOXA-58-carrying A. pittii plasmids and blaIMP-5 A. 
bereziniae genetic environments from a Portuguese Hospital is conducted, exploring 
the role of non- A. baumannii Acinetobacter species in the dissemination of 
carbapenem resistance by horizontal gene transfer. Moreover, a study conducted in 
non-clinical niches of Benguela, Province of Angola, revealed a high diversity of 
Acinetobacter species, being some CHDL-producers, and a worrisome human 
exposition to these isolates. The data obtained is presented and organized in the 
following research articles: 
 
• Grosso F, Silva L, Sousa C, Ramos H, Quinteira S, Peixe L. 2015. Extending the 
reservoir of blaIMP-5: the emerging pathogen Acinetobacter bereziniae. Future 
Microbiology. DOI: 10.2217/fmb.15.88. 
• Silva L, Grosso F, Branquinho R, Gonçalves-Ribeiro T, Sousa C, Peixe L. 2016. 
Exploring non-hospital-related settings of Angola reveals new Acinetobacter 
reservoirs for blaOXA-23 and blaOXA-58. International Journal of Antimicrobial 
Agents. DOI: 10.1016/j.ijantimicag.2016.06.003. 
• Silva L, Mourão J, Grosso F, Peixe L. 2017. Uncommon carbapenemase-
encoding plasmids in the clinically emergent Acinetobacter pittii. Journal of 
Antimicrobial Chemotherapy. DOI: 10.1093/jac/dkx364. 
 
Section 3.3. Developments on Acinetobacter species identification and 
typing. The potential of two high-throughput technologies, FTIR and MALDI-TOF 
MS, coupled with different bioinformatics tools, is evaluated for Acinetobacter species 
identification (species level) and A. baumannii characterization (infra-species level), in 
a large national and international collection of isolates. Moreover, we demonstrated 
the potential of FTIR-spectroscopy for depicting capsular (KL)-types. Of remark, the 
identification of capsular types more adapted for the survival in host (enriched in 
acidic sugars) for ST208 and ST218, the endemic clones more recently observed in our 
country and worldwide, that may also contribute for their great success. The results 
obtained are presented and organized in the following research articles: 
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• Sousa C, Silva L, Grosso F, Nemec A, Lopes J, Peixe L. 2014. Discrimination of 
the Acinetobacter calcoaceticus-Acinetobacter baumannii complex species by 
Fourier transform infrared spectroscopy. European Journal of Clinical 
Microbiology and Infectious Diseases. DOI: 10.1007/s10096-014-2078-y. 
• Sousa C, Botelho J, Silva L, Grosso F, Nemec A, Lopes J, Peixe L. 2014. 
MALDI-TOF MS and chemometric based identification of the Acinetobacter 
calcoaceticus-Acinetobacter baumannii complex species. International Journal 
of Medical Microbiology. DOI: 10.1016/j.ijmm.2014.04.014. 
• Sousa C, Silva L, Grosso F, Lopes J, Peixe L. 2014. Development of a FTIR-
ATR based model for typing clinically relevant Acinetobacter baumannii clones 
belonging to ST98, ST103, ST208 and ST218. Journal of photochemistry and 
photobiology B. DOI: 10.1016/j.jphotobiol.2014.02.015. 
• Sousa C, Botelho J, Grosso F, Silva L, Lopes J, Peixe L. 2015. Unsuitability of 
MALDI-TOF MS to discriminate Acinetobacter baumannii clones under 
routine experimental conditions. Frontiers in Microbiology. DOI: 
10.3389/fmicb.2015.00481. 
• Silva L, Rodrigues C, Grosso F, Peixe L. The secret is on sugar: capsular type 
explains the discrimination of Acinetobacter baumannii clones by Fourier-
transform Infrared (FT-IR) Spectroscopy and Multilocus Sequence Typing 
(manuscript final draft). 
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3.1. Carbapenem-resistant Acinetobacter baumannii clonal 
dynamics in Portuguese clinical settings explained by a highly 
successful interplay between antimicrobial resistance and 
virulence 
 
3.1.1. Carbapenem-resistant Acinetobacter baumannii clonal dynamics in 
Portuguese clinical settings explained by a successful interplay between 
antimicrobial resistance and virulence. 
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1. Introduction 
Acinetobacter baumannii is a common cause of serious hospital and, less 
often, community-acquired difficult-to-treat infections with resistance to multiple 
antibiotics frequently occurring worldwide [1]. Initial studies on population structure 
and epidemiology of multidrug-resistant A. baumannii strains attributed their global 
spread to three major clonal lineages, referred as international clones (ICs)-I, -II, and 
-III, whose diversity was deepened with the use of multilocus sequence typing 
(MLST). In Portugal, for almost two decades, carbapenem-resistant A. baumannii 
has been associated with very few clones, with usually only one dominating in a 
particular period [2]. Previous studies allowed us to describe the substitution of 
OXA-58 producing-ST103 by the OXA-40 producing-ST98, and, after, the 
substitution of ST98 by the worldwide disseminated ST208, at least, until 2010 [2]. 
Considering last data [3], the prevalence of carbapenem-resistant Acinetobacter spp. 
causing healthcare associated infections is still very high in Portugal (≥ 50%), 
however, there is no updated information on the recent clones responsible for this 
panorama, as well as their main characteristics.  
In the present study, we aimed to characterize the population structure of A. 
baumannii isolates recovered from Portuguese nosocomial and community settings 
(2010-2015), in order to identify key features (antibiotic susceptibility profile, 
antibiotic resistance genes and virulence traits) contributing for the emergence and 
proliferation of particular A. baumannii clones.  
 
 
2. Material and methods 
Bacterial isolates collection 
This study included a collection of 177 A. baumannii isolates (2010-2015) 
from two hospitals (North, H; and Centre of Portugal, CB), a Long-Term Care facility 
(LTCF) and a community clinical laboratory (CT). Isolates were mainly recovered 
from respiratory secretions (n=44), urine (n=43), blood cultures (n=27) and tissues 
(n=15) from patients of different wards, mainly Intensive Care Unit (n=22), Surgery 
(n=22) and Medicine (n=19) (Table 1). Isolates were initially identified by the VITEK 
2 system (Biomérieux) and further confirmed by blaOXA-51-like detection and 
rpoB/gyrB genes partial sequencing [4,5].  
 
Susceptibility testing and carbapenemase detection 
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Antimicrobial susceptibility profile to different β-lactams, aminoglycosides, 
tetracyclines, quinolones and trimethoprim-sulfamethoxazole was assessed by 
standard disc diffusion, Etest (carbapenems) and broth microdilution (colistin) 
methods, according to EUCAST (www.eucast.org) and CLSI guidelines 
(www.clsi.org). Isolates were categorized as multidrug-resistant (MDR) or 
extensively drug-resistant (XDR) bacteria according to Magiorakos and colleagues 
[7]. Carbapenemase production was assessed by the Blue-Carba biochemical assay 
[8] and carbapenem-hydrolyzing class D b-lactamases (CHDLs) genes were searched 
by PCR/sequencing [9]. 
 
Whole genome sequencing (WGS) 
From the above collection, 12 A. baumannii isolates (ST208, n=4; ST218, 
n=4; and sporadic STs, n=4), together with 4 additional isolates from a previously 
characterized collection and belonging to the old endemic Portuguese clones [ST98, 
n=2 (2002-2006); ST103, n=2 (2001-2004)] [2], were subjected to WGS. This 
selection process aimed to congregate isolates from different STs, collected from 
different settings, over a long period of time (2001-2015). Total DNA was extracted 
using the Wizard Genomic DNA purification kit (Promega Corporation, Madison, 
WI), according with the manufacturer´s instructions. DNA concentration was 
estimated using the Qubit dsDNA HS Assay Kit and the Qubit 3.0 Fluorometer 
(Invitrogen, Thermo Fisher Scientific, USA). Extracted DNA was then sequenced 
with a standard 2x125 paired-end runs protocol on Illumina HiSeq 2000 (Illumina, 
San Diego, CA, USA). The quality of the high-throughput sequence data was assessed 
by FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw 
sequence reads were then de novo assembled using SPAdes 3.9.0 
(http://bioinf.spbau.ru/spades), and the quality was assessed by QUAST 
(http://quast.bioinf.spbau.ru). Additionally, 16 A. baumannii genome sequences of 
clinical strains isolated in different countries and belonging to the same STs found in 
our collection (except for ST98 and ST103 for which no genomes were available), 
were downloaded from NCBI database (https://www.ncbi.nlm.nih.gov/genome/403) 
for comparison purposes (accession numbers in Table S1). 
 
Screening of antibiotic resistance and virulence genes 
The distribution and richness of several genes previously associated with 
antimicrobial resistance and virulence in A. baumannii was determined across the 
studied genomes using the ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) 
and the Virulence Factors Database (VFDB) of pathogenic bacteria 
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(http://www.mgc.ac.cn/cgi-bin/VFs/genus.cgi?Genus=Acinetobacter). This analysis 
included acquired genes associated with resistance to aminoglycosides, β-lactams, 
macrolides, fluoroquinolones, sulphonamides, trimethoprim, tetracyclines and 
phenicol. The virulence factors screened included genes related to adherence (outer 
membrane protein A - ompA); biofilm formation [bacterial adhesin bap, usher-
chaperone assembly system - csuA/BABCDE for pili production (which is regulated 
by the two-component system sensor kinase and response regulator (bfmRS genes), 
and pgaABCD locus for the biofilm exopolysaccharide matrix production]; iron 
uptake (basABCDEFGHIJ, barAB and bauABCDEF gene clusters for acinetobactin 
biosynthesis and release); lipooligosaccharide production (lpsB and lpxC); enterolisin 
E production (entE); heme oxygenase production (hemO); bacterial phospholipases 
production (plcC and plcD genes) and penicillin-binding protein 7/8 (PBP-7/8) 
production (pbpG). 
 
Strain typing 
Clonality of the 177 isolates was initially investigated by Fourier-Transform 
Infrared (FTIR) spectroscopy with attenuated total reflectance (ATR) as previously 
described [10,11]. Strain diversity was also assessed by MLST (Oxford scheme), using 
the sequence and profile definitions available at https://pubmlst.org/abaumannii/ 
and WGS [platform MLST 1.8 of Center for Genomic Epidemiology 
(https://cge.cbs.dtu.dk/services/MLST/]. 
 
 
3. Results and discussion 
The main characteristics of the recent collection of 177 A. baumannii isolates 
included in this study are summarized in Table 1. The ST218 was the most 
disseminated clone among healthcare facilities (115/177; 65%), being detected in 
several wards of both hospitals (H and CB) and in the community (CT) during the 
analysed period. The ST208 (single locus variant of ST218), endemic in our country 
between 2006-2010 [12], was only observed in hospital H and associated with a 
decreasing trend over the years (44/177; 25%; data not shown). All isolates belonging 
to ST218 and all but one isolate belonging to ST208 were Blue-Carba positive (OXA-
23 producers), classified as XDR, and presented non-susceptibility to the β-lactams 
tested, including carbapenems (MIC>32 mg/L, Table 1). These antibiotic resistance 
profiles explain, to a large extend, the success of ST208 strains throughout the world 
(e.g. USA, Egypt, China, Thailand, Japan, Russia, Czech Republic, Australia, 
Denmark, Iraq and Switzerland (Oxford database). However, ST218, until now less 
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widespread, but already found in Asia (Saudi Arabia, Japan, Singapore, China [13] 
and Europe (Denmark, Spain and United Kingdom) [14,15], presented higher levels 
of aminoglycoside resistance, which seems to be due to a combination of factors: 
higher production of aminoglycoside modifying enzymes, higher frequency of the 16S 
ribosomal RNA methyltransferase ArmA enzyme (Table S1) and also by the great 
facility of this lineage to develop aminoglycosides heteroresistance, a phenomenon 
very difficult to detect in clinical laboratories, that contributes for therapeutic failure 
when the antibiotic is administered [16]. All ST218 genomes studied revealed the 
presence of the β-lactamases blaOXA-51-like (blaOXA-66), blaOXA-23 [flanked by two copies 
of the ISAba1 insertion element (Tn2006; chromosomal location)] and blaADC-like 
(blaADC-30, n=4; blaADC-25, n=4), and a higher number of acquired antimicrobial 
resistance genes (e.g. aacA4, aadA1, aph(3´), armA, msr(E), mph(E), sul1, 
aac(6´)Ib-cr or catB8), when compared with ST208 isolates (Table S1). This finding 
may contribute to the exchange of ST208 by ST218 observed in the last years in 
Portugal. Both clones revealed genomes with a medium size of 4.0Kb and 38.9% of 
GC content and no plasmids carrying antibiotic-resistance genes were predicted. 
Similarly, differences in antimicrobial resistance genes content between the oldest 
clones identified in Portugal clinical settings were observed, with ST98 displaying 
advantages over ST103 (e.g. blaOXA-40, which confers higher levels of carbapenem-
resistance than blaOXA-58, strA and strB genes, that confers resistance to 
aminoglycosides, and also the tet(B) gene, for tetracycline resistance) that could 
justify the dominance of ST98 over ST1103. Sporadic STs (18/177; 10%; e.g. ST234, 
ST552, ST1557, ST1558) were more susceptible to antibiotics (confirmed by the lack 
of several resistance genes when genomes were analysed, Table S1), with only one 
isolate, from LTCF, being Blue-Carba positive due to the production of OXA-24/40. 
This carbapenemase gene, similarly to previously described among older Portuguese 
isolates, was plasmid-located (pMMCU3; pAc92, 99%Ident) and flanked by the 
typical XerC/XerD-like binding sites. However, the ST of this isolate (ST1557) was 
not even related to ST98 [17].  
In what concerns to virulence genes, some of them were detected in all A. 
baumannii isolates (regardless of the lineage), suggesting their significant roles in 
the pathogenesis of A. baumannii. These genes included the adherence-related 
ompA, the surface-adhesion bap, and the serum resistance-related pbpG gene [18]. 
Although XDR A. baumannii clonal lineages showed common virulence traits (Table 
S2), the ST218 lineage exhibited an enriched virulence profile when compared to 
ST208, mainly because of the presence of an important gene (hemO) that codifies for 
heme oxygenase, essential for uptake and utilization of iron from their mammalian 
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hosts [19]. Moreover, all of the dominant clones (ST103, ST98, ST208 and ST218) 
showed significantly more virulence traits than the sporadic ones [e.g. the pgaABCD 
locus for the biofilm exopolysaccharide matrix production and the gene clusters 
responsible for iron uptake (basABCDEFGHIJ, barAB and bauABCDEF)] - both 
present only in some of the endemic isolates) (Table S2). These results suggest that a 
positive correlation might exist between resistance and increased virulence, raising 
the question of the existence of high-risk clones among A. baumannii. This 
information could be useful for clinicians, in order to adjust treatment regimens 
based on the expected degree of virulence and the severity of the illness of the 
patient, and for the infection control specialists, through the adaptation of 
eradication protocols to specific clones.  
 
4. Conclusions  
In summary, this work provided relevant features for understanding the 
predominance of the ST208 and ST218 worldwide. Moreover, it also provides the 
potential causes for the A. baumannii clonal dynamics observed in Portuguese 
clinical settings, i.e., higher antibiotic resistance and an enlarged virulence potential. 
Moreover, the data presented here, by increasing the knowledge on features 
responsible for the circulation and persistence of these specific lineages throughout 
the world, may aid in future prevention and/or treatment strategies. 
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Acinetobacter genomospecies 10) is presently con-
sidered one of the non-baumannii Acinetobacter 
emerging pathogenic species [6]. Descriptions of 
this species include vegetable samples [7], fecal 
carriage among healthy humans [8] and different 
human clinical specimens, suggesting its wide 
distribution [9]. More recently, it has also been 
associated with chronic obstructive pulmonary 
disease, urinary tract infection, pneumonia, sep-
sis and bacteremia [6,10–11]. Reports on carbap-
enem resistance in A. bereziniae were previously 
associated with the production of IMP-1 and 
IMP-19, SIM-1, VIM-2 and NDM-1 MBLs [10–
13]. Additionally, two variants of the intrinsic 
oxacillinase OXA-228-like, OXA-229 and 
OXA-257, able to confer carbapenem resistance 
when overexpressed, were recently described in 
A. bereziniae [14,15].
This report aims the characterization of two 
A. bereziniae isolates obtained in the same hos-
pital, from the water of a newborn incubator’s 
humidity chamber and from a blood culture, 
which exhibited an unusual multidrug resistance 
phenotype, including resistance to carbapenems.
Materials & methods
Two A. bereziniae isolates, obtained at an inter-
val of 4 years in the same University Hospital in 
Portugal, were studied. Acinetobacter bereziniae 
HGSA93 was collected in 2008 from the water 
reservoir of a new-born’s incubator humidity sys-
tem, while A. bereziniae HGSA593 was obtained 
in 2012 from a blood culture of a hospitalized 
patient with chronic renal disease. Isolates 
were initially identified as Acinetobacter lwoffii 
by the vitek 2 system. Further identification 
included rpoB gene partial sequencing [16] and 
PCR searching for Acinetobacter species-specific 
oxacillinase, OXA-228-like, using previously 
described primers [14].
Antibiotic susceptibility testing was per-
formed by disc diffusion method and E-test 
following CLSI guidelines [17]. Carbapenemase 
production was assessed by the Blue-Carba 
test [18]. Furthermore, isolate crude extracts were 
used to conduct a bioassay with imipenem (with 
and without EDTA).
Acquired carbapenemase genes (MBL and 
carbapenem-hydrolyzing class D β-lactamases 
[CHDL]) were searched by PCR using prim-
ers and conditions as previously described [1,19], 
and confirmed by sequencing. Class 1 inte-
grons were searched with primers directed for 
5′CS and 3′CS regions [20] and confirmed by 
sequencing. Additionally, association of the 
MBL genes with the Tn402-like transposon 
(GenBank accession number JF810083) was 
investigated by PCR mapping with a com-
bination of primers for the MBL gene [1], 
orf5 [21] and MITEs sequences (MITE_Fw_2: 
5′-GATA ACCAATCCATTTATGACA-3′; 
MITE_Rv_2: 5′-TGACTGACCATTAAA- 
GTCTCAA-3′).
The carbapenemase genes location was 
assessed by hybridization of I-CeuI- and 
S1-digested genomic DNA with specific probes 
for the carbapenemases and 16S rRNA genes. 
Plasmid characterization was performed using 
the PCR-based replicon typing scheme for 
A. baumannii plasmids [22].
Transfer of carbapenemase genes was 
attempted by conjugation with rifampicin-
resistant mutant of A. baumannii ATCC 17978 
(kindly provided by Dr Ruth Hall), and by elec-
trotransformation with the plasmid DNA from 
HGSA593 isolate, using Acinetobacter baylyi 
ADP1 (kindly provided by Dr German Bou), 
as the recipient strain. Selection was performed 
on Mueller-Hinton agar plates supplemented 
with imipenem (0.5 mg/l) and rifampicin (100 
mg/l) for conjugation assays and only with imi-
penem (0.5 mg/l) for electrotransformation. 
Presumptive transformants were confirmed by 
searching carbapenemases genes by PCR.
Clonal relatedness for the two isolates was 
assessed by genomic DNA macrorestriction with 
Table 1. Molecular characterization of A. bereziniae isolates included in this study.
Isolate Year Source Carbapenemase genes 
(plasmid size, Kb)
Class 1 integron 
content (size, Kb)
Antibiotic resistance profile (MIC, mg/l)
HGSA93 2008 Water from a newborn 
incubator humidity system
blaIMP-5 (∼310) blaIMP-5 (1.5) IMP (>32); MEM (>32); ATM (32); FEP (>32); 
CAZ (>256); PTZ (>256); K
HGSA593 2012 Blood culture (inpatient with 
chronic renal disease)
blaIMP-5 (∼200), blaOXA-58 
(∼90)
blaIMP-5- blaOXA-4 
(2.5), aacA4 (1.2)
IMP (>32); MEM (>32; 12); ATM (32); FEP (32); 
CAZ (>256); PTZ (>256); K; CN; TOB
β-lactam MICs are presented; resistance transferred by electrotransformation is bold (when only blaOXA-58 was transferred) or bold and underlined (when both blaIMP-5 and blaOXA-58 
were transferred).
ATM: Aztreonam; CAZ: Ceftazidime; CN: Gentamicin; FEP: Cefepime; IMP: Imipenem; K: Kanamycin; MEM: Meropenem; PTZ: Piperacillin-tazobactam; TOB: Tobramycin.
10.2217/fmb.15.88 Future Microbiol. (Epub ahead of print)
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Figure 1. Apa I-, I-Ceu I- and S1-PFGE patterns from A. bereziniae isolates. (A) Apa I-PFGE, lane 
1 HGSA93, lane 2 HGSA593; (B) I-Ceu I- PFGE and respective southern blot, lane 3 HGSA93, lane 4 
HGSA593, lane 5 HGSA93 IMP-5 hybridization, lane 6 HGSA593 IMP-5 hybridization; S1-PFGE and 
respective Southern blot, lane 7 HGSA93, lane 8 HGSA593, lane 9 HGSA93 IMP-5 hybridization, lane 
10 HGSA593 IMP-5 hybridization.
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ApaI followed by pulsed-field gel electrophoresis 
(PFGE).
Results & discussion
HGSA93 and HGSA593 isolates belonged to 
A. bereziniae species, according to the rpoB 
partial gene sequencing (with both displaying 
98% nucleotide identity with A. bereziniae type 
strain CIP 70.12T, GenBank accession num-
ber DQ207475.1). The blaOXA-228, an intrin-
sic oxacillinase gene from A. bereziniae spe-
cies, was detected by PCR (100% homology 
with blaOXA-228 gene described in A. bereziniae 
strain CIP 70.12TGenBank accession number 
JQ422053.1) and presented the same promoter 
sequences (TTCAAT and TGGTAT for the -35 
and -10 sequences, respectively) that have been 
related with its low expression [14,15].
Both isolates presented an unusual antibiotic 
resistance profile that included resistance to all 
tested β-lactams. HGSA93 remained susceptible 
to aminoglycosides (except kanamycin), while 
HGSA593 was only susceptible to amikacin 
(Table 1). Blue-carba test revealed the presence 
of carbapenemase activity and the bioassay with 
EDTA strongly suggested the presence of an 
MBL, further identified as IMP-5 in both isolates 
by PCR and sequencing. Search for acquired 
CHDL revealed that HGSA593 also harbored 
blaOXA-58, which is a carbapenemase that had 
10.2217/fmb.15.88
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been endemic within this hospital among A. 
baumannii clinical isolates and disappeared 
after 2006 [5]. Sequencing of the blaIMP-5-encod-
ing class 1 integron, from HGSA93, revealed 
100% homology with the previously described 
In76 [1] and its nucleotide sequence was depos-
ited in the GenBank database (accession num-
ber KF732850.1). PCR mapping showed that 
this genetic platform was also flanked by MITE 
structures, a fact that might justify blaIMP-5 gene 
mobilization [2,3]. Curiously, sequence analysis 
indicated the presence of a weak -35 promoter 
(TTGACA instead of TTGATA) upstream 
blaIMP-5 gene [23], contrary to what was expected 
by the observed high carbapenem resistance level 
(Table 1). HGSA593 harbored similar genetic 
vicinity for blaIMP-5, but the integron content 
included an extra gene cassette (blaOXA-4) down-
stream blaIMP-5 gene. Moreover, HGSA593 
harbored another class 1 integron carrying an 
aacA4 gene, which might explain its additional 
resistance to aminoglycosides. I-CeuI- and S1 
hybridizations revealed that blaIMP-5 gene was 
located in a ∼310 Kb plasmid for HGSA93 and 
in a ∼200 Kb plasmid for HGSA593 (Figure 1) 
and blaOXA-58 was located in a ∼90 Kb additional 
plasmid. These plasmids were untypeable using 
the current replicon typing scheme [22], which is 
now commonly reported among non-baumannii 
Acinetobacter species [24]. Conjugation attempts 
were unsuccessful, but plasmids from HGSA593 
were transferred and expressed in A. baylyi 
ADP1, with transformants exhibiting resistance 
to β-lactams, including carbapenems (Table 1).
Curiously, ApaI-PFGE assay revealed that A. 
bereziniae isolates were unrelated (Figure 1), sug-
gesting that this species might easily acquire dif-
ferent plasmids and act as reservoir of clinically 
relevant resistance genes.
Conclusion
Our data highlight the ability of non-bau-
mannii Acinetobacter species to acquire rel-
evant resistance genes which could contribute 
for their emergence as nosocomial pathogens. 
Furthermore, cumulative findings suggest that 
different species of Acinetobacter seem to con-
stitute important reservoirs of resistance genes 
outside clinical settings. In this study, although 
the first A. bereziniae isolate was not associated 
with any infection episode, its detection in the 
newborn’s incubator humidity chamber, along 
with the second bloodstream isolate and previ-
ous works on this species, should indicate the 
possibility of ‘environmental’ species emerge 
as etiologic agents of nosocomial infections, 
 particularly within vulnerable populations.
Finally, we believe that further studies focused 
on the local microbial ecology of carbapenemase 
producers are imperative for the full understand-
ing of the observed endemicity of IMP-5 in our 
country and for the effective prevention of its 
dissemination.
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EXECUTIVE SUMMARY
 ●  We extended the species reservoir of the ‘exclusively Portuguese’ IMP-5 carbapenemase.
 ●  Environmental Acinetobacter bereziniae isolates could act as reservoirs for blaIMP-5.
 ●  Newborn incubator systems could be a source of carbapenemase producing Acinetobacter spp.
 ●  We confirm the pathogenic potential of carbapenem-resistant A. bereziniae.
References
Papers of special note have been highlighted as: 
s OF INTEREST ss OF CONSIDERABLE INTEREST
1 Da Silva GJ, Correia M, Vital C et^al. 
Molecular characterization of bla(IMP-5), a 
new integron-borne metallo-beta-lactamase 
gene from an Acinetobacter baumannii 
nosocomial isolate in Portugal. FEMS 
Microbiol. Lett. 215(1), 33–39 (2002).
2 Domingues S, Nielsen KM, Da Silva GJ. 
The blaIMP-5-carrying integron in a clinical 
Acinetobacter baumannii strain is flanked by 
miniature inverted-repeat transposable 
elements (MITEs). J. Antimicrob. Chemother. 
66(11), 2667–2668 (2011).
3 Zong Z. The complex genetic context of 
blaPER-1 flanked by miniature inverted-repeat 
transposable elements in Acinetobacter 
10.2217/fmb.15.88 Future Microbiol. (Epub ahead of print)
3.2. Contribution of non-baumannii Acinetobacter species 
 126 
Extending the reservoir of blaIMP-5 PRELIMINARY COMMUNICATION
future science group www.futuremedicine.com
johnsonii. PLoS ONE 9(2), e90046 (2014).
4 Grosso F, Quinteira S, Peixe L. Emergence of 
an extreme-drug-resistant (XDR) 
Acinetobacter baumannii carrying blaOXA-23 in 
a patient with acute necrohaemorrhagic 
pancreatitis. J. Hosp. Infect. 75(1), 82–83 
(2010).
5 Grosso F, Quinteira S, Peixe L. 
Understanding the dynamics of imipenem-
resistant Acinetobacter baumannii lineages 
within Portugal. Clin. Microbiol. Infect. 17(8), 
1275–1279 (2011).
6 Turton JF, Shah J, Ozongwu C, Pike R. 
Incidence of Acinetobacter species other than 
A. baumannii among clinical isolates of 
Acinetobacter: evidence for emerging species. 
J. Clin. Microbiol. 48(4), 1445–1449 (2010).
s  )NTERESTING PAPER THAT CLARIlES THE ROLE OF 
NONbaumannii Acinetobacter SPECIES AS 
IMPORTANT INFECTIOUS AGENTS
7 Berlau J, Aucken HM, Houang E, Pitt TL. 
Isolation of Acinetobacter spp. including 
A. baumannii from vegetables: implications 
for hospital-acquired infections. J. Hosp. 
Infect. 42(3), 201–204 (1999).
8 Dijkshoorn L, van Aken E, Shunburne L 
et^al. Prevalence of Acinetobacter baumannii 
and other Acinetobacter spp. in faecal samples 
from non-hospitalised individuals. Clin. 
Microbiol. Infect. 11(4), 329–332 (2005).
9 Nemec A, Musílek M, Sedo O et^al. 
Acinetobacter bereziniae sp. nov. and 
Acinetobacter guillouiae sp. nov., to 
accommodate Acinetobacter genomic species 
10 and 11, respectively. Int. J. Syst. Evol. 
Microbiol. 60(Pt 4), 896–903 (2010).
10 Lee K, Kim CK, Hong SG et^al. 
Characteristics of clinical isolates of 
Acinetobacter genomospecies 10 carrying two 
different metallo-beta-lactamases. Int. J. 
Antimicrob. Agents 36(3), 259–263 (2010).
11 Yamamoto M, Nagao M, Matsumura Y et^al. 
Regional dissemination of Acinetobacter 
species harbouring metallo-β-lactamase genes 
in Japan. Clin. Microbiol. Infect. 19(8), 
729–736 (2013).
12 Jones LS, Carvalho MJ, Toleman MA et^al. 
Characterization of plasmids in extensively 
drug-resistant Acinetobacter strains isolated in 
India and Pakistan. Antimicrob. Agents 
Chemother. 59(2), 923–929 (2015).
13 Park YK, Jung SI, Park KH, Kim SH, Ko KS. 
Characteristics of carbapenem-resistant 
Acinetobacter spp. other than Acinetobacter 
baumannii in South Korea. Int. J. Antimicrob. 
Agents 39(1), 81–85 (2012).
14 Bonnin RA, Ocampo-Sosa AA, Poirel L, 
Guet-Revillet H, Nordmann P. Biochemical 
and genetic characterization of carbapenem-
hydrolyzing β-lactamase OXA-229 from 
Acinetobacter bereziniae. Antimicrob. Agents 
Chemother. 56(7), 3923–3927 (2012).
15 Zander E, Seifert H, Higgins PG. Insertion 
sequence IS18 mediates overexpression of 
bla(OXA-257) in a carbapenem-resistant 
Acinetobacter bereziniae isolate. J. Antimicrob. 
Chemother. 69(1), 270–271 (2014).
16 La Scola B, Gundi VA, Khamis A, Raoult D. 
Sequencing of the rpoB gene and flanking 
spacers for molecular identification of 
Acinetobacter species. J. Clin. Microbiol. 
44(3), 827–832 (2006).
17 Clinical and Laboratory Standards Institute. 
Performance Standards for Antimicrobial 
Susceptibility Testing: 23rd Informational 
Supplement M100-S23. CLSI, Wayne, PA, 
USA (2013).
18 Pires J, Novais A, Peixe L. Blue-carba, an easy 
biochemical test for detection of diverse 
carbapenemase producers directly from 
bacterial cultures. J. Clin. Microbiol. 51(12), 
4281–4283 (2013).
ss  4HIS PAPER PROPOSES AN INHOUSE 
METHODOLOGY TO DETECT IN ONLY  H THE 
CARBAPENEMASE PRODUCTION DIRECTLY FROM 
BACTERIAL CULTURES
19 Woodford N, Ellington MJ, Coelho JM et^al. 
Multiplex PCR for genes encoding prevalent 
OXA carbapenemases in Acinetobacter spp. Int. 
J. Antimicrob. Agents. 27(4), 351–353 (2006).
20 Levesque C, Piche L, Larose C, Roy PH. PCR 
mapping of integrons reveals several novel 
combinations of resistant genes. Antimicrob. 
Agents Chemother. 39(1), 185–191 (1995).
21 Valverde A, Cantón R, Galán JC, Nordmann 
P, Baquero F, Coque TM. In117, an unusual 
In0-like class 1 integron containing CR1 and 
bla(CTX-M-2) and associated with a 
Tn21-like element. Antimicrob. Agents 
Chemother. 50(2), 799–802 (2006).
22 Bertini A, Poirel L, Mugnier PD, Villa L, 
Nordmann P, Carattoli A. Characterization 
and PCR-based replicon typing of resistance 
plasmids in Acinetobacter baumannii. 
Antimicrob. Agents Chemother. 54(10), 
4168–4177 (2010).
ss  6ERY IMPORTANT PAPER THAT PROPOSES A SCHEME 
FOR Acinetobacter PLASMIDS CLASSIlCATION THAT 
ENABLED TO BETTER UNDERSTAND THE RESISTANCE 
EPIDEMIOLOGY AND THE ROLE OF HORIZONTAL 
TRANSFER IN ITS DISSEMINATION
23 Brízio A, Conceição T, Pimentel M, Da Silva 
G, Duarte A. High-level expression of IMP-5 
carbapenemase owing to point mutation in 
the -35 promoter region of class 1 integron 
among Pseudomonas aeruginosa clinical 
isolates. Int. J. Antimicrob. Agents. 27(1), 
27–31 (2006).
24 Fu Y, Jiang J, Zhou H et^al. Characterization 
of a novel plasmid type and various genetic 
contexts of bla OXA-58 in Acinetobacter spp. 
from multiple cities in China. PLoS ONE 
9(1), e84680 (2014).
10.2217/fmb.15.88
3.2. Contribution of non-baumannii Acinetobacter species 
 127 
 
Exploring non-hospital-related settings of Angola reveals new 
Acinetobacter reservoirs for blaOXA-23 and blaOXA-58 
 
 
Liliana Silva1, Filipa Grosso2, Raquel Branquinho2, Teresa Gonçalves Ribeiro2, Clara 
Sousa3, Luísa Peixe2 
 
 
1UCIBIO/REQUIMTE, Departamento de Ciências Biológicas, Laboratório de 
Microbiologia, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo 
Ferreira n° 228, 4050-313 Porto, Portugal; ESALD, Instituto Politécnico de Castelo 
Branco, Castelo Branco, Portugal. 2UCIBIO/REQUIMTE, Departamento de Ciências 
Biológicas, Laboratório de Microbiologia, Faculdade de Farmácia, Universidade do Porto, 
Rua de Jorge Viterbo Ferreira n° 228, 4050-313 Porto, Portugal. 3LAQV/REQUIMTE, 
Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 
Porto, Portugal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
International Journal of Antimicrobial Agents 2016; 48(2):228-30 
 
 
Authorized reproduction of the final published PDF version of this paper in this thesis 
 
3.2. Contribution of non-baumannii Acinetobacter species 
 128 
mcr-1-mediated colistin resistance would force strains to rapidly
eradicate from the normal gut flora. Previous reports on short-
term colonisation of colistin-resistant E. coli are consistent with this
[3]. However, travel and the constant influx of new and better
adapted strains is a continuous cause of concern.
Presently, ESBL resistance or other co-resistance was not linked
to pIP2-01, but as an IncI2 plasmid in E. coli our biggest fear is that
ESBLs andmcr-1 evolutionary paths converge and together find their
way to nosocomial species, possibly causing severe outbreaks in the
future. Analyses made in retrospect indicate thatmcr-1 alone or in
co-location with ESBLs are present, although undetected, in most
continents [4]. So far, the earliest report is of an mcr-1-positive
Chinese chicken isolate dating from the 1980s [5].
In conclusion, we report the first detection of plasmid-mediated
mcr-1 in Norway. This finding adds to the documentation of the
global dissemination of plasmid-mediatedmcr-1, including spread
via normal flora E. coli. The origin of pIP2-01 remains uncertain, al-
though the patient’s travel history substantiates import from India.
This observation establishes the presence ofmcr-1-harbouring plas-
mids in Norway since 2014.
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Exploring non-hospital-related settings in
Angola reveals new Acinetobacter reservoirs
for blaOXA-23 and blaOXA-58
Sir,
Infections caused by carbapenem-resistant Acinetobacter spp. have
a significant impact on patient morbidity andmortality. Carbapenem
resistance arises mostly by the production of carbapenem-
hydrolysing class D β-lactamases (CHDLs), which are not limited to
Acinetobacter baumannii but also occur in other Acinetobacter spp.
increasingly associated with human infections [1]. However, little
is known about the presence of CHDLs and their origins and res-
ervoirs among Acinetobacter from non-clinical sources. Furthermore,
in Africa, available data regarding Acinetobacter epidemiology and
carbapenem resistance are limited to A. baumannii clinical iso-
lates mainly from northern countries [2]. Angola, a sub-Saharan
country with close relations with Europe, Asia and South America,
is characterised by poor sanitary conditions that increase the po-
pulation’s vulnerability, currently reflected by the record numbers
of malaria and yellow fever (http://www.cdc.gov/yellowfever/
maps/africa.html).
In this study, the occurrence, diversity and antimicrobial resis-
tance, in particular to carbapenems, of Acinetobacter spp. from non-
clinical sources from Benguela Province (Angola) was evaluated as
part of a larger surveillance project on bacterial resistance to clin-
ically relevant antibiotics [3].
From 63 samples [3] collected in different communes of Ben-
guela Province, 29 revealed the presence of Acinetobacter, including
rectal swabs from healthy volunteers (8/18), aquatic environments
(river, human drinking water, wastewater; 8/20), rectal swabs from
healthy animals (calf/cows; 3/10) and their respective environ-
ments (water, feed, floor/walls; 7/8) from four different farms, and
drinking water from awild park (3/3) (Supplementary Table S1). The
remaining samples (rectal swabs frommonkeys and goats) were neg-
ative for Acinetobacter. Presumptive Acinetobacter isolates (n = 73)
recovered from CHROMagar™ Orientation with/without cefotaxime
(1mg/L), ceftazidime (1mg/L) or imipenem (1mg/L) were further
identified using a Bruker Biotyper® matrix-assisted laser desorption/
ionisation time-of-flightmass spectrometry (MALDI-TOF/MS) system
aswell as rpoB/gyrB analysis [1,4]. Ten different Acinetobacter spp. were
identified, with MALDI-TOF/MS results being congruent with rpoB/
gyrB, except for A gerneri, A. bereziniae and A. pittii, first identified as
Alcaligenes faecalis, A. guillouiae and A. baumannii, respectively. In ad-
dition, MALDI-TOF/MS identified three isolates as A. towneri, however
rpoB/gyrB revealed only 92–93% nucleotide similaritywith this species,
being given the provisional name of A. towneri-like sp.
A. baumannii was the most predominant species (26/73)
(Supplementary Table S1). Interestingly, some particular clones es-
tablished by pulsed-field gel electrophoresis (PFGE) with the
restriction enzyme ApaI (Supplementary Table S1) were detected
both from healthy volunteers and water samples (untreated waste-
water, river and drinking water for animals), raising the possibility
of a water–human cycle of transmission. A. pittiiwas the secondmost
prevalent species (17/73) and, to our knowledge, was identified for
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the first time in rivers, wastewater and healthy farm animals
(Supplementary Table S1). Farms were the most enriched environ-
ment, presenting a high variety of Acinetobacter spp.
Susceptibility to different β-lactams, aminoglycosides, tetracy-
clines and quinolones was determined by disk diffusion and Etest
methods according to European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) and Clinical and Laboratory Standards
Institute (CLSI) guidelines, with the majority of isolates showing
reduced susceptibility to at least one of the antimicrobial agents,
mostly β-lactams (Supplementary Table S1). Carbapenemases were
searched for by the Blue-Carba assay and PCR for all isolates [1].
Four isolates were Blue-Carba-positive, presenting an imipenem
minimum inhibitory concentration (MIC) greater than the epide-
miological cut-off value (ECOFF) but lower than the clinical resistance
breakpoint (Table 1). PCR assays identified blaOXA-23 among A. towneri-
like isolates (n = 3) and blaOXA-58 in one A. johnsonii isolate (Table 1).
Curiously the OXA-23-producing A. towneri-like isolates were clon-
ally unrelated, obtained from Lobito River and untreated wastewater
(20 km distant). Moreover, these samples harboured additional re-
sistant bacteria (Table 1) [3]. The OXA-58-producing A. johnsonii
was obtained from treated tap water also positive for A. baumannii
and A. pittii, suggesting an important role for water in the trans-
mission of Acinetobacter spp. to humans in this region. To our
knowledge, this is the first evidence of OXA-58-producingmultidrug-
resistant A. johnsonii isolates from a non-related-hospital source.
I-CeuI- and S1-PFGE hybridisations [1] revealed the chromosomal
location of blaOXA-23 and the association of blaOXA-58 with an ca. 75-
kb untypable plasmid. The blaOXA-58 transformants, obtained by
electrotransformation of a rifampicin-resistant mutant A. baumannii
ATCC 17978 strain, acquired resistance to β-lactams, particularly
imipenem (MIC = 4 mg/L), and to tetracycline (Table 1).
These results, along with a recent study on an A. johnsonii isolate
from hospital sewage and also bearing a blaOXA-58-carrying untypable
plasmid, add evidence that this species could act as an important
carbapenem resistance reservoir [5].
In summary, this work revealed a high diversity of Acinetobacter
spp. scattered in different settings in this region and the occurrence
of CHDL-producing non-baumannii Acinetobacter spp. in non-
clinical niches. Remarkably, expression of OXA-23 and OXA-58 in
these species remained low, which may facilitate their silent dis-
semination. However, we cannot exclude the development of high
levels of carbapenem resistance under antibiotic selective pres-
sure or with genetic transfer to other Acinetobacter spp., as we
observedwith A. baumannii transformationwith the blaOXA-58-carrying
plasmid. Although the origin of the carbapenemases in these par-
ticular species remains unclear, there is a possible local enrichment
of particular CHDL-producers, alerting for the risk of less explored
environmental Acinetobacter spp. in other settings worldwide.
Moreover, human exposure to CHDL-producing Acinetobacter de-
scribed here, likely associated with ineffective water treatment, is
particularly worrisome for vulnerable populations living in Angola.
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Table 1
Characterisation of carbapenemase-producing Acinetobacter spp. isolates.
Species (n) Origin/sample Communea PFGE
typeb
Acquired CHDL
and genetic
environment
CHDL gene
location
CarbapenemMIC (mg/L) Resistance
to other
antibiotics
Concomitant
resistant bacteria
(n)dParent Transformant
MEM IPMc MEM IPM
A. johnsonii (1) Drinking water for
humans/56
Baía Farta AjoI blaOXA-58 (ISAba3
downstream)
Ca. 75 kb
untypable
plasmide
1.5 1.5 2.0 4.0f FEP, CAZ,
CRO, TET,
CIP
–
A. towneri-like
sp. (3)g
Lobito river water/39 Lobito AtI blaOXA-23 (ISAba1
upstream)
Chromosome 1 3 NA NA – Klebsiella pneumoniae
with SHV-12 (1)
Untreated wastewater
from a treatment
station/45
Benguela AtII blaOXA-23 (ISAba1
upstream)
Chromosome 1.5 1.5 NA NA FEP –
Wastewater from an
urban sewer line/58
Catumbela AtIII blaOXA-23 (ISAba1
upstream)
Chromosome 1.5 2 NA NA – Klebsiella oxytocawith
blaCTX-M-15 (1)
PFGE, pulsed-field gel electrophoresis; CHDL, carbapenem-hydrolysing class D β-lactamase; MIC, minimum inhibitory concentration; MEM, meropenem; IPM, imipenem;
FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; TET, tetracycline; CIP, ciprofloxacin; NA, not applicable.
a Samples were collected from Benguela Province, which comprises nine municipalities (Benguela, Lobito, Bocoio, Balombo, Ganda, Cubal, Caimbambo, Baía Farta and
Chongorói), divided into more than 30 communes.
b Clonality was established by SmaI (for Acinetobacter junii and A. johnsonii) or ApaI (for other Acinetobacter spp.) PFGE. Pattern analysis was performed by InfoQuest with
PFGE types comprising isolates with SmaI/ApaI patterns presenting similarity levels >74.5%.
c MICs higher than the epidemiological cut-off value (ECOFF) (1 mg/L) but lower than the clinical resistance breakpoint (2–8 mg/L) or within intermediate susceptibility
clinical range in A. towneri-like (sample 39).
d Ribeiro et al [3].
e Untypeable by the current Acinetobacter replicon typing scheme [1].
f MIC higher than that observed in the donor strain.
g New primers were designed for gyrB A. towneri-like sp. isolates amplification and sequencing: gyrB_AcT1_F, GTGGCCTAGATGCTGTTCGT; gyrB_AcT1_R,
TTACCCGCGATAGATTTTGC; gyrB_AcT2_F, AAGGTTTAACCGCGATTGTG; and gyrB_AcT2_R, GGCCAATACGTTGCAGATTT.
Antimicrobial resistance transfer by transformation appears in bold.
229Letters to the Editor / International Journal of Antimicrobial Agents 48 (2016) 220–230
3.2. Contribution of non-baumannii Acinetobacter species 
 130 
References
[1] Grosso F, Silva L, Sousa C, Ramos H, Quinteira S, Peixe L. Extending the reservoir
of blaIMP-5: the emerging pathogen Acinetobacter bereziniae. Future Microbiol
2015;10:1609–13.
[2] Manenzhe RI, Zar HJ, Nicol MP, Kaba M. The spread of carbapenemase-producing
bacteria in Africa: a systematic review. J Antimicrob Chemother 2015;70:23–40.
[3] Ribeiro TG, Novais Â, Peixe L, Machado E. Atypical epidemiology of CTX-M-15
among Enterobacteriaceae from a high diversity of non-clinical niches in Angola.
J Antimicrob Chemother 2016;71:1169–73.
[4] Yamamoto S, Harayama S. PCR amplification and direct sequencing of gyrB genes
with universal primers and their application to the detection and taxonomic
analysis of Pseudomonas putida strains. Appl Environ Microbiol 1995;61:1104–9.
Erratum in: Appl Environ Microbiol 1995;61:3768.
[5] Feng Y, Yang P, Wang X, Zong Z. Characterization of Acinetobacter johnsonii isolate
XBB1 carrying nine plasmids and encoding NDM-1, OXA-58 and PER-1 by genome
sequencing. J Antimicrob Chemother 2016;71:71–5.
Liliana Silva
UCIBIO/REQUIMTE, Departamento de Ciências Biológicas,
Laboratório de Microbiologia, Faculdade de Farmácia,
Universidade do Porto, Rua de Jorge Viterbo Ferreira n° 228, 4050-
313 Porto, Portugal
ESALD, Instituto Politécnico de Castelo Branco, Castelo Branco,
Portugal
Filipa Grosso
Raquel Branquinho
Teresa Gonçalves Ribeiro
UCIBIO/REQUIMTE, Departamento de Ciências Biológicas,
Laboratório de Microbiologia, Faculdade de Farmácia,
Universidade do Porto, Rua de Jorge Viterbo Ferreira n° 228, 4050-
313 Porto, Portugal
Clara Sousa
LAQV/REQUIMTE, Departamento de Ciências Químicas,
Faculdade de Farmácia, Universidade do Porto, Porto, Portugal
Luísa Peixe *
UCIBIO/REQUIMTE, Departamento de Ciências Biológicas,
Laboratório de Microbiologia, Faculdade de Farmácia,
Universidade do Porto, Rua de Jorge Viterbo Ferreira n° 228, 4050-
313 Porto, Portugal
* Corresponding author. UCIBIO/REQUIMTE,
Departamento de Ciências Biológicas,
Laboratório de Microbiologia, Faculdade de Farmácia,
Universidade do Porto, Rua de Jorge Viterbo Ferreira n° 228, 4050-
313 Porto, Portugal. Tel.: +351 22 042 8580; fax: +351 226 093 390.
E-mail address: lpeixe@ff.up.pt (L. Peixe)
20 May 2016
11 June 2016
http://dx.doi.org/10.1016/j.ijantimicag.2016.06.003
230 Letters to the Editor / International Journal of Antimicrobial Agents 48 (2016) 220–230
3.2. Contribution of non-baumannii Acinetobacter species 
 131 
Supplementary Table S1 
Diversity of Acinetobacter spp. isolates recovered from different origins in Angola (2013) 
 
Origin/sample identification Species (no.) PFGE type a Antibiotic resistance profile Commune b 
Healthy volunteers     
Rectal swab HV 19 A. baumannii (1) AbI CRO Benguela 
HV 28 A. baumannii (1) AbII CRO 
A. ursingii (2) AuI (2) CRO, FEP 
HV 29 A. baumannii (3) AbIII, AbIV, AbV CRO 
A. baumannii (2) AbVI (2) CRO 
HV 34  A. baumannii (3) AbVII (3) CRO 
A. ursingii (1) AuII CRO 
HV 35  A. bereziniae (1) NA CRO 
A. baumannii (1) AbV CRO, TET 
HV 37  A. ursingii (1) AuIII  CRO, CAZ 
 HV 31  A. junii (2) AjI (2) – Baía Farta 
Healthy animals and their respective environments    
Farm A Animal feed/65 A. pittii (3) ApI, ApII, ApIII CRO, (CAZ) Benguela 
Floor, walls/5 A. gerneri (1) NA CRO, TET 
Drinking water/52 A. junii (1) AjII – 
A. pittii (2)  ApIV (2) CRO 
Farm B Floor, walls/10 A. variabilis (1) NA CRO, TET Benguela 
Farm C Rectal swabs of 
healthy animals - 
calf/13 
A. baumannii (1) AbVIII CRO Benguela 
Drinking water/40 A. baumannii (2) AbIX (2) CRO 
Farm D Rectal swabs of 
healthy animals - 
calf/14 
A. pittii (1) ApV CRO Benguela 
A. soli (1) AsI CRO 
Rectal swabs of 
healthy animals - 
cow/15 
A. soli (2) AsII (2) CRO 
Animal feed/48 A. baumannii (1) AbX CRO, AMK, GEN, TOB, 
TET 
Drinking water/55 A. junii (3) AjIII (3) (CRO) 
Wild park Drinking water/43 A. baumannii (2) AbXI, AbXII CRO Dombe Grande 
A. junii (1) AjIV CRO 
Drinking water/44 A. baumannii (4) AbXI (4) CRO 
A. junii (1) AjV CRO 
Drinking water/63 A. pittii (1) ApVI CRO 
Aquatic environments     
Drinking water for 
humans 
DW/56 A. baumannii (1) AbXIII CRO, CAZ Baía Farta 
A. pittii (3) ApVII (3) CRO, (CAZ) 
A. johnsonii (1) AjoI CRO, CAZ, FEP, TET, CIP 
River (R) R/38 A. pittii (2) ApVIII, ApIX CRO Catumbela 
R/39 A. baumannii (1) AbIII CRO Lobito 
A. johnsonii (2) AjoII, AjoIII (CRO), (FEP) 
A. junii (2) AjVI (2) (CAZ) 
A. pittii (1) ApX CRO 
A. soli (1) AsIII CRO, TET 
A. towneri-like sp. (1) AtI IPM, MEM 
R/42 A. baumannii (2) AbXI (2) (CRO) Dombe Grande 
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Wastewater from 
a treatment station 
Untreated W/45 A. baumannii (1) AbI CRO Benguela 
A. junii (1) AjVII CIP 
A. towneri-like sp. (1) AtII FEP 
Treated W/46 A. junii (2) AjVIII, AjIX (CIP) 
Wastewater from 
an urban sewer 
line 
W/58 A. pittii (1) ApVII CRO, CAZ Catumbela 
A. towneri-like sp. (1) AtIII – 
W/59 A. pittii (3) ApII, ApXI (2) CRO Benguela 
PFGE, pulsed-field gel electrophoresis; CRO, ceftriaxone; FEP, cefepime; TET, tetracycline; CAZ, ceftazidime; AMK, amikacin; 
GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; NA, not applicable. 
a Clonality was established by SmaI (for Acinetobacter junii and Acinetobacter johnsonii) or ApaI (for other Acinetobacter spp.) 
pulsed-field gel electrophoresis (PFGE). Pattern analysis was performed by InfoQuest with PFGE types comprising isolates with 
SmaI/ApaI patterns presenting similarity levels >74.5%. 
b Samples were collected from Benguela Province, which comprises nine municipalities (Benguela, Lobito, Bocoio, Balombo, 
Ganda, Cubal, Caimbambo, Baía Farta and Chongorói), divided in more than 30 communes. 
Bold indicates common clones among different samples. Parenthesis indicate variability of a given resistance determinant. 
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Objectives: Two carbapenemase-carrying plasmids, pLS488 (blaOXA-23) and pLS535 (blaOXA-58) fromAcinetobacter pittii
clinical isolates,were characterized in this study, including their ability to be transferred toAcinetobacter baumannii.
Methods: The clinical isolates were obtained from drainage fluid of a patient with biliary tract cancer and from
an exudate of a patient with a hip infection (Portuguese University Hospital, 2012). Isolate characterization
included antimicrobial susceptibility tests, carbapenemase production by Blue-Carba, carbapenem-hydrolysing
class D b-lactamase (CHDL) gene search by PCR sequencing, ApaI-PFGE, CHDL genetic location and plasmid size
by hybridization andWGS. Plasmid transfer was performed by conjugation or electroporation.
Results: pLS488 constitutes the first conjugative plasmid reported to carry a carbapenem resistance gene
in A. pittii and is part of a potential new incompatibility group that might also account for the dissemination of
OXA-23 in A. baumannii. pLS535 belongs to the Acinetobacter GR7 incompatibility group and presents a new
scaffold for OXA-58. This plasmid lacked the machinery for conjugation, but was transferable by electroporation
to A. baumannii. Both isolates, which displayed the same PFGE pattern, represent the first report of
CHDL-carrying A. pittii in Portuguese hospitals.
Conclusions: Altogether, these results emphasize the importance of A. pittii, or particular A. pittii clones, as a
source of resistance genes, facilitating their dissemination among different bacterial species.
Introduction
Carbapenem resistance in Acinetobacter spp. has been mostly
associatedwith the production of OXA-23, OXA-24/40 andOXA-58
carbapenem-hydrolysing class D b-lactamases (CHDLs).1,2 The
spread of these CHDLs among Acinetobacter baumannii has been
strongly influenced by clonal expansion, but also by horizontal
gene transfer (HGT).1,3 However, the contribution of HGT to the
spread of CHDL among other Acinetobacter species, in particular
Acinetobacter pittii, which is increasingly reported in clinical set-
tings (mainly in Asia, but also in Europe and America, and was re-
cently described in Portugal in lettuce, fruits and raw meat),2,4,5
has scarcely been explored. To date, only one complete blaOXA-58-
carrying plasmid sequence (pOXA58-AP_882) has been described
for this species, with no descriptions of blaOXA-23-associated
plasmids.6 In order to obtain new insights into the contribution of
A. pittiimobile elements to CHDL dissemination, we report here the
characterization of two carbapenemase-carrying plasmids,
pLS488 (blaOXA-23) and pLS535 (blaOXA-58), exploring at the same
time their ability to be transferred toA. baumannii.
Materials and methods
Bacterial strains, susceptibility testing and
carbapenemase detection
The clinical isolates included in this study were obtained from a Portuguese
university hospital that has experienced an endemicity of carbapenemase-
producing A. baumannii for several years. Inmore recent years, an increase
was observed in the frequency of non-A. baumannii species associatedwith
infection and colonization. Thus, following a surveillance screening for
carbapenemase producers among non-A. baumannii isolates, two A. pittii
isolates (HGSA488 andHGSA535), collected 3months apart and presenting
decreased susceptibility to carbapenems, were further characterized.
HGSA488 was isolated in 2012 from drainage fluid of a patient with biliary
tract cancer admitted to the surgery unit, and HGSA535 was isolated from
an exudate of a patient with hip infection admitted to the orthopaedic unit.
These isolates were initially misidentified as A. baumannii by the VITEK 2
system (bioMe´rieux), but were confirmed as A. pittii by MALDI-TOF MS and
rpoB/gyrB partial gene sequencing.7,8 Antimicrobial susceptibility profiles
of different b-lactams, aminoglycosides, tetracyclines, quinolones, tri-
methoprim/sulfamethoxazole and colistin were obtained by standard
disc diffusion, Etest (carbapenems) and broth microdilution (colistin)
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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methods, according to EUCAST (www.eucast.org) and CLSI guidelines.9
Carbapenemase production was assessed by the Blue-Carba biochemical
assay.10 CHDL genes were searched for by PCR sequencing, using primers
and conditions previously described.11 Their genetic location and plasmid
size were assessed by hybridization of S1 gels with specific probes. Genetic
relatedness was characterized by ApaI-PFGE andMLST (Oxford and Pasteur
Schemes).
WGS, assembly and plasmid sequence analysis
Total DNA from HGSA488 and HGSA535 was extracted using the Wizard
Genomic DNA purification kit (Promega Corporation, Madison, WI) according
to themanufacturer’s instructions. DNA concentrationwas estimated using a
Qubit dsDNA HS Assay Kit and a Qubit 3.0 Fluorometer (Invitrogen, Thermo
Fisher Scientific, USA). Extracted DNA was then sequenced with a standard
2%125 paired-end runs protocol on an Illumina HiSeq 2000 (Illumina, San
Diego, CA, USA). The quality of the high-throughput sequence data was as-
sessed by FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). Raw sequence reads were then de novo assembled using
plasmidSPAdes 3.9.0 (http://bioinf.spbau.ru/spades),12 in order to identify
plasmid contigs, and the quality was assessed by QUAST (http://quast.bioinf.
spbau.ru). The draft plasmids were automatically annotated with RAST
(http://rast.nmpdr.org) and further manually curated by Geneious v. 9.1.6.
(Biomatters Limited, Auckland, New Zealand) using BLASTn/BLASTp (https://
blast.ncbi.nlm.nih.gov/Blast.cgi). Conventional PCRs with further Sanger
sequencing of ampliconswere performed for plasmid circularization [primers
pLS488_F (AACCCCACACTACCATCAGC), pLS488_R (CGCTAGGATTCTCTTCAG
CTGA), pLS535_F (TGCAAGCATCTACAGTGCCT) and pLS535_R (AGTTGA
GGATCAGAACGTAGGG)] and for the detection of the new replicase found in
plasmid pLS488 [primers rep_pLS488_F (GTGTTTTGCGGCTTGTTGGA) and
rep_pLS488_R (TTGGGTCTTTTTGGCTCGGT)], following the same PCR condi-
tions proposed by Bertini et al.13 Complementary gene identification analysis
was done using ISfinder (https://www-is.biotoul.fr), ResFinder (https://cge.cbs.
dtu.dk/services/ResFinder/) and the Virulence Factors of Bacterial Pathogens
database (http://www.mgc.ac.cn/VFs/main.htm).
Mating and electrotransformation experiments
Transfer of plasmids carrying carbapenemase genes was attempted by
standard conjugation (filter-mating method at a 1:1 donor/recipient ratio,
37 !C) and electroporation assays, using a rifampicin-resistant mutant of
A. baumannii ATCC 17978 as a recipient strain. Presumptive transconju-
gants were selected using Mueller–Hinton II agar plates supplemented
with imipenem (0.5mg/L) and rifampicin (100mg/L), and presumptive
transformants were selected with imipenem (0.5mg/L). Confirmation was
performedwith antibiogramandPCR search for carbapenemase genes.
Nucleotide sequence accession numbers
The complete nucleotide sequences of pLS488 and pLS535 plasmids have
been submitted to GenBank under accession numbers MF078634 and
MF078635, respectively.
Results and discussion
General features of HGSA488 and HGSA535 isolates
HGSA488 displayed an MDR phenotype,14 being resistant to all
b-lactams tested (carbapenems MICs.32mg/L), except ceftazi-
dime, and susceptible to all non-b-lactams (including colistin,
MIC"0.5mg/L). This isolate was Blue-Carba positive and pre-
sented blaOXA-23 associated with plasmid pLS488 (Figure 1).
HGSA535 displayed resistance to almost all b-lactams (piperacil-
lin, piperacillin/tazobactam, ticarcillin, amoxicillin/clavulanic acid,
aztreonam, cefotaxime and ceftriaxone), except cefepime, cef-
tazidime, imipenem (MIC"2.0mg/L) and meropenem
(MIC"0.75mg/L), and was susceptible to almost all non-b-lac-
tams (including colistin, MIC"0.25mg/L). It is notable that al-
though this isolate was Blue-Carba negative and the imipenem
MIC was lower than the clinical resistance breakpoint (4–8mg/L),
it was higher than the epidemiological cut-off value (ECOFF)
(1mg/L), which suggested the acquisition of a carbapenem re-
sistance mechanism, further confirmed by WGS as blaOXA-58,
which is associated with plasmid pLS535 (Figure 2). Besides the
blaOXA-23 and blaOXA-58 genes identified, respectively in HGSA488
and HGSA535 isolates, other resistance genes were detected in
both genomes, including the natually occurring A. pittii b-lacta-
mases blaOXA-500 and blaADC-18.
15 The presence of several genes
previously associated with virulence in A. baumannii was also
observed; these genes were linked to biofilm formation (adeG,
csuD, bap), immune evasion (lpsB, lpxA, lpxB, lpxC, lpxD, lpxL), iron
uptake systems (barAB, basA, basB, basD, bauA, entE, hemO),
serum resistance (pbpG), outer membrane protein phospholipase
(plcC) and quorum sensing (abaI, abaR, bfmRS), which can confer
an advantage for the maintenance of this lineage in clinical set-
tings. Both isolates belong to ST1030/ST93 (Oxford and Pasteur
schemes, respectively) and present the same ApaI-PFGE band
pattern (data not shown).
Characterization of plasmid pLS488
The de novo assembly of the A. pittii HGSA488 produced a single
51316bp contig, which corresponded to the pLS488 plasmid. This
plasmid was further closed by PCR and sequencing of the ampli-
cons, with a final length of 51291bp, in agreement with the result
obtained from S1 nuclease PFGE-based sizing ("51kb, data not
shown). This plasmid comprises 50 ORFs, including genes associ-
ated with a transposon structure harbouring blaOXA-23 (Tn2008)
and presenting a GC content of 35.5% (Figure 1), a value compat-
iblewith the GC content ofA. pittii genome.
The plasmid pLS488 backbone was highly related (81% query
cover, 99% identity) to a previously described blaOXA-23-harbouring
plasmid from an A. baumannii strain isolated from the urine of a
hospitalized cat with cystitis in Germany (pIHIT7853, GenBank:
KX118105.1). The similarity between these plasmids without any
known relationship between the isolates suggests that these could
be widely disseminated in animals and humans all over the world.
On both plasmids, blaOXA-23 is embedded in a Tn2008 transposon,
flanked by an ATPase gene downstream and a complete ISAba1
27bp upstreamof bla [with inverted and double-mutated inverted
repeat left (IRL) and inverted repeat right (IRR)]. Tn2008 was also
described in several clinical A. baumannii isolates, predominantly
in China and the USA, though generallywithout characterization of
the genetic background.16,17 Curiously, our previous local epidemi-
ology studies18 showed that OXA-23 has been associated with a
different genetic background from the one here described, always
being located in transposon Tn2006 on chromosomes of
A. baumannii species. Also similar to pIHIT7853, pLS488 displayed
a DNA primase (99% identity), involved in DNA replication, the con-
served replication module comprising the characteristic parAB-
partitioning operon and the plasmid replicase [94% identity with
the one frompIHIT7853 (accession number KX118105.1)] that en-
sure the maintenance and inheritance of the plasmid. However,
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unlike those found in other Acinetobacter plasmids (mainly
repAci6 plasmids), the replicase (rep) of our plasmid and of
pIHIT7853 belong to the superfamily RdgC, a family of DNA-bind-
ing proteins that modulate the activity of the RecA recombinase,
which is involved in replication and homologous recombination
processes. RdgC proteins are restricted to the b- and c-subsections
of Proteobacteria, mainly found in Escherichia coli, Salmonella
enterica and Klebsiella pneumoniae, but also in Pseudomonas spp.
These two rep genes may represent a new replicase group (sug-
gesting higher plasmid diversity among Acinetobacter species) not
included in the A. baumannii PCR-based replicon typing scheme
proposed by Bertini et al.13 Thus, we designed an additional pair of
primers to detect a 482bp fragment that can simplify the identifi-
cation of this replicase among other Acinetobacter plasmids.
pLS488 also contains a helicase, a resolvase anda restriction endo-
nuclease, enzymes not found in pIHIT7853.
Genes of the conjugation system, including the origin of trans-
fer gene (oriT), the MOBP-type relaxase gene (traI) and the type IV
coupling protein (T4CP) gene (virD4/traG) for initiation of conjuga-
tion, as well as markers of the type IV secretion system (T4SS),
including the translocation channel protein genes (virB3/trbD,
virB6/trbL, virB8/trbF, virB9/trbG and virB10/trbI), the pilus protein
genes (virB2/trbC and virB5/trbJ) and the ATPase genes (virB4/trbE,
virB11/trbB and virD4/traG), were also present, indicating that
pLS488 is conjugative. To our knowledge, this is the first conjuga-
tive plasmid reported so far to carry a carbapenem resistance
gene in A. pittii. Consistent with this, attempts to obtain OXA-23-
producing A. baumannii transconjugants were successful [with
co-transferred resistance to all b-lactams (carbapenem
MICs.32mg/L)], emphasizing the importance of A. pittii isolates
as a source of resistance genes.
Characterization of plasmid pLS535
The de novo assembly of the A. pittiiHGSA535 genome produced a
single 11818bp contig, which corresponded to the pLS535 plas-
mid. This plasmidwas further closed by PCR and sequencing of the
amplicons to give a final length of 11388bp, in agreement with
the result obtained from S1 nuclease PFGE-based sizing (!11kb,
data not shown). This plasmid comprises 16 ORFs, presents a GC
content of 33.7% (Figure 2) and has substantial nucleotide differ-
ences (34%–37%QC, 98%–99% identity) fromother blaOXA-58-har-
bouring plasmids, such as the A. pittii plasmid pAG304 (accession
number JQ241790.1), previously described in China, but also with
plasmids of other Acinetobacter species, such as pWA3 (accession
number JQ241791.1) and pAba3207a (accession number
NZ_CP015365.1) from A. baumannii isolates (China andMexico, re-
spectively) and pXBB1-9 (accession number NZ_CP010351.1) from
anAcinetobacter johnsonii isolate (China). The common fragments
included the transcription regulator araC1 and the threonine efflux
protein lysE, and also genes associated with the platform where
OXA-58 is embedded: in the right-hand extremity, with a complete
copy of ISAba3 identified 30bp downstream of the stop codon of
blaOXA-58; and in the left-hand extremity, with an inverted
Figure 1. Schematic representation of plasmid pLS488 of A. pittii strain HGSA488. Broad arrows in the outer circle indicate genes coding for resistance
factors (orange), conjugative transfer genes (blue), replication module (yellow), insertion sequences/mobile elements (green), other factors (red) and
hypothetical proteins (grey). orf1, DNA primase; orf2, resolvase Ser-recombinase superfamily; orf3, restriction endonuclease subunit R; orf4, DNA
methylase; orf5, helicase. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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DISAba3, identified 20bp upstream of the start codon of blaOXA-58.
This DISAba3 was truncated 427bp after the start codon of the
transposase gene of ISAba3; this was caused by the C terminus
being replaced by the point-mutated IRL of ISAba32 (found in
pD36-4, a sul2-harbouringA. baumannii plasmid).
Flanking the blaOXA-58 locus (downstream of the lysE gene and
6bp upstream of the IRL of ISAba32) were two Re27 sequences
(ATTTAACATAATGGCGGTTATACGAAG and ATTTAACATAATGGCTGT
TATACGAAA), suggesting that a recombination process was re-
sponsible for the acquisition of the blaOXA-58 locus and might ex-
plain the interruption in ISAba32. Inside the DISAba3, promotor
sequences (TTTCTT and TTCTTT) were found, accounting for the
expression of OXA-58 and the imipenem MICs being higher than
the ECOFF.
On the right-hand end of Re27, a putative VapC–MazE toxin–
antitoxin systemof the type IImodulewas found.
Even though this plasmid lacked themachinery for conjugation,
which explains the failure of the conjugation experiments, we
were able to transfer it by electroporation,withA. baumannii trans-
formants acquiring resistance to all b-lactams (carbapenems
MICs.32mg/L).
Unlike the blaOXA-58-carrying A. pittii plasmids (mainly associ-
ated with rep types Aci9, Aci10 and repB)6,19,20 and the blaOXA-58-
carrying A. baumannii plasmids from European countries (mostly
associatedwith repAci1),21 the replicase protein of this plasmid be-
longs to the Rep3 superfamily (GR7 incompatibility group) and
shared 82% nucleotide identity with replicase p3ABSDF0002 from
plasmid p3ABSD, as described in France (accession number
CU468233.1).
Conclusions
In this study we characterized two new CHDL-carrying A. pittii plas-
mids, pLS488 and pLS535. pLS488 is the first conjugative plasmid
associated with a carbapenem resistance gene reported in A. pittii
and belongs to a potential new incompatibility group, which may
also contribute to the dissemination of OXA-23 amongA. baumannii.
pLS535 presents a newscaffold associatedwithOXA-58. In addition,
both isolates represent the first report, to our knowledge, of CHDL-
carryingA. pittii in Portuguesehospitals. This study also highlights the
potential ofA. pittii, or a particularA. pittii clone, to acquire and act as
a source of CHDL resistance genes,with the ability to integrate differ-
ent genetic backgrounds and the potential for further dissemination.
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Abstract The main goal of this work was to assess the ability
of Fourier transform infrared spectroscopy with attenuated total
reflectance (FTIR-ATR) to discriminate between the species of
the Acinetobacter calcoaceticus–Acinetobacter baumannii
(Acb) complex, i.e. A. baumannii, A. nosocomialis, A. pittii,
A. calcoaceticus, genomic species “Between 1 and 3” and
genomic species “Close to 13TU”. A total of 122 clinical
isolates of the Acb complex previously identified by rpoB
sequencing were studied. FTIR-ATR spectra was analysed by
partial least squares discriminant analysis (PLSDA) and the
model scores were presented in a dendrogram form. This
spectroscopic technique proved to be effective in the discrimi-
nation of the Acb complex species, with sensitivities from 90 to
100 %. Moreover, a flowchart aiming to help with species
identification was developed and tested with 100 % correct
predictions for A. baumannii, A. nosocomialis and A. pittii test
isolates. This rapid, low cost and environmentally friendly tech-
nique proved to be a reliable alternative for the identification of
these closely related Acinetobacter species that share many
clinical and epidemiological characteristics and are often difficult
to distinguish. Its validation towards application on a routine
basis could revolutionise high-throughput bacterial identification.
Introduction
The genus Acinetobacter currently comprises 29 distinct
species with valid names (http://www.bacterio.cict.fr/a/
acinetobacter.html) and a number of taxa which include
either genomic species (gen. sp.) delineated by DNA–DNA
hybridisation [1] or species with effectively (but not validly)
published names. Some of these species are difficult to
identify using current methods available in routine
clinical laboratories, in particular those belonging to the
Acinetobacter calcoaceticus–Acinetobacter baumannii (Acb)
complex, which encompasses four phenotypically and geno-
typically related species with valid names, i.e. A. baumannii,
A. nosocomialis, A. pittii an A. calcoaceticus, and two provi-
sional gen. sp., i.e. the so-called “Between 1 and 3” and
“Close to 13TU” [2].
Among the members of the Acb complex, A. baumannii is
the most clinically important species, which is frequently
involved in nosocomial infections including serious outbreaks
and associated with increasing reports of multidrug- and
pandrug-resistant strains, as well as with higher mortality rates
and poorer outcomes when compared with the related species
[3, 4].
Moreover, we have assisted to increasing reports of noso-
comial infections of non-A. baumannii species of the Acb
complex [5]. These species differ from A. baumannii in char-
acteristics regarding infectious potential, antimicrobial sus-
ceptibility and mortality rates, which dictates the need for
precise identification to guide the therapy and improve the
clinical outcome [4].
A number of genotypic methods have been proposed for
Acinetobacter species identification [1]. The most widely
used identification approaches include polymerase chain
reaction (PCR) amplification and sequencing of species-
specific DNA regions (e.g. the intrinsic oxacillinases from
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different Acinetobacter species) [6] or, more recently, partial
rpoB gene sequence analysis [7]. However, these methods are
labourious, time-consuming and expensive. The development
of infrared and mass spectrometers such as Fourier transform
infrared spectroscopy (FTIR) and matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry
(MALDI-TOF MS) [8] and the availability of sophisticated
mathematical tools have lead to a growing interest in the
application of spectroscopy in bacterial identification
and typing. FTIR combined with multivariate data
analysis has already demonstrated an interesting potential
for the discrimination of pathogenic and/or Gram-
positive and Gram-negative bacteria at different levels
(species, subspecies, serotype and, more recently, at the
clonal lineage level) [9, 10]. FTIR spectra result from the
interaction of infrared radiation with the bacterial isolate,
providing a specific fingerprint that reflects the structure
and composition of the whole cell [11, 12]. In the atten-
uated total reflectance (ATR) mode, the infrared beam
made contact with the bacterial isolate and became
Table 1 Epidemiologic details of the Acinetobacter spp. isolates used in this work
Species No. of
isolates
Sequence typea Country Year of
isolation
Specimen References
A. baumannii 17 9, 10, 11, 12, 15, 34,35,
36, 37, 38, 39, 40, 47
CZ 1992–2011 Sputum, tracheal secretion, IV cannula,
wound, nasal swab, urine, tracheal aspirate
[14, 15]
2 1 CZb 2011–2012 Sputum, wound [13]
7 1, 2, 3, 18, 27, 48, 55 N 1982–2002 Urine, sputum, pharynx, wound, blood
1 57 UK 1988 Nailfold
1 52 Not known <1949 Urine
37d 208c, 218c P 2010–2012 Urine, bronchial secretion, sputum e
A. nosocomialis 4 CZ 1991–1997 Burn, bronchial secretion, trachea
10 68, 71, 76 N 1975–2003 Sputum, urine, blood, autopsy, bronchus,
skin, rectum, burn
2 S 1980–1981 Gastric fistula, urine [16]
1 68 D 1984–1985 Sputum
1 C 2001 Skin
1 UK 2000 Bronchial secretion
1 74 Not known <1950 Not known
1d B 2010 Not known e
A. pittii 6 CZ 1984–2008 Burn, urine [2]
9 70, 72, 75 N 1981–1999 Blood, urine, toe web, bronchus
1 H 1994 Trachea
2 73 S 1980 Wound [16]
1 93 D 1993 Axilla
1 63 Not known <1967 Cerebrospinal fluid
1d B 2010 Not known e
A. calcoaceticus 2 CZ 1991, 2006 Burn, sputum
5 61, 62 N 1900–2006 IV cannula, urinary catheter, eye,
amputation stump
2 92 S Wound [16]
Genomic species
“Close to 13TU”
1 CZ 1996 Tracheal secretion [14]
2 90, 91 D 1990–1991 Blood, ulcer [17]
1 US 1995–2002 Blood
Genomic species
“Between 1 and 3”
2 88, 89 D 1990–1991 Sputum, abscess [17]
CZ, Czech Republic; N, Netherlands; UK, United Kingdom; S, Sweden; D, Denmark; C, China; H, Hungary; US, United States; B, Brazil; P, Portugal
a Sequence type (ST) based on the Institut Pasteur MLST scheme (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html
b One isolate imported from Cyprus
c ST designation based on the Oxford MLST scheme (http://pubmlst.org/abaumannii/)
d Isolates used to test the model
e Unpublished data
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attenuated depending on the bacteria in contact with the
beam. This is a simple, quick, low cost and environmen-
tally friendly technique that can be used in the elucidation of
the bacterial chemical features [11, 12].
In this study, we demonstrate that closely related
Acinetobacter species belonging to the Acb complex can
be discriminated by their molecular composition using
FTIR-ATR combined with multivariate data analysis. To
Fig. 1 Acinetobacter spp.
Fourier transform infrared
spectroscopy with attenuated total
reflectance (FTIR-ATR) mean
spectra processed with the
standard normal variate (SNV)
and a Savitzky–Golay filter
(seven points filter size,
second-degree polynomial,
second derivative) in the
regions (A) 1,500–1,200 cm−1
and (B) 1,200–900 cm−1.
Legend: A. baumannii,
A. nosocomialis, A. pittii,
A. calcoaceticus, gen. sp.
“Between 1 and 3”, gen. sp.
“Close to 13TU”. (Colour figure
online)
Eur J Clin Microbiol Infect Dis (2014) 33:1345–1353 1347
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our knowledge, this is the first time that FTIR-ATR
spectroscopy is shown to effectively discriminate these
relevant species using a large collection of epidemiologically
unrelated strains.
Materials and methods
Bacterial isolates
A total of 122 isolates of the Acb complex obtained from
human specimens were included in the present study
(Table 1). Of these, 83 taxonomically precisely characterised
isolates were selected from previous taxonomic and epidemi-
ological studies to reflect the breadth of currently known
phenetic diversity within the Acb complex and were used
to evaluate the ability of FTIR-ATR in their discrimina-
tion: A. baumannii (n=28), A. nosocomialis (n=20), A. pittii
(n=20), A. calcoaceticus (n=9), gen. sp. “Between 1 and 3”
(n=2) and gen. sp. “Close to 13TU” (n=4). An additional 39
test isolates of A. baumannii (n=37), A. pittii (n=1) and
A. nosocomialis (n=1) were included to test the reliability of
the discrimination. All isolates were identified by rpoB
sequencing.
FTIR-ATR spectra acquisition
Isolates were grown onMueller–Hinton agar (37°C, 18 h) and
colonies were directly transferred from the agar plates to
the ATR crystal. FTIR-ATR spectra were acquired using
a PerkinElmer Spectrum BX FTIR System spectropho-
tometer with a PIKE Technologies Gladi ATR accessory
from 4,000–400 cm−1 with a resolution of 4 cm−1 and 32
scan co-additions. For each strain, three biological
replicates (obtained on three consecutive days) and three
instrumental replicates (obtained on the same day from the
same agar plate) were obtained and analysed, corre-
sponding to a total of nine spectra for each isolate. Between
each isolate measurement, a background was acquired. Due
to the large amount of data generated, a mean spectrum
(obtained from the nine replicates) was considered in all the
analyses.
Spectra pre-processing and modelling
FTIR-ATR spectra were processed with the standard normal
variate (SNV) [18], followed by the application of a Savitzky–
Golay filter (seven smoothing points, second-order polynomi-
al and second derivative) [19] and mean-centred. Partial least
squares discriminant analysis (PLSDA) was the selected su-
pervised method for data analysis [20]. FTIR-ATR spectra
were analysed by PLSDA after pre-processing with mean-
centring. The PLSDA scores were used as the source for
hierarchical cluster analysis (HCA). The purpose of HCA
was the generation of dendrograms highlighting the associa-
tion between isolates. Dendrograms were performed directly
on unprocessed PLSDA scores using the Euclidean distance
and the Ward’s algorithm [18]. All chemometric models were
performed in Matlab version 6.5 release 13 (MathWorks,
Natick, MA) and the PLS Toolbox version 3.5 for Matlab
(Eigenvector Research, Manson, WA).
Results and discussion
Spectral overview
The FTIR-ATR spectra obtained from the 83 isolates studied
in this work exhibit the main biomolecules’ characteristic
infrared absorption bands: lipids (3,000–2,800 cm−1),
proteins/amides I and II (1,700–1,500 cm−1), phospholipids/
DNA/RNA (1,500–1,185 cm−1), polysaccharides (1,185–
900 cm−1) and the fingerprint region (900–600 cm−1) [12].
Unprocessed spectra showed high similarity among the six
species (data not shown), with some spectral processing tools
being necessary to enlarge spectral variance.
Table 2 Fourier transform infrared spectroscopy with attenuated total reflectance (FTIR-ATR) peaks identified as biomarkers for the Acinetobacter
calcoaceticus–Acinetobacter baumannii (Acb) complex species identification
Peaks (cm−1)
Phospholipids/DNA/RNA Carbohydrates region
Species 1391 1385 1383 1379 1375 1318 1314 1156 1150 1123 1043 1036 1030 1025 1022 957 953 947
A. baumannii X X X X X X X
A. nosocomialis X X X X X X X
A. pittii X X X X X X X X
A. calcoaceticus X X X X X X X X
Gen. sp. “Between 1 and 3” X X X X X X X X
Gen. sp. “Close to 13TU” X X X X X X X X
1348 Eur J Clin Microbiol Infect Dis (2014) 33:1345–1353
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After spectra processing, some differences were observed
in the regions of phospholipids/DNA/RNA (Fig. 1a) and
carbohydrates (Fig. 1b). These regions were previously used
with success in the discrimination of A. baumannii [10] and
Streptococcus pneumoniae [23] and were, therefore, used in
the subsequent analysis. The most pronounced spectral differ-
ences are marked in Fig. 1a, b with black arrows and
summarised in Table 2. Differences in the peak shape
observed at 1,445, 1,370, 1,260, 1,220 and 968 cm−1, com-
bined with the presence or absence of specific absorption
peaks (Table 1), were helpful in species discrimination.
As seen in Fig. 1a, the band at 1,220 cm−1, usually attrib-
uted to the phosphodiester functional groups of DNA/RNA
polysaccharide backbone structures, is very similar in
A. baumannii and A. nosocomialis, suggesting a higher degree
of similarity concerning the DNA content between these two
Fig. 2 Dendrograms obtained from the partial least squares discriminant
analysis (PLSDA) model scores: models A to E (the agglomerative
method used was Ward’s algorithm for models A, B, D and E, and the
farthest neighbour for model C). Legend: A. baumannii,
A. nosocomialis, A. pittii, A. calcoaceticus, gen. sp. “Be-
tween 1 and 3”, gen. sp. “Close to 13TU”. (Colour figure online)
Eur J Clin Microbiol Infect Dis (2014) 33:1345–1353 1349
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species. According Sahl et al. [24], A. baumannii and
A. nosocomialis possess some common genes that are absent
in the genomes of the remaining Acb complex species, which
is in agreement with the similarity that we found in the DNA
content of these two species. The spectra of A. calcoaceticus
and gen. sp. “Between 1 and 3” were most distant, owing to
the presence of specific absorption peaks (Table 1). Spectral
differences in the remaining four species were restricted to
small peak shifts emphasising the need for multivariate data
analysis to better depict spectral species-specific features.
Acinetobacter species discrimination by chemometric
methods
Mean spectra were analysed by PLSDA and the model scores
were presented in the form of dendrograms, as described
previously. The first PLSDA model (Fig. 2, model A), built
considering all the isolates belonging to the six species.
allowed the discrimination of A. calcoaceticus from the other
five species in one cluster in the dendrogram. A second
PLSDA model (Fig. 2, model B) was then applied to the
remaining five species, allowing the discrimination of gen.
sp. “Between 1 and 3” in a single cluster. PLSDAmodels C, D
and E (Fig. 2) were consecutively applied and allowed the
discrimination of gen. sp. “Close to 13TU”, A. nosocomialis
and A. pittii from A. baumannii, respectively. In model D, all
the A. nosocomialis isolates were well predicted. However, the
cluster also contains 2/28 A. baumannii and 1/20 A. pittii
isolates, resulting in 100 % sensitivity and 94 % specificity
for the discrimination of A. nosocomialis. In model E, one
A. baumannii and two A. pittii isolates clustered inaccurately,
meaning that the model had 96 % and 90 % sensitivity and
90 % and 96 % specificity for the discrimination of
A. baumannii and A. pittii, respectively. The results herein
obtained clearly demonstrate the potential of FTIR-ATR spec-
troscopy in the identification of closely related species of the
Acinetobacter genus. Its reliability for routine species identi-
fication will be further tested in a greater number of Acb
complex isolates.
Flowchart development and test
The results obtained with the different models allowed the
establishment of a flowchart aiming to help with species
identification (Fig. 3). Spectra of the 39 test isolates were
acquired and processed as previously described and projected
into the models (models A to E, Fig. 2), according to the
established flowchart (Fig. 4). All the test isolates were well
assigned to the respective Acb complex species. The
robustness of this FTIR-ATR-based method for the identifica-
tion of the species belonging to the Acb complex is supported
by the epidemiological unrelatedness of the test isolates.
Fig. 3 Flowchart developed for
the identification ofAcinetobacter
calcoaceticus–Acinetobacter
baumannii (Acb) complex
species
1350 Eur J Clin Microbiol Infect Dis (2014) 33:1345–1353
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The high phenetic similarity between the Acb complex
species prevents their rapid and reliable identification using
routine diagnostic systems [1]. Therefore, time-effective and
low-cost techniques are in urgent demand due to the clinical
importance of some of these species, mainly A. baumannii but
also A. nosocomialis and A. pittii [5]. Despite the potential of
FTIR-ATR, its ability to discriminate Acinetobacter species
was not consistently demonstrated, due to serious flaws in the
Fig. 4 Test isolates projected into
the five developed models
according to the flowchart.
Legend: (a) A. nosocomialis,
(b) A. baumannii and
A. pittii. Isolates used to develop
the model are represented in grey
( ). (Colour figure online)
Eur J Clin Microbiol Infect Dis (2014) 33:1345–1353 1351
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bacterial collections tested [21, 22]. In this study, a differential
molecular composition among the Acb complex species was
depicted through its FTIR-ATR spectra. Using FTIR-ATR
spectra coupled with chemometric analysis, the discrimination
of closely related Acinetobacter species was achieved, and a
flowchart was also proposed for the identification of the Acb
complex species.
Conclusions
Fourier transform infrared spectroscopy with attenuated total
reflectance (FTIR-ATR) coupled with appropriate chemomet-
ric methods demonstrated a reliable ability to identify
the closely related species belonging to the Acinetobacter
calcoaceticus–Acinetobacter baumannii (Acb) complex. The
results obtained herein may be of great relevance due to the
possibility to identify species with significantly different
clinical importance quickly, reliably and with low cost.
Furthermore, this study unveils molecular signatures
(carbohydrates and phospholipids) of members of the Acb
complex that might be further explored to improve the overall
knowledge of these bacteria.
Application of fast, reliable and low-cost methods,
such as FTIR-ATR, as a diagnostic tool to identify relevant
Acinetobacter species would significantly impact infection
control policies and individual patient management in the
clinical context.
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a  b  s  t  r  a  c  t
MALDI-TOF  MS  is becoming  the  technique  of choice  for  rapid  bacterial  identification  at species  level in
routine  diagnostics.  However,  some  drawbacks  concerning  the identification  of  closely  related  species
such as those  belonging  to  the Acinetobacter  calcoaceticus-Acinetobacter  baumannii  (Acb)  complex  lead
to  high  rates  of  misidentifications.  In this  work  we successfully  developed  an  approach  that  combines
MALDI-TOF  MS and  chemometric  tools  to  discriminate  the six  Acb  complex  species  (A.  baumannii,  Acine-
tobacter  nosocomialis,  Acinetobacter  pittii,  A. calcoaceticus,  genomic  species  “Close  to  13TU”  and  genomic
species  “Between  1 and  3”).  Mass  spectra  of  83 taxonomically  well  characterized  clinical  strains,  reflecting
the  breadth  of  currently  known  phenetic  diversity  within  the  Acb  complex,  were  achieved  from  intact
cells  and  cell  extracts  and  analyzed  with  hierarchical  cluster  analysis  (HCA)  and  partial  least  squares
discriminant  analysis  (PLSDA).  This  combined  approach  lead  to 100%  of  correct  species  identification
using  mass  spectra  obtained  from  intact  cells.  Moreover,  it was  possible  to discriminate  two  Acb  com-
plex  species  (genomic  species  “Close  to  13TU”  and  genomic  species  “Between  1  and  3”)  not  included  in
the  MALDI  Biotyper  database.
©  2014  Elsevier  GmbH.  All  rights  reserved.
Introduction
Mass spectrometry was proposed for bacterial identification
about 35 years ago, although with severe confines namely due to
the limitations in the ionization of large biomolecules (Anhalt and
Fenselau, 1975). The possibility of surpassing this issue with the
new MALDI-TOF MS  (Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry) apparatus made this technique
very desirable for clinical routine offering the possibility of rapid
and inexpensive identification of bacteria at the species level (Karas
et al., 1985; Heller et al., 1987). In recent years, we  assisted to
an impressive increasing number of studies aiming the evalua-
tion of this technique as a reliable tool for bacterial discrimination,
including of closely related species (Pribil and Fenselau, 2005;
Carbonnelle et al., 2010; Croxatto et al., 2012). Acinetobacter genus
∗ Corresponding author at: Universidade do Porto, Faculdade de Farmácia,
REQUIMTE – Research Laboratory, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto,
Portugal. Tel.: +351 22 2078946; fax: +351 22 2003977.
E-mail addresses: lpeixe@ff.up.pt, lpeixe@gmail.com (L. Peixe).
has been the target of some of these studies (Espinal et al., 2011;
Álvarez-Buylla et al., 2012) due to the clinical relevance of some of
its species and the frequent misidentifications namely among the
Acinetobacter calcoaceticus-Acinetobacter baumannii (Acb) complex
species (Nemec et al., 2011). A. baumannii is recognized as the most
clinically relevant species, being involved in severe nosocomial
infections (Park et al., 2013), frequently demonstrating multidrug
resistance (Lim et al., 2007; Grosso et al., 2010) and associated with
high mortality rates (Park et al., 2013). More recently, non-A. bau-
mannii Acinetobacter infections, also associated to resistant strains
and with different clinical outcomes (Lai et al., 2012), have been
increasingly reported highlighting the need for accurate identifica-
tion of Acinetobacter species.
Previous attempts made with MALDI-TOF MS  aiming species
identification relied on direct comparisons with MALDI Biotyper
database or in small alterations to the procedure recommended by
the manufacturer concerning cell preparation (Espinal et al., 2011;
Álvarez-Buylla et al., 2012; Mencacci et al., 2013). In this study,
we evaluated the potential of MALDI-TOF MS  coupled with chemo-
metric tools (PLSDA – Partial Least Squares Discriminat Analysis
and HCA – Hierarchical Cluster Analysis) to discriminate the Acb
http://dx.doi.org/10.1016/j.ijmm.2014.04.014
1438-4221/© 2014 Elsevier GmbH. All rights reserved.
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complex species (A. baumannii,  A. nosocomialis, A. pittii, A. cal-
coaceticus, genomic species (gen. sp.) “Close to 13TU” and gen. sp.
“Between 1 and 3”), considering both intact and cell extracts (IC
and CE). The results obtained herein clearly show that a combined
MALDI-TOF MS and chemometric approach highly improve the rate
of correct identifications among closely related species as those
belonging to the Acb complex.
Material and methods
Bacterial strains
The study collection included 83 unrelated and taxonomically
well characterized strains obtained from clinical specimens in
different countries and periods of time and belongs to diverse
sequence types in order to provide maximal diversity. The strains
were selected from published studies (Nemec et al., 1999, 2004,
2011; Krizova et al., 2012) to reflect the breadth of currently known
phenetic diversity within the Acb complex: A. baumannii (n = 28),
A. nosocomialis (n = 20), A. pittii (n = 20), A. calcoaceticus (n = 9), gen.
sp. “Close to 13TU” (n = 4) and gen. sp. “Between 1 and 3” (n = 2).
The strains were previously identified at the species level by rpoB
sequencing and most of them were also characterized by other
taxonomic methods such as multilocus sequence typing (MLST)
or AFLP whole-genome fingerprinting (Nemec et al., 1999, 2004,
2011; Krizova et al., 2012). In addition, all the strains were distinct
at the strain level as evidenced by several genotyping methods.
Details about the strains included in this study are summarized in
Tables 1 and 2.
MALDI-TOF MS
MALDI-TOF MS  experiments were performed directly with
intact cells and with cell extracts for comparison. Intact cells
were obtained from an overnight culture in Mueller-Hinton agar
(37 ◦C/18 h). Cell extracts were prepared according the manufac-
turer instructions. Briefly, overnight cultures in Muller-Hinton agar
were suspended in HPLC water and treated with ethanol (75%).
After centrifugation and removal of the supernatant, cells were
extracted with 25 !L of 70% formic acid followed by addition of
25 !L of acetonitrile and vortexing at 2000 rpm for 1 min. Sam-
ples, both intact bacterial cells and cell extracts, were spotted onto
MALDI ground steel target (AnchorChip) followed by drying and
the addition of 1 !L of the chemical matrix (saturated solution of
"-cyano-4-hydroxycinnamic acid in 50% of acetonitrile and 2.5% of
trifluoroacetic acid). Spectra were randomly obtained from blind
samples in the linear positive mode at a laser (nitrogen) frequency
of 20 Hz in the range of 2–20 kDa with a Microflex III instrument
(Bruker Daltonic, Bremen, Germany). Each recorded spectrum is the
results of six series of 40 single laser shots in different locations. The
experiments were performed in quadruplicate using four distinct
spots of the MALDI target (instrumental replicates) at least in two
different days (biological replicates) with two different bacterial
cultures or extracts. External calibration of the mass spectra was
performed using Escherichia coli DH5 alpha standard peaks (BTS).
MALDI-TOF peaks were directly compared with the reference
spectra of the integrated database using MALDI Biotyper Software
(MALDI Biotyper Version 3.0 Build 25 – Bruker Daltonics) and sub-
jected to chemometric analysis.
Chemometric analysis
Due to the large amount of data generated by MALDI exper-
iments, mean spectra for each isolate were generated from the
instrumental and biological replicates and considered for further
analysis. Mass spectra were previously analyzed with the peakfind
function of the PLS Toolbox for Matlab (settings: 9 points for the
Savitzky–Golay filter, 6 units for the peak tolerance and 19 points to
estimate local maxima) to evaluate the intra and interspecies vari-
ability among the six species. Additionally, for clustering purposes
spectra were analyzed by partial least squares discriminant analysis
(PLSDA) and hierarchical cluster analysis (HCA) (Barker and Rayens,
2003; Sousa et al., 2014) after pre-processing with mean-centring.
In PLSDA, to each known sample (xi) is assigned a vector of zeros
with the value one at the position corresponding to its species (yi).
The structure of the PLSDA model is described by Eqs. (1) and (2).
Model loadings (P and Q) and corresponding scores (T and U) are
obtained by sequentially extracting the components or latent vari-
ables (LV) from matrices X (the spectra) and Y (the matrix codifying
the STs).
X = TPt + E (1)
Y = UQt + F (2)
The algorithm correlates the scores of each block (T and U), yield-
ing an internal regression matrix. This internal regression can be
transformed on a regression matrix (B). In this case, the regres-
sion matrix is composed by three vectors: one regression vector
corresponding to each ST. E and F are the residual matrices and
depend on the number of latent variables selected. Predictions for
new samples are obtained by multiplying a new spectrum (xnew)
by the regression matrix (B).
ynew = xnewB (3)
The prediction (ynew = [ynew,1, ynew,2,. . .,ynew,n]) is then converted
in a class assignment. In PLSDA a probability value for each assign-
ment is estimated for each sample. The model was calibrated and
tested with the leave-one-sample-out cross-validation procedure
in order to prevent overfitting. The cross validation (where 30%
of randomly selected samples are used to test the model) was
performed 100 times. The PLSDA scores were used as the source
for the HCA. The purpose of HCA was  the generation of dendro-
grams highlighting the association between strains. Dendrograms
were generated directly on unprocessed PLSDA scores using the
k-nearest neighbor agglomerative method (Næs et al., 2002).
Sensitivity and specific values of the chemometric approach
were obtained through a cross validation strategy of the PLSDA
model (Sousa et al., 2014) where 70% of the strains where ran-
domly selected to calibrate the model and 30% to test the model
(the procedure was  repeated 100 times).
All chemometric models were performed in Matlab version 7.4
Release 2007a (MathWorks, Natick, MA)  and PLS Toolbox version
4.2.1 for Matlab (Eigenvector Research, Manson, WA).
Results
Species identification with the integrated database of the MALDI
Biotyper software
Species identification through direct spectra comparison with
the integrated Biotyper database revealed 34 A. baumannii,  18 A.
nosocomialis, 21 A. pittii and 10 A. calcoaceticus using IC and 36 A.
baumannii, 17 A. nosocomialis, 20 A. pittii and 10 A. calcoaceticus
with CE (Table 3). It is of note that none of the species was  iden-
tified with mean scores greater than 2.300 meaning, according to
the manufacturer, that only a probable identification at the species
level can be achieved using the integrated database of the MALDI
Biotyper Software.
Considering IC, all A. baumannii,  A. pittii and A. calcoaceticus
strains were accurately identified. Nevertheless, two  strains of A.
nosocomialis (2/20) and four strains of gen. sp. “Close to 13TU”
(4/4) were identified as A. baumannii and the two strains of gen.
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Table  2
The rpoB gene similarity values within and between the species of the ACB complex.a
Species A. baumannii A. nosocomialis Genomic sp.
‘Close to 13TU’
A. pittii A. calcoaceticus Genomic sp.
“Between 1 and 3”
A. baumannii 98.7–100
A. nosocomialis 94.2–95.4 98.7–100
Genomic sp. ‘Close to 13TU’ 94.3–94.9 94.9–95.6 99.2–100
A.  pittii 92.5–93.5 92.7–93.4 91.6–92.3 99.0–100
A.  calcoaceticus 90.9–92.2 90.2–91.8 90.4–91.6 92.3–93.7 98.1–100
Genomic sp. “Between 1 and 3” 91.0–91.8 91.1–91.8 90.8–91.2 92.3–92.9 96.8–97.9 99.3
a Calculations are based on the 861 bp region encompassing the nucleotide positions 2915–3775 of the rpoB coding region. Pairwise similarity values are expressed as the
percentages of identical nucleotides in the corresponding positions of two aligned sequences.
sp. “Between 1 and 3” strains were misidentified (2/2), one as A.
pittii and one as A. calcoaceticus.
In the case of CE, only A. baumannii and A. calcoaceticus strains
were correctly identified. Four strains of A. nosocomialis (4/20)
and four of gen. sp. “Close to 13TU” (4/4) were misidentified as
A. baumannii;  one strain of A. pittii (1/20) was misidentified as A.
nosocomialis and two strains of gen. sp. “Between 1 and 3” were
misidentified (2/2) one as A. pittii and one as A. calcoaceticus.
It is of note that higher sensitivity and specificity were obtained
using IC as compared to CE, for species identification through the
MALDI Biotyper database (Table 4).
Spectral overview
Fig. 1(A (IC) and B (CE)) summarizes the position of the peaks
found with peakfind function for each strain. The position of the
peaks was achieved from the mean mass spectra for each strain,
obtained as described previously, and no intra-strain variability
was observed (data not shown). Considering IC, species mass peaks
were mainly concentrated in the region below 10,000 m/z  (about
99%) and almost no peaks could be found above 13,000 m/z. Some
degree of spectral variability was also observable within each
species (no more than 5%); however a consistent species pattern
was notorious. Mass spectra of the CE lead to a major number of
peaks than IC mainly in the region above 10,000 m/z and higher
intra-species variability (about 5–10%). Nevertheless, a species
peak pattern was also seen.
A detailed spectra analysis of each species was  also performed
in the region between 3000 and 10,000 m/z due to its higher inter-
species variability, Fig. 2(A (IC) and B (CE)). Peaks at 4662, 5176,
6949, 7435 and 9323 m/z, present in both IC and CE (only with small
shifts), were found to be common in all the species being probably
associated with the Acinetobacter genus. Moreover, all the species
seems to have at least one specific peak found with IC and CE (A.
baumannii:  5749 m/z; A. nosocomialis: 8139 m/z; A. pittii: 5779 m/z;
A. calcoaceticus: 5833 m/z; gen. sp. “Close to 13 TU”: 9542 m/z; gen.
sp. “Between 1 & 3”: 3908 m/z).
Chemometric analysis
Dendrograms obtained for IC and CE were generated with 4 and
8 latent variables encompassing 70.4% and 80.4% of the spectral
variability, respectively.
Considering IC, the resulting dendrogram (Fig. 3A) exhibits six
perfectly defined clusters each comprising strains of a single species
and in accordance with their identification by rpoB. The cross vali-
dation procedure showed 89% of sensitivity for A. calcoaceticus and
100% for the remaining 5 species and 95% of specificity for A. noso-
comialis and 100% for the other species (Table 4). Concerning CE
the discrimination of the six species is unfeasible with results of
the cross validation for sensitivity from 75% to 100% and for speci-
ficity lower than 100% except for A. pittii (Table 4). The dendrogram
(Fig. 3B) showed three well defined clusters corresponding to gen.
sp. “Between 1 and 3”, gen. sp. “Close to 13TU” and A. pitti strains.
However some degree of overlapping was  observed between the
clusters containing A. calcoaceticus, A. baumannii and A. nosocomi-
alis being the discrimination of these 3 species unachievable with
CE.
Discussion
In this work, we developed a combined MALDI-TOF MS  and
chemometrics approach to accurately discriminate six closely
related species belonging to the Acb complex.
Several recent studies (Böhme et al., 2010; Espinal et al., 2011;
Álvarez-Buylla et al., 2012) have addressed the potential of this
high throughput technique for Acinetobacter species identifica-
tion; however always through direct MALDI Biotyper database
Table 3
Acinetobacter species identification and mean score values obtained through intact cell (IC) and cell extract (CE) direct mass spectra comparison with MALDI Biotyper database.
Speciesa (n◦ strains) IC identification CE identification
Species (n◦ strains) Scoreb Species (n◦ strains) Scoreb
A. baumannii (28) A. baumannii (28) 2–2.3 A. baumannii (28) 2–2.3
A.  nosocomialis (20) A. nosocomialis (18) 2–2.3 A. nosocomialis (16) 2–2.3
A.  baumannii (2) 2.095 A. baumannii (4) 1.901
A.  pittii (20) A. pittii (20) 2–2.3 A. pittii (19) 2–2.3
A. nosocomialis (1) 1.981
A.  calcoaceticus (9) A. calcoaceticus (9) 2–2.3 A. calcoaceticus (9) 2–2.3
Gen.  sp. “Close to 13TU” (4) A. baumannii (4) 2–2.3 A. baumannii (4) 2–2.3
Gen.  sp. “Between 1 and 3” (2) A. pittii (1) 1.878 A. pittii (1) 1.816
A.  calcoaceticus (1) 1.797 A. calcoaceticus (1) 1.855
a rpoB based identification.
b Results were expressed as log (score) values in the range of 0–3. Scores between 2.300 and 3.000 indicate a trustworthy identification at species level, between 2.000
and  2.299 trustworthy at genus level and probable at species level, between 1.700 and 1.999 probable at genus level and lower than 1.699 no identification can be made.
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Table  4
Specificity and sensitivity of Acb complex species identifications obtained through direct database comparison and chemometric analysis, of intact cells (IC) and cell extracts
(CE)  mass spectra.
Species Direct database comparison Chemometric methodsa
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
IC CE IC CE IC CE IC CE
A. baumannii 100 100 89 85 100 96 100 96
A.  nosocomialis 90 80 100 98 100 100 95 97
A.  pittii 100 95 98 98 100 100 100 100
A.  calcoaceticus 100 100 99 99 89 100 100 99
Gen.  sp. “Close to 13TU” N.A. N.A. N.A. N.A. 100 75 100 98
Gen.  sp. “Between 1 and 3” N.A. N.A. N.A. N.A. 100 100 100 98
Sensitivity –  proportion (or percentage) of strains correctly identified at the species level; Specificity –  proportion (or percentage) of all the strains that are correctly identified
as  not belonging to a given species. N.A. –  not applicable.
a Values related to the cross validation method leave-one-out.
comparisons and reporting a high rate of species misidentifica-
tions. The results obtained in our work lead to a higher percentage
of correct species identifications through the MALDI Biotyper
database (90% considering IC and 87% considering CE) than previous
studies (Böhme et al., 2010; Espinal et al., 2011) which possi-
bly result from database improvements, namely more reference
profiles of A. baumannii (n = 5) and A. calcoaceticus (n = 1) were
added and A. nosocomialis (n = 5) profiles were newly included.
Fig. 1. Peak positions (m/z) of the 83 strains obtained with IC (A) and CE (B). Legend: , A. baumannii;  , A. nosocomialis; , A. pittii; , A. calcoaceticus; , gen. sp. “Close
to  13TU”; , gen. sp. “Between 1 and 3”. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
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Fig. 2. Peak profiles of the six species in the region of 3000 to 9000 m/z (obtained from the mean spectra of each species) for IC (A) and CE (B). Legend: , A. baumannii;
, A. nosocomialis; , A. pittii; , A. calcoaceticus; , gen. sp. “Close to 13TU”; , gen. sp. “Between 1 and 3”. (For interpretation of the references to color in this
figure  legend, the reader is referred to the web version of the article.)
In fact, the erroneous identifications of A. nosocomialis obtained
by Espinal and co-workers were attributed to its absence in the
database at that time (MALDI Biotyper Version 2.0SR1 Build 223
database). However, despite the introduction of a new species and
the increasing number of bacterial mass profiles of each species
increasing the number of correct identifications compared with
previous works, one still obtained misidentifications for A. nosoco-
mialis and A. pittii. Recently, Sˇedo and co-workers (Sˇedo et al., 2013)
in an attempt to solve the database misidentifications developed
an alternative protocol based on the change in matrix composition
to improve the rate of correct identifications of the Acb complex
species (most of the strains used by Sˇedo and co-workers were
included in this work). Nevertheless, despite the improvements
achieved, some issues as the impossibility of automatic mass spec-
tra acquisition or the need of a new reference database, makes
this alternative protocol impractical for routine laboratory use.
Moreover, strains belonging to species not included in the MALDI
Biotyper database will be incorrectly identified with this approach
(direct database comparison). As different Acinetobacter species
may  present distinct antimicrobial susceptibility and/or virulence
profiles (Grosso et al., 2011; Lai et al., 2012) their correct identifica-
tion in the clinical context is important. Considering that even with
database enlargements or alternative protocols misidentifications
still occur and that species not included in the reference database
will be falsely allocated to species included in the database, pro-
tein profiles database enlargement seems to be not enough, as
3.3. Developments on Acinetobacter species identification and typing 
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Fig. 3. Dendrogram obtained from the PLSDA model scores with Mahalanobis distance and the agglomerative algorithm distance to k-nearest neighbor for IC (A) and CE (B).
Legend: , A. baumannii; , A. nosocomialis; , A. pittii; , A. calcoaceticus; , gen. sp. “Close to 13TU”; , gen. sp. “Between 1 and 3”. (For interpretation of
the  references to color in this figure legend, the reader is referred to the web  version of the article.)
also suggested by others (Espinal et al., 2011), to solve these
drawbacks.
A detailed spectra analysis seems to allow the identification of
particular genus and species specific m/z ratios (Fig. 2A and B), some
of them already reported by others (Böhme et al., 2010; Espinal
et al., 2011; Sˇedo et al., 2013). However, these m/z ratios seem to
be not enough for unambiguous species identification owing to the
divergences of the genus and species specific peaks found in the
different works (Böhme et al., 2010; Espinal et al., 2011). Böhme
and co-workers pointed three peaks (m/z 2873, m/z 5744, m/z
7429) as being A. baumannii specific, however A. baumannii was  the
only species belonging to the Acinetobacter genus included in their
work. Espinal and co-workers identified m/z 2873 and m/z 5750
(m/z shift of 6 from Böhme’s work) as A. baumannii species specific.
In this study, we  found the m/z 5749 peak (as by Sˇedo’s work); how-
ever, in contrast to Böhme’s and Espinal’s work the 2873 m/z peak
was also found in A. nosocomialis. Moreover, we found significant
shifts for some peaks of A. baumannii,  A. nosocomialis and A. pittii
from Espinal’s work. These results suggest that species assignment
based on few m/z  peaks may  be associated with high rates of
misidentification. The current limitations described concerning
Acb complex species identifications emphasize the need of an
3.3. Developments on Acinetobacter species identification and typing 
 160 
 
 
 
  
 
C. Sousa et al. / International Journal of Medical Microbiology 304 (2014) 669–677 677
alternative methodology. As demonstrated in this work, the use
of specific chemometric methods optimized for each genus could
be an alternative for species identification with very similar
protein signatures as those belong to the Acinetobacter genus. The
PLSDA model optimized (Fig. 3A and B) considering IC presents
six perfectly individualized clusters corresponding to the six
species in agreement with the rpoB based identification. With
CE species discrimination was poorer maybe due to the fact that
fewer proteins were reached during the extracts preparation. In
fact, fewer peaks were found for CE (Fig. 2A and B). These results
suggests that more complete protein profiles as those obtained
with IC could lead to better identifications rates for closely related
species. Moreover, using IC sample preparation time and analysis
cost can be dramatically reduced.
Considering sensitivity and specificity values (Table 4) obtained
for species identification through MALDI-TOF Biotyper database
and through the application of an optimized chemometric model to
the mass spectra, it is clear that the chemometric approach present
higher values for both parameters for both IC and CE. Moreover,
with the approach proposed in this work it was  also possible to
clearly discriminate gen. sp. “Close to 13 TU” and gen. sp. “Between
1 and 3” as distinct species from A. baumannii,  A. nosocomialis, A. pit-
tii,  and A. calcoaceticus which was not possible through the direct
MALDI-TOF Biotyper database identification.
Conclusions
In this work we demonstrated that Acb complex species iden-
tification by MALDI-TOF MS  can be successfully attained by mass
spectra fingerprinting approach combined with optimized chemo-
metric methods. A high rate of misidentifications among the
Acb complex species were found through direct MALDI Biotyper
database identification. However, the PLSDA of mass spectra lead
to 100% of correct species identifications using intact cells when
compared with rpoB species identification. The application of fast,
reliable and low cost methods, such as MALDI-TOF MS combined
with appropriate chemometric tools would significantly impact
bacterial identification in the clinical context.
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a b s t r a c t
In this work we developed and validated a FTIR-ATR (Fourier transform infrared spectroscopy with
attenuated total reflectance) based model for typing Acinetobacter baumannii clinical isolates belonging
to ST98, ST208 and ST218 included into the worldwide spread clonal complex (CC) 92 and ST103.
FTIR-ATR spectra of seventy-seven previously characterized isolates (Multi Locus Sequence Type-MLST,
Pulsed-Field Gel Electrophoresis-PFGE and carbapenem-hydrolyzing class D b-lactamase-CHDL) were
acquired and modeled by partial least squares discriminant analysis (PLSDA). The model was tested
and successfully validated with a diverse collection of isolates (n = 148) recovered from different coun-
tries and periods of time belonging to modeled and non-modeled STs.
! 2014 Elsevier B.V. All rights reserved.
1. Introduction
Acinetobacter baumannii has emerged in the last decade as an
increasingly important nosocomial pathogen, particularly due to
its ability to acquire antimicrobial resistance determinants.
Outbreaks caused by multidrug resistant A. baumannii have been
identified worldwide, with several reports of isolates resistant to
all available antimicrobial agents [1]. This emergence has been
associated with highly successful strains, in particular those
belonging to the European Clone II, and more recently ascribed
to the clonal complex 92 (CC92), according with the Multi Locus
Sequence Typing (MLST) scheme hosted by the Oxford Database
[2–5]. Several typing methods have been applied aiming A. bau-
mannii population structure characterization, such as Pulsed-Field
Gel Electrophoresis (PFGE), amplified fragment length polymor-
phism (AFLP) analysis, other PCR fingerprinting methods, multi-
ple-locus variable tandem repeat number analysis (MVLA) and
MLST schemes. However, the need for immediate interventions
in the epidemiological context of A. baumannii infection demands
for less expensive, less laborious and quicker approaches. Fourier
transform infrared spectroscopy (FTIR) coupled with multivariate
data analysis (chemometric tools) is considered as a good candi-
date for this purpose. In a previous work, we [6] demonstrated
the ability of FTIR spectroscopy to discriminate among three A. bau-
mannii clones (ST98, ST103 and ST208) disseminated in Portuguese
hospitals. In this work, we aimed to develop a robust mathematical
model for typing A. baumannii clones based on Fourier transform
infrared spectroscopy with attenuated total reflectance (FTIR-
ATR) and partial least squares discriminant analysis (PLSDA) that
could be routinely used. The mathematical model was developed
with a collection of 77 A. baumannii clinical isolates belonging to
four different clones (ST98, ST103, ST208 and ST218) and validated
by subjecting it to a test collection of 148 isolates (some of them
belonging to the aforementioned STs). These isolates were typed
by MLST according with Oxford Database MLST scheme [2] and
the STs were compared with the FTIR-ATR model predictions.
2. Material and methods
2.1. Bacterial strains
2.1.1. Modeled isolates (used to develop the model)
Seventy-seven A. baumannii clinical isolates were selected
among a previously published collection of 318 CHDL-producing
http://dx.doi.org/10.1016/j.jphotobiol.2014.02.015
1011-1344/! 2014 Elsevier B.V. All rights reserved.
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Acinetobacter spp. recovered from 6 geographically distant Portu-
guese hospitals (2001–2009). The selected isolates are representa-
tives of the main lineages disseminated in Portugal before 2009:
ST98 (n = 25); ST103 (n = 24); ST208 (n = 25; corresponding to a
reassignment of ST92 isolates) and ST218 (n = 3) [4]. Only three
ST218 isolates were found during this period. The main character-
istics of the isolates used in this study, including the relationship
between carbapenem-hydrolyzing class D b-lactamase (CHDL)
content, PFGE types, sequence groups and the STs obtained accord-
ing with Oxford Database MLST scheme (http://pubmlst.org/abau-
mannii/) were presented in Table 1.
2.1.2. Test isolates (used to test and validate the model)
One hundred and forty-eight A. baumannii clinical isolates from
seven different countries and periods of time (1991–2012): France
(n = 6), Germany (n = 7), Czech Republic (n = 9), Italy (n = 11), Brazil
(n = 12), Croatia (n = 9) and Portugal (n = 94) were used to assess
the FTIR-ATR based method’s robustness. Test isolates included
STs used to develop the model and distinct ones (21 different
STs) to assess the ability of the model to predict non-modeled STs.
2.2. FTIR-ATR spectral acquisition
FTIR-ATR spectra of all isolates were acquired from an overnight
subculture on Mueller Hinton agar exactly after 18 h of grow at
37 !C to avoid spectral interferences due to the age of colony. Dif-
ferent batches of media were used during the experimental work
and no spectral differences were observed (data not shown).
FTIR-ATR spectra were acquired using a PerkinElmer Spectrum
BX FTIR System spectrophotometer equipped with a DTGS detector
and a PIKE Technologies Gladi ATR accessory from 4000 to
400 cm!1 with a resolution of 4 cm!1 and 32 scan co-additions.
Colonies were directly transferred from the agar plates to the
ATR crystal, followed by drying on the optical surface until a thin
film was obtained. For each strain, 9 spectra were acquired corre-
sponding to three biological replicates (obtained in three indepen-
dent days with primary fresh subcultures) and three instrumental
replicates (obtained from the same agar plate). Between each iso-
late measurement a background was acquired.
2.3. Spectra pre-processing and modeling
FTIR-ATR spectra were processed with standard normal variate
(SNV) [7] followed by the application of a Savitzky-Golay filter (9
smoothing points, 2nd order polynomial and 2nd derivative) [8]
and mean-centring. After pre-processing, spectra were modeled
by PLSDA- partial least squares discriminant analysis [9]. In this
method, to each isolate spectrum (xi) was assigned a vector of
zeros with the value one at the position corresponding to its ST
(yi) [10]. Isolates were divided in calibration (70%) and test sets
(30%). The leave-one-sample-out cross validation strategy (applied
on the calibration set only) was adopted to optimize the number of
latent variables, the threshold for the probability of class assign-
ment and the confidence limit of the Q statistic (squared residuals)
[8]. For each class (ST), a PLSDA prediction threshold level was
optimized in order to maximize specificity and sensitivity (a num-
ber between 0 and 1). Probabilities of class assignment are calcu-
lated based on these thresholds and predictions. More
information regarding the structure of the PLSDA model and its
application in a similar context was described elsewhere [6].
The cross-validation results showed that a minimum 95% prob-
ability was necessary to correctly assign samples to the correct
class. Therefore, if the probability for a given ST was higher than
95% then the assignment was considered valid for that ST [11]. If
the predicted probabilities for all STs were lower than 95%, the re-
sult was said to be non-conclusive and that sample was considered
not to belong to any of the four modeled STs (meaning that the
sample belong to a ST not included in the model). Besides model
estimations, each sample was analyzed accordingly to the model
adjustment. This fit was estimated by analyzing the model residu-
als (statistic Q or sum of squared errors) and comparing these
residuals with the confidence limit Q95% obtained for the calibra-
tion set isolates (estimated by cross-validation) [7]. A suitable
measure was obtained by dividing that statistic Q by the corre-
sponding 95% confidence limit (Q/Q95%). Values substantially supe-
rior to 1 mean that predictions cannot be considered valid once
they present significant deviations when compared to any of the
modeled STs (that sample is either an outlier meaning that belongs
to an ST not considered in this model).
Additionally, projections of test isolates onto the developed dis-
criminant model allowed the identification of these isolates
according to one of the four STs or as a distinct ST. A classification
can only be considered valid if that isolate spectrum fits the PLSDA
model (Q/Q95% < 1) and the probability of class assignment for one
class is superior to 95%.
All data analysis was performed in Matlab version 7.9 (Math-
Works, Natick, MA) and the PLS Toolbox version 5.5.1 for Matlab
(Eigenvector Research, Manson, WA).
2.4. Multi Locus Sequence Type
Multi Locus Sequence Type (MLST) was performed in the test
isolates to evaluate the accuracy of the developed mathematical
model proposed for typing. MLST was performed according with
the conditions proposed by the A. baumannii MLST website
Table 1
Portuguese A. baumannii isolates used to develop the PLSDA model.
Sequence Typea (n)b Sequence group (SG) ApaI-PFGE type Acquired CHDLc Hospitald (n) Years Refs.
98(25) SG1 A OXA-40 HGSA (23) 2001–2008 [4,6]
CHCB (2)
103(24) SG4 B, C OXA-58 HGSA (24) 2001–2004 [4,6]
208(25) SG1 A4 OXA-23 HA (3) 2006–2009 [4,6]
HGSA (13)
HPH (2)
HST (7)
218(3) SG1 A5 OXA-23 HGSA (2) 2009 This study
VC (1)
a Sequence Type (ST) determined according with Oxford Database MLST scheme (http://pubmlst.org/abaumannii/).
b n, total of isolates.
c CHDL, carbapenem-hydrolyzing class D b-lactamase.
d HA, Hospital de Amarante (North), HGSA, Hospital Geral de Santo António (North), HPH, Hospital de Pedro Hispano (North), HST, Hospital de São Teotónio (Centre), CHCB,
Centro Hospitalar da Cova da Beira (Centre), VC, Centro Hospitalar Póvoa de Varzim – Vila do Conde (North).
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(http://pubmlst.org/abaumannii/) sited at the University of Oxford
[2].
2.5. Pulsed Field Gel Electrophoresis
Pulsed-Field Gel Electrophoresis (PFGE) was performed in some
test isolates whenever there was a need for further clarification on
the similarity of isolates. Genome macrorestriction was performed
with the ApaI enzyme and pattern analysis was conducted with In-
foQuestTM FP v5.4 (BioRad Laboratories, Hercules, CA, USA) using
the Dice coefficient with the unweighted pair group method to
determine band similarity. Isolates clustering together with >85%
similarity levels were considered to belong to the same PFGE type
[12–14].
3. Results and discussion
3.1. Spectral overview
FTIR-ATR spectra exhibit the typical shape of intact bacterial
spectra containing the absorption bands of lipids (3000–
2800 cm!1), proteins/amides I and II (1700–1500 cm!1), mixed
Fig. 1. Acinetobacter baumannii FTIR-ATR spectra processed with SNV and Savitzky-
Golay (9 points filter size, 2nd degree polynomial, 2nd derivative) corresponding to
the mean ± one standard deviations in the region 1500–900 cm!1. Legend:
ST98, ST103, ST208 and ST218.
Fig. 2. Score plot corresponding to the first three LVs of the PLSDA regression model
using the 1500–900 cm!1 spectral region. Legend: ST98 ( ); ST103 ( ); ST208 ( );
ST218 ( ). Filled and unfilled symbols correspond to calibration and test samples,
respectively.
Fig. 3. Loadings of the PLSDA model calibrated with 77 Acinetobacter baumannii
isolates. Legend: loading 1 (black line), loading 2 (dark gray line) and loading 3
(gray line).
Fig. 4. Score plot corresponding to the three first LVs of the PLSDA regression model
with the projected test isolates using the 1500–900 cm!1 spectral region. Legend:
ST98 ( ); ST103 ( ); ST208 ( ); ST218 ( ) and test isolates (s).
Fig. 5. Normalized squared residuals statistic (Q/QLIM95%) obtained for the projec-
tion of 148 test isolates with indication of the 95% confidence limit. Legend: ( )
well predicted isolates as not belonging to the model, ( ) badly predicted isolates,
( ) well predicted isolates as belonging to the model.
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Table 2
Comparison between predicted STs by the FTIR-ATR model and those obtained by MLST scheme. Results are expressed as probabilities of belonging to each ST.
Isolate Country ST assignments
MLSTa FTIR-ATR probabilities FTIR-ATR predicted ST
ST98 ST103 ST208 ST218
U11177 G 15 0.00 0.00 10.34 89.66 N/A
U1901 G 16 0.00 0.00 12.30 87.70 N/A
2941 B 113 0.00 0.00 66.38 33.62 N/A
2969 B 113 0.00 0.00 69.51 30.49 N/A
3019 B 113 0.00 0.00 60.73 39.27 N/A
3171 B 113 0.00 0.00 66.73 33.27 N/A
3231 B 113 0.00 0.00 65.27 34.73 N/A
3258 B 113 0.00 0.00 78.73 21.27 N/A
3280 B 113 0.00 0.00 64.76 35.24 N/A
3298 B 113 0.00 0.00 66.13 33.87 N/A
3300 B 113 0.00 0.00 65.23 34.77 N/A
3135 B 132 0.00 0.00 49.36 50.64 N/A
3359 B 133 0.00 0.00 65.49 34.51 N/A
3356 B 134 0.00 18.87 78.41 2.72 N/A
954392 G 195 0.00 0.00 44.14 55.86 N/A
RC1 CR 208 0.00 0.00 >99.9 0.00 208
RC2 CR 208 0.00 0.00 95.45 4.55 208
RC3 CR 208 0.00 0.00 >99.9 0.00 208
RC4 CR 208 0.00 0.00 >99.9 0.00 208
RC5 CR 208 0.00 0.00 95.90 4.10 208
RC6 CR 208 0.00 0.00 97.72 2.28 208
RC7 CR 208 0.00 0.00 >99.9 0.00 208
RC8 CR 208 0.00 0.00 >99.9 0.00 208
RC9 CR 208 0.00 0.00 >99.9 0.00 208
Ac1 P 208 0.00 0.00 >99.9 0.00 208
Ac2 P 208 0.00 0.00 >99.9 0.00 208
Ac5 P 208 0.00 0.00 >99.9 0.00 208
Ac7 P 208 0.00 0.00 >99.9 0.00 208
Ac20 P 208 0.00 0.00 99.01 0.99 208
Ac21 P 208 0.00 0.00 >99.9 0.00 208
Ac30 P 208 0.00 0.00 >99.9 0.00 208
Ac39 P 208 0.00 0.00 >99.9 0.00 208
Ac68 P 208 0.00 0.00 >99.9 0.00 208
Ac69 P 208 0.00 0.00 >99.9 0.00 208
Ac73 P 208 0.00 0.00 >99.9 0.00 208
Ac78 P 208 0.00 0.00 >99.9 0.00 208
Ac81 P 208 0.00 0.00 >99.9 0.00 208
Ac85 P 208 0.00 0.00 96.28 3.72 208
AB13A I 218 0.00 0.00 0.00 >99.9 218
1510706 G 218 0.00 0.00 0.00 >99.9 218
147N I 218 0.00 0.00 0.00 >99.9 218
211P I 218 0.00 0.00 0.00 >99.9 218
Ac3 P 218 0.00 0.00 0.00 >99.9 218
Ac4 P 218 0.00 0.00 0.00 >99.9 218
Ac6 P 218 0.00 0.00 0.00 >99.9 218
Ac8 P 218 0.00 0.00 0.00 >99.9 218
Ac9 P 218 0.00 0.00 0.00 >99.9 218
Ac10 P 218 0.00 0.00 0.00 >99.9 218
Ac11 P 218 0.00 0.00 0.00 >99.9 218
Ac12 P 218 0.00 0.00 0.00 >99.9 218
Ac13 P 218 0.00 0.00 0.00 >99.9 218
Ac14 P 218 0.00 0.00 0.00 >99.9 218
Ac15 P 218 0.00 0.00 0.00 >99.9 218
Ac16 P 218 0.00 0.00 0.00 >99.9 218
Ac17 P 218 0.00 0.00 0.00 >99.9 218
Ac18 P 218 0.00 0.00 0.00 >99.9 218
Ac19 P 218 0.00 0.00 0.00 >99.9 218
Ac22 P 218 0.00 0.00 0.00 >99.9 218
Ac23 P 218 0.00 0.00 0.00 >99.9 218
Ac24 P 218 0.00 0.00 0.00 >99.9 218
Ac25 P 218 0.00 0.00 0.00 >99.9 218
Ac26 P 218 0.00 0.00 0.00 >99.9 218
Ac27 P 218 0.00 0.00 0.00 >99.9 218
Ac28 P 218 0.00 0.00 0.00 >99.9 218
Ac29 P 218 0.00 0.00 0.00 >99.9 218
Ac31 P 218 0.00 0.00 0.00 >99.9 218
Ac32 P 218 0.00 0.00 0.00 >99.9 218
Ac33 P 218 0.00 0.00 0.00 >99.9 218
Ac34 P 218 0.00 0.00 0.00 >99.9 218
Ac35 P 218 0.00 0.00 0.00 >99.9 218
Ac36 P 218 0.00 0.00 0.00 >99.9 218
(continued on next page)
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Table 2 (continued)
Isolate Country ST assignments
MLSTa FTIR-ATR probabilities FTIR-ATR predicted ST
ST98 ST103 ST208 ST218
Ac37 P 218 0.00 0.00 0.00 >99.9 218
Ac38 P 218 0.00 0.00 0.00 >99.9 218
Ac40 P 218 0.00 0.00 0.00 >99.9 218
Ac41 P 218 0.00 0.00 0.00 >99.9 218
Ac42 P 218 0.00 0.00 0.00 >99.9 218
Ac43 P 218 0.00 0.00 0.00 >99.9 218
Ac44 P 218 0.00 0.00 0.00 >99.9 218
Ac45 P 218 0.00 0.00 0.00 >99.9 218
Ac46 P 218 0.00 0.00 0.00 >99.9 218
Ac47 P 218 0.00 0.00 0.00 >99.9 218
Ac48 P 218 0.00 0.00 0.00 >99.9 218
Ac49 P 218 0.00 0.00 0.00 >99.9 218
Ac50 P 218 0.00 0.00 0.00 >99.9 218
Ac51 P 218 0.00 0.00 0.00 >99.9 218
Ac52 P 218 0.00 0.00 0.00 >99.9 218
Ac53 P 218 0.00 0.00 0.00 >99.9 218
Ac54 P 218 0.00 0.00 0.00 >99.9 218
Ac55 P 218 0.00 0.00 0.00 >99.9 218
Ac56 P 218 0.00 0.00 0.00 >99.9 218
Ac57 P 218 0.00 0.00 0.00 >99.9 218
Ac58 P 218 0.00 0.00 0.00 >99.9 218
Ac59 P 218 0.00 0.00 0.00 >99.9 218
Ac60 P 218 0.00 0.00 0.00 >99.9 218
Ac61 P 218 0.00 0.00 0.00 >99.9 218
Ac62 P 218 0.00 0.00 0.00 >99.9 218
Ac63 P 218 0.00 0.00 0.00 >99.9 218
Ac64 P 218 0.00 0.00 0.00 >99.9 218
Ac65 P 218 0.00 0.00 0.00 >99.9 218
Ac66 P 218 0.00 0.00 0.00 >99.9 218
Ac67 P 218 0.00 0.00 0.00 >99.9 218
Ac70 P 218 0.00 3.61 0.00 96.39 218
Ac71 P 218 0.00 0.00 0.00 >99.9 218
Ac72 P 218 0.00 0.00 0.00 >99.9 218
Ac74 P 218 0.00 0.00 0.00 >99.9 218
Ac75 P 218 0.00 0.00 0.00 >99.9 218
Ac76 P 218 0.00 0.00 0.00 >99.9 218
Ac77 P 218 0.00 0.00 0.00 >99.9 218
Ac79 P 218 0.00 0.00 0.00 >99.9 218
Ac80 P 218 0.00 0.00 0.00 >99.9 218
Ac82 P 218 0.00 0.00 0.00 >99.9 218
Ac83 P 218 0.00 0.00 0.00 >99.9 218
Ac84 P 218 0.00 0.00 0.00 >99.9 218
Ac87 P 218 0.00 0.00 0.00 >99.9 218
Ac88 P 218 0.00 0.00 0.00 >99.9 218
Ac89 P 218 0.00 0.00 0.86 99.14 218
Ac90 P 218 0.00 0.00 0.00 >99.9 218
Ac91 P 218 0.00 0.00 0.00 >99.9 218
Ac92 P 218 0.00 0.00 0.00 >99.9 218
Ac93 P 218 0.00 0.00 0.00 >99.9 218
Ac94 P 218 0.00 0.00 0.00 >99.9 218
18498 F 231 0.00 0.00 67.12 32.88 N/A
84D I 231 0.00 0.00 66.05 33.95 N/A
CRO10 C 348 0.00 0.00 66.55 33.45 N/A
18335 F 391 0.00 0.00 59.62 40.38 N/A
192D I 437 10.18 0.00 89.82 0.00 N/A
218M I 437 0.00 0.00 >99.9 0.00 208
25B I 437 0.00 0.00 >99.9 0.00 208
55C I 437 0.00 0.00 >99.9 0.00 208
78C I 437 0.00 0.00 >99.9 0.00 208
U9491 G 439 0.00 0.00 81.92 18.08 N/A
CRO2 C 441 0.00 0.00 60.71 39.29 N/A
CRO5 C 441 0.00 0.00 64.64 35.36 N/A
CRO6 C 441 0.00 0.00 63.06 36.94 N/A
CRO7 C 441 0.00 6.29 60.80 32.91 N/A
CRO8 C 441 0.00 0.00 61.96 38.04 N/A
CRO9 C 441 0.00 0.00 61.32 38.68 N/A
KRAKAU43 G 441 70.63 0.00 29.37 0.00 N/A
231Q I 513 0.00 0.00 0.00 >99.9 218
234Q I 513 0.00 0.00 0.00 >99.9 218
U10651 G 514 50.23 0.00 0.00 49.77 N/A
Ac86 P 515 0.00 0.00 11.47 88.53 N/A
17588 F 732 0.00 5.87 29.64 64.49 N/A
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region of phospholipids/DNA/RNA (1500–1185 cm!1), polysaccha-
rides (1185–900 cm!1) and the fingerprint region (900–600 cm!1)
[15,16]. The phospholipids/DNA/RNA and carbohydrates regions
(Fig. 1) exhibiting the highest spectral variance, have already been
used with great success for the discrimination of A. baumannii
clones by FTIR [6] and were chosen for all subsequent analysis.
3.2. Model development
A collection of 77 Portuguese isolates belonging to four different
STs (ST98, ST103, ST208 and ST218) were used to develop the
PLSDA model based on FTIR-ATR spectroscopy. This dataset was di-
vided in two subsets: one for calibration and one for testing. This
division ensured that all sample replicates were kept together and
that a proportional number of representative STs existed in both
sets. The best number of latent variables (LVs) was estimated from
the calibration set using the leave-one-out cross validation strategy
as described in a previous work [6]. Results indicated that the best
model included three LVs. To verify the predictive ability of the
model, the test set spectra were projected onto the model. It is pos-
sible to verify on the model scores plot (Fig. 2) a very good ability to
discriminate between the four STs (ST98, ST103, ST208 and ST218).
ST208 was discriminated from ST98, ST103 and ST218 by the first
latent variable of the PLSDAmodel (corresponding tomodel loading
1, Fig. 3), ST98 was discriminated from ST103 by the second latent
variable (corresponding to the second loading) and ST218 from
ST98 and ST103 by the third latent variable (corresponding to
model loading three). It is of note that PLSDA model loadings are
somehow similar to those obtained in our previous work [6] being
the more pronounced differences between the four clones observed
in the regions 1400–1350 cm!1 and 1200–950 cm!1. The herein
PLSDA developed model presents a higher discrimination ability
when compared with our previous work due to a higher number
of isolates and/or STs and to some minor adjustments in data pre-
processing.
Moreover, the projection of the test set isolates shows an excel-
lent agreement with calibration isolates on the scores plot (Fig. 2).
Considering the test set it was possible to identify a 99.3% rate of
correct predictions for the ST [6].
3.3. Model test and validation
Spectra of the test isolates were projected on the previously
built PLSDA model for ST prediction (Fig. 4) and the residuals sta-
tistic for each projected isolate were represented in Fig. 5. The
model predictions, expressed as probabilities of belonging to a cer-
tain ST, together with the MLST results are summarized in Table 2.
According to the projections in the PLSDA model, visualized as
model scores (Fig. 4), all the isolates were predicted as belonging
to ST208, ST218 or to diverse STs not included in the developed
model. Moreover, none of the test isolates was assigned as ST98
or ST103 which was in agreement with the respective probabilities
(lower than 95% for ST98 and ST103, Table 2) and the MLST results.
All ST208 and ST218 isolates (106/106) were well predicted by
FTIR-ATR based model with probabilities higher than 95% and pre-
sented a Q/Q95% lower than 1 supporting the reliability of the mod-
el predictions. Among the isolates from diverse STs, thirty-five (35/
42) were well predicted as not belonging to any of the modeled STs
(with probabilities lower than 95% for all the modeled STs). More-
over, all but one isolate (U10651) presented a Q/Q95% value supe-
rior to 1 meaning that they didn’t fit the model and belong to a
different ST (Fig. 5).
Nevertheless, five ST437 isolates were predicted as ST208 and
two ST513 were predicted as ST218 (Table 2), with probabilities
higher than 95% (except 192D for which the probability of belong-
ing to ST208 was 89.8%) and a Q/Q95% value lower than 1. It is of
Table 2 (continued)
Isolate Country ST assignments
MLSTa FTIR-ATR probabilities FTIR-ATR predicted ST
ST98 ST103 ST208 ST218
18282 F 732 0.00 9.46 27.96 62.58 N/A
17666 F 733 0.00 0.00 34.77 65.23 N/A
CRO3 C 740 0.00 27.02 57.94 15.04 N/A
AB3FSL I Newb 0.00 0.00 54.85 45.15 N/A
CRO4 C Newb 0.00 0.00 58.97 41.03 N/A
a Sequence type obtained in this study by Bartual MLST scheme (http://pubmlst.org/abaumannii/).
b Alelic profiles: AB3FSL (2-21-107-32-26-198-5); CRO4 (10-12-4-11-4-102-5); N/A- not assigned to any of the four modeled STs; CR-Czech Republic, P-Portugal,
G-Germany, I-Italy, F-France, B-Brazil and C-Croatia.
Fig. 6. Dendrogram of ApaI-PFGE fingerprints analysis for single locus variant isolates from ST208/ST437 and ST218/ST513.
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note that ST437/ST208 and ST513/ST218 are single locus variants
for the gyrB and recA genes, respectively. In order to clarify the iso-
lates similarity of these two pairs of SLV, PFGE experiments were
performed (Fig. 6). PFGEs profiles exhibited similarity coefficients
>85%, which is considered the cut-off value to belong to the same
Acinetobacter PFGE clone (13, 14). The PFGE patterns comparison
between the SLV ST208/ST437 revealed similarity coefficient of
87.8%, and between the SLV ST218/ST513 the similarity coefficient
was 87.9%. Moreover, isolates belonging to the same ST presented
PFGE patterns with similarity coefficients values varying between
87.8% and 100% (Fig. 6).
These results clearly validate the FTIR-ATR model to discrimi-
nate A. baumannii clones belonging to ST98, ST103, ST208 and
ST218 resulting in a reproducible and highly discriminatory meth-
odology that could be used in routine A. baumannii typing. Compet-
ing spectroscopic techniques as Raman spectroscopy seems to
exhibit a lower discrimination power concerning bacteria typing
at subspecies level presenting less sensitivity and specificity
[17,18]. Moreover, to the specific purpose of this work, this tech-
nique presents several advantages when compared with whole
genome sequencing: rapidity, a significantly lower cost and less
data handling.
4. Conclusions
FTIR-ATR spectroscopy detected specific molecular features on
clinically relevant A. baumannii clonal lineages assigned according
to Oxford MLST scheme to ST98, ST103, ST208 and ST218 stressing
the significance of these lineages and reinforcing the epidemiolog-
ical interest in their identification.
This spectroscopic technique coupled with appropriate chemo-
metric methods showed a good discrimination ability of clinically
relevant A. baumannii clonal lineages providing a rapid, easy and
low cost methodology for hospital surveillance of A. baumannii at
a large-scale basis, which could improve infection control and indi-
vidual patient decisions in a clinical context.
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MALDI-TOF MS (matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry) is now in the forefront for routine bacterial species identification
methodologies, being its value for clonality assessment controversial. In this work we
evaluated the potential of MALDI-TOF MS for assisting infection control by depicting
Acinetobacter baumannii clones. Mass spectra of 58 A. baumannii clinical isolates
belonging to the worldwide spread lineages (ST98, ST103, ST208, and ST218) isolated
in our country, were obtained and analyzed with several chemometric tools (pseudo
gel views, peakfind function, and partial least squares discriminant analysis). The clonal
lineages were obtained using the “Oxford” scheme, belonging ST98, ST208, and ST218
to the international clone II and ST103 to an epidemic clonal lineage (SG5). Additionally,
mass spectra of a highly diverse international collection of 38 isolates belonging to
22 sequence types (STs) were obtained for further comparisons. Pseudo gel views
and direct peak pattern analysis did not allow the discrimination of A. baumannii
isolates belonging to ST98, ST103, ST208, or ST218. Moreover, a partial least square
discriminant analysis of the mass spectra considering two spectral ranges (2–20 kDa
and 4–10 kDa) revealed a poor degree of discrimination with only 64.6 and 65.8% of
correct ST assignments, respectively. Also, mass spectra of the international isolates
(n = 38, 22STs) revealed a very congruent peak pattern among them as well as among
the four lineages included in this work. Despite the increasing interest of MALDI-TOF
MS for bacterial typing at different taxonomical levels, we demonstrated, using routine
experimental conditions, the unsuitability of this methodology for A. baumannii clonal
discrimination.
Keywords: Acinetobacter baumannii, typing, MALDI-TOF MS, subspecies, chemometrics, sequence type
Introduction
During the last decade, the rate of nosocomial infections caused by multidrug-resistant
Acinetobacter baumannii (MDRAB) has increased worldwide. In particular, the growing number
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of carbapenem-resistant A. baumannii isolates, mainly due to
the production of carbapenem-hydrolyzing class D β-lactamases
(CHDLs) jeopardizes the treatment of infections caused by
this agent (Higgins et al., 2010). The quick and reliable
clonality assessment is crucial to rapidly trace its dissemination,
assist antibiotherapy, and implement measures to constrain its
dissemination.
Pulsed-field gel electrophoresis (PFGE), amplified fragment
length polymorphism (AFLP) analysis, multilocus sequence
typing (MLST), DiversilabTM typing, other PCR fingerprinting
methods, and multiple-locus variable tandem repeat number
analysis (MVLA) are among the current methods used for
genotyping bacteria (Grosso et al., 2011b; Karah et al., 2012;
Zander et al., 2012; Zarrilli et al., 2013). PCR and sequence-
based methods which describe isolates numerically are easy to
use in international networks. Specifically for A. baumannii,
Sequence Groups (SGs) identification or Trilocus (Turton
et al., 2007) sequence-based typing (3LST – selectively amplifies
alleles of ompA, csuE, and blaOXA−51 genes), blaOXA−51−like
genotyping and two MLST schemes1 (“Oxford” and Institute
Pasteur) are available. The 3LST, blaOXA−51−like genotyping, and
DiversilabTM typing (which consists in a repetitive extragenic
palindromic PCR – rep-PCR) allow the rapid identification of the
main multidrug-resistant A. baumannii lineages, being already
established the concordance between some of these methods
(Zarrilli et al., 2013). The MLST schemes share three loci but
reveal different discriminatory abilities, with our data pointing
for a higher resolution, congruent to PFGE analysis and CHDL
content, of the “Oxford” scheme (Grosso et al., 2011b). MLST
analysis in several collections resulted in the recognition of major
clonal complexes (CCs) and sequence types (STs) responsible
for antimicrobial resistance dissemination, such as CC92 (ST92,
ST208, ST218), CC109 (ST109), CC103 (ST103, ST133), and
CC113 (ST113) according with the Oxford scheme (Zarrilli et al.,
2013).
However,most of thesemethods are too expensive and/or time
consuming. Spectroscopic techniques might constitute reliable
alternatives for bacterial typing at different taxonomic levels,
with variable degrees of success reported from their application
to several microorganisms (Mencacci et al., 2013; Šedo et al.,
2013; Vaz et al., 2013; Branquinho et al., 2014a,b; Novais et al.,
2014; Sousa et al., 2014a). Recently, we developed and validated
a mathematical model for typing A. baumannii clones, most of
them included in this study, based on spectra obtained by a
competitive spectroscopic technique, Fourier transform infrared
spectroscopy with attenuated total reflectance (FTIR-ATR), that
could be routinely used (Sousa et al., 2014b). Moreover, using
matrix assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) and chemometrics we were
able to circumvent difficulties associated with the discrimination
by MALDI-TOF MS of Acinetobacter species within the
A. baumannii-calcoaceticus complex (Böhme et al., 2010; Espinal
et al., 2011; Sousa et al., 2014a). In which concerns the
suitability of MALDI-TOF MS for bacterial typing at subspecies
level, controversial data is available (Barbuddhe et al., 2008;
1http://pubmlst.org/abaumannii/
Dieckmann and Malorny, 2011; Gekenidis et al., 2014; Lasch
et al., 2014; Novais et al., 2014; Wolters et al., 2011).
In this work, we evaluated the ability of MALDI-TOF MS
combined with several chemometric tools for assisting infection
control by depicting A. baumannii clones.
Materials and Methods
Rational of the Study
To evaluate the potential of MALDI-TOF MS to discriminate
A. baumannii clones, mass spectra of 58 Portuguese clinical
isolates belonging to ST98, ST103, ST208, and ST218 according
with the “Oxford” scheme were obtained and analyzed with
several chemometric tools. Mass profiles analysis was performed
by different approaches: (i) spectral overview on the basis of
pseudo gel views; (ii) analysis of the mass peak pattern according
the number of peaks found with the Matlab function peakfind;
and (iii) partial least squares discriminant analysis (PLSDA).
The last two approaches also allowed the estimative of correct
predictions for each ST and the PLSDA model was performed
considering the entire (2–20 kDa) and a selected (4–10 kDa)
spectral range where the majority of the mass peaks (about
90%) were located. Additionally, mass spectra of 38 isolates
from different countries and belonging to 22 distinct STs were
obtained and the respective pseudo gel views compared among
each other and with the ones of ST98, ST103, ST208, and ST218
isolates. We further explored a possible correlation between the
mass profiles of the isolates tested and clustering/classification
obtained with other methods for major lineages A. baumannii
identification, as AFLP, SG typing, and the MLST scheme of
Institute Pasteur.
Bacterial Isolates
Fifty-eight A. baumannii clinical isolates were selected among
a previously published collection of 318 CHDL-producing
Acinetobacter spp. recovered from six geographically distant
Portuguese hospitals (2001–2012). The selected isolates are
representatives of the main lineages disseminated in Portugal
before 2012: ST98 (n = 10); ST103 (n = 9); ST208 (n = 17;
corresponding to a reassignment of ST92 isolates), and ST218
(n = 22; Grosso et al., 2011a,b; Sousa et al., 2014b). Additionally,
38 isolates belonging to 22 different STs were used for further
comparisons. The main characteristics of the isolates used in this
study, including the relationship between CHDL content, PFGE
types, SGs, and the STs obtained according with Institute Pasteur
and “Oxford” scheme1 among others were presented in Table 1.
MALDI-TOF MS Experiments
Mass spectra were obtained from cell extracts prepared according
the manufacturer instructions. Briefly, overnight cultures in
Muller-Hinton agar were suspended in HPLC water and treated
with ethanol (75%). After centrifugation and removal of the
supernatant, cells were extracted with 25 µL of 70% formic
acid followed by addition of 25 µL of acetonitrile and vortexing
at 2000 rpm for 1 min. Samples were spotted onto MALDI
ground steel target (AnchorChip) followed by drying and the
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addition of 1 µL of the chemical matrix (saturated solution
of α-cyano-4-hydroxycinnamic acid in 50% of acetonitrile and
2.5% of trifluoroacetic acid). Spectra were randomly obtained
from blind samples in the linear positive mode at a laser
(nitrogen) frequency of 20 Hz in the range of 2–20 kDa
with a Microflex III instrument (Bruker Daltonic, Bremen,
Germany). Each recorded spectrum is the result of six series
of 40 single laser shots in different locations. The experiments
were performed in quadruplicate using four distinct spots of
the MALDI target (instrumental replicates) at least in two
different days (biological replicates) with two different bacterial
cultures or extracts. External calibration of the mass spectra
was performed using Escherichia coli DH5 alpha standard peaks
(BTS).
Data Analysis
Due to the large amount of data generated by MALDI
experiments, mean spectrum for each isolate was generated
from the instrumental and biological replicates and considered
for further analysis. Zero-line and low S/N ratio mass spectra
were not considered to the average. The pseudo gel views were
generated by the dedicated Matlab-based software MicrobeMS2
that provides direct access to the spectra of Bruker’s proprietary
file format. In these gel views the intensities are gray-scaled (log
scale) being the mass/charge ratios (m/z) the abscissa and spectral
indices the ordinate values. In these bar code spectra only the
information of peak presence or absense is employed, while the
peak intensity is neglected.
Mass spectra were also analyzed with the peakfind function
of the PLS Toolbox for Matlab (arguments: 9- number of points
in Savitzky–Golay filter, 6- tolerance on the estimated residuals;
peaks heights are estimated to be > tolerance∗residuals) and 19-
window width for determining local maxima to evaluate the
intra and inter-ST variability among the four distinct STs. The
method starts by estimating the peak mass-to-charge ratios of
each ST. For this task, spectra of all isolates belonging to one ST
were averaged, the result was submitted to the peak identification
method and the peak locations were stored in a vector generating
a “peak prototype” for each ST. This method was repeated for
all STs. Then, the same peak identification method was run for
each isolate individually. Peak positions of each “ST prototype”
2http://www.mara-ms.com
TABLE 1 | Epidemiological details of the Acinetobater baumannii isolates included in this study.
ST (CC)b ST (CC)c SG (AFLP)a nd PFGEe CHDLf Country Years Reference
98 (92) 2 (2) SG1 (II) 10 A OXA-40 Portugal 2001–2008 Grosso et al. (2011b), Sousa et al. (2014b)
208 (92) 2 (2) SG1 (II) 17 A4 OXA-23 Portugal 2006–2010 Grosso et al. (2011b), Sousa et al. (2014b)
218 (92) 2 (2) SG1 (II) 22 A5 OXA-23 Portugal 2010 Sousa et al. (2014b); This study
103 (103) 15 (15) SG5 9 B, C OXA-58 Portugal 2001–2004 Grosso et al. (2011b), Sousa et al. (2014b)
15 G1ompA/G2csuE 1 O − Germany 1991 Seifert et al. (2005), Sousa et al. (2014b)
16 SG2 (I) 1 L − Germany 1991 Seifert et al. (2005), Sousa et al. (2014b)
113 (113) 79 (79) SG1 (II) 4 D OXA-23 Brazil 2006–2007 Grosso et al. (2011a)
132 162 G1OXA66/G2ompA/csuE 2 F OXA-23 Brazil 2007 Grosso et al. (2011a)
133 (103) 15 (15) SG4 3 E OXA-23 Brazil 2006–2007 Grosso et al. (2011a)
134 316 G2ompA/OXA69 1 K OXA-23 Brazil 2007 Grosso et al. (2011a)
195 SG1 (II) 1 P OXA-23 Germany 2010 Sousa et al. (2014b)
231 G2OXA− 69/ompA 2 J, X OXA-23 Germany, Italy 2004–2012 Sousa et al. (2014b)
236 SG1 (II) 1 T − Italy 2012 This study
348 SG1 (II) 1 R OXA-72 Croatia 2001–2007 Goic-Barisic et al. (2011), Sousa et al. (2014b)
391 G1ompA 1 U − Germany 2012 Sousa et al. (2014b)
437 (92) 2 (2) SG1 (II) 5 A4 OXA-58 Italy 2004–2008 D’Arezzo et al. (2009), Sousa et al. (2014b)
439 SG2 (I) 1 M − Germany 1991 Seifert et al. (2005), Sousa et al. (2014b)
441 SG2 (I) 4 H − Germany,
Croatia
2001–2007 Sousa et al. (2014b)
513 (92) 2 (2) SG1 (II) 2 A5 OXA-23 Italy 2007–2009 D’Arezzo et al. (2011), Sousa et al. (2014b)
514 G1csuE/G2OXA− 69 1 N − Germany 1991 Sousa et al. (2014b)
515 1 I − Portugal 2010 Sousa et al. (2014b)
732 G1ompA 2 V, W − Germany 2012 Sousa et al. (2014b)
733 G1ompA 1 Y OXA-23 Germany 2012 Sousa et al. (2014b)
740 SG2 (I) 1 Q − Croatia 2001–2007 Sousa et al. (2014b)
775 SG2 (I) 1 G − Croatia 2001–2007 Sousa et al. (2014b)
776 G1OXA66/ompA/G2csuE 1 S − Italy 2012 Sousa et al. (2014b)
aSG, sequence group typing (PCR-based sequence groups based on ompA, csuE, and blaOXA− 51 genes); AFLP, amplified fragment length polymorphism correspondence
to international clones I–III); bSequence Type (ST) and Clonal Complex (CC) determined according with the “Oxford” scheme; cSequence Type (ST) and Clonal Complex
(CC) determined according with Institut Pasteur MLST scheme; dn total of isolates; eApaI-Pulsed Field Gel Electrophoresis type; fCHDL, acquired carbapenem-hydrolyzing
class D β-lactamase.
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FIGURE 1 | Mass profiles of ST98, ST103, ST208, and ST218 isolates in the region of 2–13 kDa [obtained from the mean spectra of each sequence
types (ST)].
were compared with peak positions of each isolate. When a
“ST prototype” peak location matched a peak location of an
isolate, a value 1 was assigned for that peak; otherwise a value
0 was assigned. This procedure creates a vector of 0s and 1s
for each pair “ST prototype”/isolate. Note that peak locations
were considered to match if they were located within a mass-to-
charge ratio difference lower than 7 m/z units [if for a certain
peak location n, | m/z(prototype)n–m/z(sample)n| < 7, that
peak is considered to match]. For each isolate, a percentage
of matching peaks was estimated for each ST. Isolates were
considered to belong to the ST yielding the highest percentage
of peak matches.
For clustering purposes spectra were analyzed by PLSDA
after the pre-processing mean-centring (Savitzky and Golay,
1964; Geladi and Kowalsky, 1986; Barker and Rayens, 2003).
This pre-processing method allows removing the influence of
different sample amounts and/or equipment variations in the
peaks intensity. In PLSDA, to each known sample (xi) is assigned
a vector of 0s with the value 1 at the position corresponding to
its ST (yi). The structure of the PLSDAmodel is described by Eqs
1 and 2. Model loadings (P and Q) and corresponding scores (T
and U) are obtained by sequentially extracting the components
or latent variables (LVs) from matrices X (the spectra) and Y (the
matrix codifying the STs).
X = TPt + E (1)
Y = UQt + F (2)
The algorithm correlates the scores of each block (T and U),
yielding an internal regression matrix. This internal regression
can be transformed on a regression matrix (B). In this case, the
regression matrix is composed by three vectors: one regression
vector corresponding to each ST.E and F are the residual matrices
and depend on the number of LV selected. Predictions for new
samples are obtained by multiplying a new spectrum (xnew) by
the regression matrix (B).
ynew = xnewB (3)
The prediction (ynew = [ynew,1,ynew,2,....,ynew,n]) is then
converted in a class assignment. In PLSDA a probability value
for each assignment is estimated for each sample. The model
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FIGURE 2 | Pseudo gel view representation obtained from the average mass spectra of each Acinetobacter baumannii isolate of ST98, ST103, ST208,
and ST218 (A) and of A. baumannii isolates of the international collection (B).
number of LV was optimized using the leave-one-sample-out
cross-validation procedure in order to prevent overfitting. All
chemometric models were performed in Matlab version 7.4
Release 2007a (MathWorks, Natick, MA, USA) and PLS Toolbox
version 4.2.1 for Matlab (Eigenvector Research, Manson, WA,
USA).
Results
Spectral Overview
Mean mass profiles of the isolates belonging to the four studied
STs are presented in Figure 1. A very similar peak pattern can
be found among the isolates of a single ST (data not shown) and
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among the four STs with almost no differences between them.
The common peaks found among the four STs are summarized
in the figure. Figure 2 exhibits the pseudo gel views generated
with MicrobeMS software considering all the isolates included
in this study (ST98, S103, ST208, ST218 plus the 22 STs of the
international collection). A high degree of consistency in the peak
pattern can be found among the isolates of a single ST but also
among the four STs (Figure 2A). It was impossible to obtain any
degree of isolate discrimination according the ST solely based in
the presence and/or absence of specific mass peak profiles even
considering isolates epidemiologically unrelated and belonging to
diverse STs (Figure 2B).
Peakfind Function of Matlab
Supplementary Figure S1 summarizes the peak positions founded
with the peakfind function in the mass spectra from all isolates.
No peaks were found above 17 kDa. Similarly to the observations
in the pseudo gel view analysis, a very consistent peak pattern
was observed among all the isolates with a low inter and intra-
ST spectral variability. The comparison of each isolate peak
profile with the four mean-ST peak profiles (see Materials and
Methods) was used for estimating the ST of each isolate, Figure 3.
Nevertheless, it was only possible to correctly predict the ST
for 58.6% of the isolates. ST103 isolates were always correctly
predicted; however, 19/58 isolates were erroneously predicted
as ST103, meaning a high sensitivity (9/9 = 100%) and low
specificity (30/51= 58.8%) for the ST103 prediction. Moreover, it
was possible to correctly predict 70% of the ST98 isolates; 41.2%
of the ST208 isolates and 50% of the ST218 isolates.
Partial Least Squares Discriminant Analysis
The PLSDAmodels developed considering the entire (2–20 kDa)
and a selected (4–10 kDa) spectral range are presented in
FIGURE 3 | Sequence type assignments for all isolates considering the
spectral matching method. Colors identify the real ST of each isolate and
bars correspond to the method’s ST predictions (58.6% of correct
predictions). Legend: ST98, ST103, ST208, and ST218.
Figures 4A,B, respectively. Considering the entire spectral range
(Figure 4A) it was not possible to clearly discriminate the four
STs as no individualized clusters could be found in the score map
of the model. The PLSDA model was able to correctly predict
the STs of 64.6% of the isolates (Table 2) being ST103 the one
with a larger percentage of correct predictions (75.7%). The worst
cases were observed for ST98 and ST208 for which plus than 40%
of the isolates were erroneously predicted. Similarly, the PLSDA
model obtained with the selected spectral range (4–10 kDa) did
not allow the discrimination of the four STs (Figure 4B) still
being ST103 the best predicted (73.7%), Table 2. Moreover, the
total percentage of correct predictions was slightly higher (65.8%)
for each of the three remaining STs considering the 4–10 kDa
range.
Partial least squares discriminant analysis models were also
developed (whenever possible and according to the available
information, please see Table 1) to correlate the mass profiles
of the isolates with the results obtained from less discriminatory
typing methods as AFLP, SG, and MLST scheme of Institute
Pasteur. However, the clustering analysis was not congruent with
any of these methods (data not shown).
Discussion
In the last years an impressive growing number of studies
unveiling the MALDI-TOF MS potential for routine bacterial
species identification has been published (Böhme et al., 2010;
Carbonnelle et al., 2010; Branquinho et al., 2014a,b; Sousa
et al., 2014a). However, the suitability of this mass spectrometry
technique for bacterial discrimination at the subspecies level
has been barely explored, with contradictory outcomes for
particular species (Barbuddhe et al., 2008; Dieckmann and
Malorny, 2011; Wolters et al., 2011; Gekenidis et al., 2014;
Lasch et al., 2014; Novais et al., 2014). The goal of this
work was to assess the ability of MALDI-TOF MS to depict
A. baumannii clones, with particular interest for the worldwide
spread lineages (ST98, ST103, ST208, and ST218), contributing
to a better understanding of the capabilities and limitations
of this technique in bacterial typing. Analysis of the mass
spectra of the four STs was attempted using three approaches
and revealed some mass-to-charge ratios already identified as
Acinetobacter genus and A. baumannii species-specific (Böhme
et al., 2010; Espinal et al., 2011; Šedo et al., 2013; Sousa et al.,
2014a). However, the high similarity among mass profiles of the
A. baumannii lineages analyzed prevented the STs discrimination
either by peak pattern direct analysis (Figure 1) or based on
the presence/absence of specific peaks depicted in the pseudo
gel views (Figure 2A). Moreover, attempting to assign a ST
based on the comparison of each isolate’s mass profile with the
mean-ST profile also resulted in a low percentage of correct
identifications (58%, Figure 3B). Previous studies, including
from our group (Novais et al., 2014; Sousa et al., 2014a), have
demonstrate that the use of specific and optimized chemometric
tools in MALDI-TOF MS data analysis improves the bacterial
discrimination derived from this spectroscopic methodology.
In this context, we attempted to discriminate the isolates
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FIGURE 4 | Score plot corresponding to the first three latent variables (LVs) of the partial least squares discriminant analysis (PLSDA) regression
model using the entire, 2–20 kDa, (A) and a selected, 4–10 kDa, (B) spectral range. Legend: ! ST98, " ST103, • ST208, and # ST218.
TABLE 2 | Confusion matrix for both of the A. baumannii PLSDA discrimination models, considering 20 LV (values are in %).
ST obtained with MLST(a)
Spectral range 2–20 kDa Spectral range 4–10 kDa
ST98 ST103 ST208 ST218 ST98 ST103 ST208 ST218
ST predicted by MALDI-TOF MS ST98 56.2 5.7 12.6 14.4 56.6 8.1 13.1 12.7
ST103 3.5 75.7 5.3 2.3 2.8 73.7 4.7 3.2
ST208 17.2 8.8 56.8 13.7 19.5 10.0 60.6 13.6
ST218 23.1 9.8 25.3 69.6 21.1 8.2 21.5 70.4
aSequence type determined according with “Oxford” scheme (http://pubmlst.org/abaumannii/).
with a PLSDA analysis considering two distinct mass ranges
(Figures 4A,B). Although the degree of discrimination slightly
improved, only 64.6 and 65.8% of correct STs predictions were
obtained for the two considered mass ranges, demonstrating
the current inadequacy of MALDI-TOF MS for discrimination
of major A. baumannii STs. The difficulty to differentiate these
STs based on MALDI-TOF MS analysis could possibly be
associated with the relatedness of their allelic profiles. In fact,
ST98 is a double locus variant of ST208 and ST218 in gyrB
and gpi and ST208 a single locus variant of ST218 in the
gpi allele. Despite the low ability to discriminate the four STs,
A. baumannii ST103 isolates always presented the higher rate
of correct ST predictions whether considering the comparison
of the ST-mean mass profiles or the chemometric approach.
It is of note that the allelic profile of ST103 isolates is the
most dissimilar one, presenting only one common allele with
ST98, the gpi one3. This fact could contribute to a more
dissimilar ribosomal protein/peptide profile of ST103 isolates
and its subsequent higher rate of correct identifications. The
difficulty to differentiate these four STs based on their mass
spectra suggests that these clones possess a very similar profile
in what concerns to the molecules routinely observed in these
MALDI experiments.
3http://pubmlst.org/abaumannii/
As a high throughput technique, MALDI-TOF MS competes
with other spectroscopic techniques as Raman (Maquelin et al.,
2006), and Fourier Transform Infrared Spectroscopy (FTIR)
for bacterial typing at different taxonomic levels. It is of
note, the suitability of FTIR to discriminate A. baumannii
lineages, including the STs included in this study (Sousa
et al., 2014b), which is also a sensitive, quick and low
cost technique. Nevertheless, with the recognition of the
interest in the microbiological diagnostic of MALDI-TOF
MS, associated with the increasing availability of MALDI-
TOF MS equipment in routine laboratories, there is a
particular interest on methodology developments assisting
bacterial epidemiology. In this way, further assays testing
the ability of MALDI-TOF MS to discriminate A. baumannii
lineages with different sample preparation conditions and
matrix solutions should be conducted. It also should be noted
that, despite our MALDI data had been compared with four
distinct classification methods (two different MLST schemes,
AFLP and SG), presenting different typing resolutions, it was
not congruent with the grouping obtained with any of these
approaches. In this way, it does not offer, in these experimental
conditions, an advantage over other rapid methods such
as DiversiLab rep-PCR-based typing, trilocus sequence-based
typing, or single-locus-sequence-based typing of blaOXA−51-
like genes. However, we do not exclude the possibility that
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other classification method could somehow fit MALDI-TOF MS
data.
Conclusion
In this work we evaluate the ability of MALDI-TOF MS to
discriminate A. baumannii clones. This mass spectroscopic
technique, which revealed in previous studies a high
discrimination power for species identification within the
A. calcoaceticus–A. baumannii complex, demonstrates an
insufficient result when used for discrimination at the clonal
level. These findings suggest that the detected molecules, mainly
ribosomal peptides and/or proteins, remain unchanged during
clonal diversification in this species. Further studies, namely
using different sample preparation conditions, are needed to
provide further insights on the suitability of MALDI-TOFMS for
typing A. baumannii at a subspecies level.
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1. Introduction 
Acinetobacter baumannii is amongst the most troublesome Gram-negative 
bacterial pathogens worldwide, mainly due to the extended antibiotic resistance 
phenotypes and ability to rapidly disseminate and persist in healthcare settings 
(ECDC), European centre for disease prevention and control, 2017; Lee et al., 2017). 
In Portugal, we detected a recent endemicity of Sequence Type (ST) 218, which has 
been replacing the worldwide-disseminated ST208 since 2010 [3]. Surface 
polysaccharides are major virulence determinants that protect bacteria from 
phagocytosis and the bactericidal effect of serum, or host immune response, however, 
little is known regarding the capsular polysaccharides (KL) from A. baumannii major 
clones [4]. Moreover, in other bacteria it has already been established an association 
between capsular types and particular diseases or severity of infections [5]. Thus, it is 
of utmost importance to determine the role of A. baumannii capsule in host-
pathogen interactions, as well as the genotypic and phenotypic features of A. 
baumannii KL, and how they affect the clonal dynamics among the major lineages 
associated with human infections. 
This study aimed to characterize, by Fourier transform infrared (FT-IR) 
spectroscopy and whole genome sequencing (WGS), the capsular types of different A. 
baumannii isolates belonging to endemic/epidemic lineages, in order to correlate the 
capsular characteristics with the microevolution and predominance of specific STs. 
 
2. Material and methods 
Bacterial strains 
One-hundred twenty-three previously characterized A. baumannii isolates 
from different clinical settings [two hospitals in the North (H, n=105) and Centre of 
Portugal (CB, n=11), a long-term care facility (LTCF, n=1) and a community clinical 
laboratory (CT, n=6)], belonging to different STs (ST98, n=2; ST103, n=2; ST208, 
n=22; ST218, n=93; sporadic STs, n=4) were studied [3,6]. With the exception of 
sporadic STs, they represent a snapshot of multidrug/extremely drug resistant (MDR 
and XDR, respectively) clones responsible for outbreaks or endemic situations in 
Portugal for a large period of time (2001-2015). Details about the bacterial isolates 
are summarized in Table 1. 
 
FT-IR-ATR: spectra acquisition and processing 
Isolates were grown on Mueller-Hinton agar (37ºC, 18h) and directly applied 
on the attenuated total reflectance (ATR) crystal. Spectra were acquired using a 
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Perkin Elmer Spectrum BX FTIR System spectrophotometer in the ATR mode 
(4000-600 cm-1, 4 cm-1 resolution and 32 scan co-additions) and pre-processed as 
previously described [7]. Spectra were further analysed by an unsupervised (principal 
component analysis, PCA) chemometric method, considering the polysaccharides 
region (W4, 900-1200 cm-1) [8,9]. All chemometric analysis was performed using 
Matlab R2015a (MathWorks, Natick, MA) and PLS Toolbox version 3.5 for Matlab 
(Eigenvector Research, Manson, WA, USA).  
 
Whole genome sequencing (WGS) 
From the above collection, 16 A. baumannii isolates, representing different 
STs [ST98 (n=2), ST103 (n=2), ST208 (n=4), ST218 (n=4) and sporadic STs (n=4)], 
and time periods, were selected for WGS. DNA was extracted using the Wizard 
Genomic DNA purification kit (Promega Corporation, Madison, WI), according with 
the manufacturer´s instructions. DNA concentration was estimated using the Qubit 
dsDNA HS Assay Kit and the Qubit 3.0 Fluorometer (Invitrogen, Thermo Fisher 
Scientific, USA). Extracted DNA was then sequenced with a standard 2x125 paired-
end runs protocol on Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). The 
quality of the high-throughput sequence data was assessed by FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw sequence reads 
were then de novo assembled using SPAdes v3.9.0 (http://bioinf.spbau.ru/spades), 
and the quality was assessed by QUAST (http://quast.bioinf.spbau.ru). RAST server 
(http://rast.nmpdr.org) was used for an automatic annotation that was further 
manually curated by Geneious R10 software (Biomatters Limited, Auckland, New 
Zealand) using BLASTn/BLASTp (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
Genetic characterization of KL locus 
The full KL gene cluster, which encodes for capsule synthesis, assembly and 
export machinery, extending from the lipid II flippase (mviN) to L-lactate 
dehydrogenase (lldD) genes (approximately 30 kb), was extracted from whole 
genome data and annotated with Geneious R10. Easyfig 
(http://mjsull.github.io/Easyfig/) was used to compare the backbone of the different 
KL clusters.  
 
 
3. Results and discussion 
 With FT-IR analysis, spectral diversity (92.2% in four principal components) 
revealed two well-defined clusters, I (n=23) and II (n=91), a stretched III (n=6), and 
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3 dispersed isolates (Figure 1). FT-IR-clustering, genetic characterization of the KL 
locus and MLST (using Oxford scheme, which includes gpi gene, contained in the KL 
locus and codifying for a glucose-6-phosphate isomerase) were, in general, 
congruent, unveiling putative associations between KL-types and particular STs over 
large periods of time.  
Cluster I, encompassed all isolates from ST208 (n=22) sharing the same KL 
locus (KL_X). The same KL-type (100% identity) was also described among MDR 
strains AYP-A2 (CP024124.1) from Australia, CMC-CR-MDR-Ab4 (CP016295.1) and 
AF-673 (CP018256.1) from EUA, and a very similar one (99% identity) was described 
in South Korea (strain CBA7, CP020586.1), China (HRAB-85, CP018143.1) and Italy 
(strain ACICU, CP000863.1). This locus contains the operon psaABCDEF (Figure 2) 
that encode enzymes for the biosynthesis of pseudaminic acid, described for the first 
time in Pseudomonas aeruginosa (Pse5Ac7Ac). The only exception observed in this 
cluster, the isolate H366, belonged to a different clone (ST1558) and displayed a 
different KL gene cluster (with the operon mnnABC for the synthesis of mannose) 
(Figures 1 and 2). This exception makes us believe that, in addition to the KL-type, 
other factors [e.g. other sugars of the cell surface like the lipooligosaccharides (LOS)] 
could additionally influence the FTIR-based assignments.  
 Cluster II included ST218 isolates (n=91), with the same KL locus (KL_Y, 
100% identity) of the MDR OXA-23-positive A. baumannii strains TCDC-AB0715 
from Taiwan and BJAB0868 from China (both belonging to ST2 or Global clone II) 
[10,11]. Interestingly, this locus is associated with genes (glycosyltransferases and the 
operon lgaABCDEF) involved in the biosynthesis and processing of legionaminic acid 
(Leg5Ac7R), the precursor for the uncommon sugar α-8-epi-legionaminic acid 
(Figure 2). This sugar, like the pseudaminic acid from ST208, belongs to the 
superfamily of nonulosonic acids (complex nine carbon α-keto monosaccharides) 
that have structural similarities with the eukaryotic sialic acid [12]. However, these 
two acidic sugars have different stereochemistry, with legionaminic acid better 
resembling the structure of sialic acid from mammalian host cell´s surface 
glycoproteins, enabling the bacterial pathogens to mimic host cell surface, and thus 
escaping from host immune surveillance to facilitate their colonization and invasion 
[12]. Although this relation needs further studies, this sugar may constitute an 
advantage for ST218 isolates, which could be one of the reasons for its success in 
relation to ST208 [3]. It is of note an isolate belonging to ST218 (H482, Figure 1) that 
appears apart from the cluster. However, the only capsular genetic difference found 
between this isolate and the remaining ST218 isolates was an alteration in the 
tyrosine protein kinase, Wzc (insertion of the TCT codon on wzc gene sequence, 
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which leads to the synthesis of an extra lysine amino acid at the position 499). Wzc is 
a protein and, hence, is not included in the region used for FTIR analysis. However, 
its essential function in capsule export makes us believe that some modification in 
this process may have occurred, pointing out the need of further studies. 
Cluster III (n=6) encompassed isolates from different STs: Ac55 and H25 
from ST98, H735 and H736 from ST218, and Ac23 and Ac246 from ST103 (Figure 1). 
Interestingly, the analysis of the KL clusters revealed that all of these isolates shared 
the same capsular locus (KL_Z, 100% identity), which possessed the fnlABC operon, 
responsible for the biosynthesis of N-acetyl-L-fucosamine.  
Dispersed isolates (n=3) were unrelated, belonged to sporadic STs (ST234, 
ST552 and ST1557) and harboured different KL-types (Figures 1 and 2). Despite the 
capsular locus of two of these isolates contain the operons psaABCDEF (316.1) and 
rmlBADC (H745) for the synthesis of pseudaminic acid and rhamnose, respectively, 
they do not present the polymerase-encoding gene (wzy), crucial for the sugar-linked 
repeat units polymerization. This observation corroborated a previous study 
performed by Dalong Hu and colleagues [13], who did not find the pseudaminic sugar 
in a capsular structure similar to that observed for 316.1 isolate, suggesting that these 
sugars are not incorporated into the capsular structure. Moreover, none of the KL-
types harboured by sporadic isolates appear to be widespread or related with an 
epidemic ST.  
Taken together, the results obtained evidenced a good correlation between 
FT-IR-based assignments and the genetic assessment of the KL locus. An apparent 
low potential for KL diversification within each of A. baumannii clones studied was 
observed (being a clone usually associated with a specific capsule), highlighting the 
role of clonal selection in the actual epidemiological scenario of A. baumannii, at 
least in the clinical setting. However, when subtle changes on bacterial surface 
components or a capsular switch occurs, FT-IR spectroscopy proved to have a good 
discriminatory potential to identify them, which can be useful to detect 
alterations/switch, as a result of host-pathogen adaptation or recombination events, 
in the local population of A. baumanni involved in infections. Furthermore, although 
the presence of legionaminic and pseudaminic acid in A. baumannii capsules have 
been punctually recognized in MDR isolates [14,15], we firstly clarify the abundance 
of these sugars among KL-types of a representative collection of A. baumannii 
MDR/XDR strains. 
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4. Conclusions  
This work demonstrated, for the first time, the potential of FT-IR coupled 
with chemometric analysis to differentiate A. baumannii capsular types (at least in 
lineages with clinical significance), confirming the suitability of this method for a 
quick and low-cost bacterial characterization. Although the results obtained have 
shown that the capsular gene cluster do not unambiguously correlate with any 
particular ST (e.g. ST218 can be equipped with at least 2 different types of gene 
clusters, although one clear predominant), the high prevalence of capsule derivatives 
enriched in acidic sugars and apparently more adapted to the host interaction, among 
the international XDR A. baumannii lineages ST208 and ST218, in different 
geographic regions and time periods is of relevance, and needs to be further explored. 
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Figure 2. Comparison of the KL gene clusters from A. baumannii 
representative strains. The STs for the respective strains and cluster length (on 
the left side), and the predicted KL-types (on the right side) were also shown. 
Homologous regions are connected by areas of different shades of grey, reflecting the 
degree of nucleotide identity (from 66% to 100%) 
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The general conclusions that can be extracted from the achievement of the specific 
aims proposed are summarized as follows: 
 
Carbapenem-resistant Acinetobacter baumannii clonal dynamics in 
Portuguese clinical settings explained by a highly successful interplay 
between antimicrobial resistance and virulence. 
1. For more than two decades, high rates (>45%) of carbapenem-resistant A. baumannii 
have been reported in Portuguese clinical settings, associated in each time period with a 
particular ST. ST218, which gradually replaced the previously dominant lineage ST208, 
is now the main lineage contributing for carbapenem-resistance among the 
Portuguese clinical settings analyzed. Based on a detailed genomic analysis of these clones 
(obtained by WGS), a better understanding of clonal replacement was provided. It was 
observed that higher levels of aminoglycoside resistance, mainly due to the 
presence of 16S ribosomal RNA methyltransferase ArmA enzyme; an enlarged 
virulence potential, in particular due to the heme oxygenase, essential for uptake and 
utilization of iron, and a capsular type mimicking the host cell surfaces and enabling the 
bacteria escape from the immune system, are the main advantages displayed by ST218 
when compared with ST208.  
 
2. Despite the lineage substitution, chromosome located blaOXA-23 is still the most 
prevalent carbapenem resistance determinant associated with A. baumannii during the 
analyzed period (2010-2015). Curiously, no antibiotic resistance associated-plasmids were 
found among the A. baumannii collection, except one isolate found in a LTCF and 
belonging to a sporadic clone (ST1557), which displayed blaOXA-24/40 in a plasmid identical 
to pAc92, previously associated with the ST98 lineage. 
 
Contribution of non-baumannii Acinetobacter species as reservoirs of 
resistance genes in clinical and non-clinical settings. 
3. A clear potential of non-baumannii Acinetobacter species to acquire and act as a 
source of carbapenem-resistance determinants, with the ability to integrate different 
genetic backgrounds and potential for further dissemination, was observed. Two new 
CHDL-carrying plasmids (blaOXA-23-carrying pLS488 and the blaOXA-58-carrying pLS535) 
were identified among A. pittii, a species increasingly detected causing infection in 
Portuguese hospitals. The pLS488 (51 Kb) displayed a new replicase (rep) gene that 
belonged to the superfamily RdgC, and was the first conjugative plasmid associated 
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with a carbapenemase gene in this species, which was successfully transferred to A. 
baumannii. The pLS535 (12 Kb) belonged to the GR7 incompatibility group (Rep3 
superfamily) and, although lacked the conjugation machinery was transferable by 
electroporation to A. baumannii. In addition, the blaIMP-5 gene, previously detected 
among A. baumannii and Pseudomonas aeruginosa clinical isolates, was identified for the 
first time in two A. bereziniae isolates, one from hospital equipment and other causing 
infection. In both isolates, blaIMP-5 gene was associated with large transferable plasmids, 
embedded in the same genetic element previously reported (In76), which highlights the 
possibility of interspecies transfer and may contribute for further dissemination of 
important carbapenemases among Acinetobacter. 
 
4. A high diversity of Acinetobacter species, scattered in different niches of Benguela 
(Angola) was observed, enlarging their recognized niches. The occurrence of a blaOXA-58-
producing A. johnsonii and blaOXA-23-producing A. towneri-like species (a 
potential new species) from a non-related-hospital source was here firstly reported, 
suggesting the involvement of unknown stressors for the emergence of these relevant 
resistance genes. Worrisome, was identified in this region, a possible water-human 
transmission cycle for Acinetobacter spp., including CHDL producers. 
 
Developments on Acinetobacter species identification and typing. 
5. It is demonstrated, for the first time, the potential of Fourier Transform infrared (FTIR) 
spectroscopy, coupled with chemometric analysis, for the identification of closely 
related species belonging to the ACB complex, and also for the discrimination of 
clinically relevant A. baumannii lineages (ST98, ST103, ST208 and ST218, Oxford 
scheme). Moreover, it was possible to correlate the differences observed in FTIR-
assignments with the capsular gene clusters harboured by MDR/XDR A. baumannii 
clones. Our data points to a high resolution of FTIR-ATR coupled with 
chemometric analysis for capsular types identification. 
 
6. We demonstrate the suitability of MALDI-TOF MS for species identification within 
the ACB complex. Nevertheless, a limited discriminative potential for MDR A. 
baumannii clones was verified, which might be explained by the high degree of 
conservation of ribosomal proteins. 
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